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Osteoarthritis is a debilitating condition with an increasing global burden. Regenerative 
strategies to treat damaged articular cartilage aim to relieve pain and maintain joint 
function. Procedures for osteochondral repair, such as drilling or microfracture of the 
subchondral bone, are thought to restore cartilage by delivering bone marrow cells to the 
defect site. However, the specific identity or contribution of these cells to the repair 
process is not well understood.  
Mesenchymal stem/stromal cells are thought to contribute to tissue repair by either 
progenitor or trophic action. In the bone marrow niche mesenchymal stem/stromal cells 
(BMSCs) contribute to haematopoietic stem and progenitor cell (HSPC) maintenance and 
the dynamics of this are disrupted by osteochondral repair procedures. In addition, the 
bone marrow niche can be further manipulated by the HSPC mobilising agent 
granulocyte-colony stimulating factor (G-CSF). This cytokine has previously been shown 
to improve the repair of osteochondral tissues, however, the cellular mechanisms 
underlying this response are poorly described. This thesis investigates BMSC and HSPC 
interactions in bone and cartilage repair, and the mechanism by which G-CSF may act to 
improve repair outcomes. 
To look at BMSC–HSPC interactions a co-culture system was designed and then used to 
demonstrate that HSPCs inhibit the differentiation of BMSCs towards osteogenic and 
chondrogenic lineages. To explore the interaction and role of these cells in vivo during 
osteochondral repair, a mouse defect model was established. Defects were 729 (± 
42.6) µm wide at the articular surface, occupied 41.6 (± 2.5) % of the width of the patella 
groove and penetrated 1205 (± 58.6) µm into the distal femur. The coefficient of variation 
(CV) for each parameter was below 6%. The area of injury demonstrated regenerated 
articular cartilage, an observation not previously described in the typically poor healing 
C57BL/6 strain of mice. Further, cells known to respond to G-CSF were seen to have 
specific spatial profiles in the osteochondral repair tissue over time. For example, at 24 
hours post-surgery, defect sites were filled with a blood clot within which neutrophils 
(anti-NIMP) were embedded. After 1 week, these cells were no longer present within the 
injury whilst macrophages (anti-CD68) had infiltrated the wound site having previously 
been rarely observed at 24hrs. 
To begin to understand the role of BMSCs in this repair model, Nestin-GFP reporter mice 




treated with G-CSF showed an increase in Nestin-driven GFP in their spleens. In addition, 
GFP was detected in the defect of G-CSF treated mice at 4 days post-surgery.  
To explore the role of G-CSF on BMSCs directly, in vitro techniques were used. These 
studies demonstrated the presence of a functional G-CSF receptor in the non-
haematopoietic bone marrow-derived BMSCs. The impact on MSC cell function was 
explored, including proliferation and differentiation, showing minimal impact and 
suggesting a more likely role for G-CSF in the regulation of the trophic activity of BMSCs. 
The data presented in this thesis further illustrates that the cross talk of multiple bone 
marrow cell types influences their cell fate. The osteochondral model developed during 
these studies can be exploited further to investigate the role of individual cell types during 
repair. In addition, the studies presented here illustrate that the actions of G-CSF are likely 
exerted on a diverse range of cell types during the repair process and a better 
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1.1. Osteoarthritis: The Clinical Challenge  
Osteoarthritis (OA) is a degenerative musculoskeletal condition characterised by the 
progressive loss of articular cartilage, associated wear on nearby bone, degradation of 
local cellular structures, and inflammation. Its prevalence continues to increase and joint 
replacement remains the mainstay of treatment for end-stage disease. It is generally 
believed that untreated focal cartilage defects, for example caused by trauma, progress 
towards OA through a cascade of events. Early treating of these defects may hold the key 
to preventing subsequent progression to extensive cartilage degradation and the need for 
surgical intervention. While there are several techniques currently used in clinical practice, 
none are thought to be optimal. 
1.1.1. Epidemiology and the cost of OA  
OA has a multifactorial aetiology, considered to be the result of an interplay between 
systemic and environmental factors (Sandell, 2012; Chen et al., 2017; Mobasheri et al., 
2017). Age is a major risk factor, with radiological evidence of the disease evident in most 
individuals aged over 65 years. In general, there is a negative correlation between age 
and the innate ability to maintain and repair tissues throughout the body. Furthermore, 
with regard to the joint, increased age is associated with an increased chance of joint 
trauma and biomechanical changes to joints as well as decreased physical activity, which 
can lead to decreased muscle strength and joint stability (OARSI, 2016). 
On the other hand, it is widely accepted that trauma and overuse of joints, particularly by 
participants in sports or physical jobs associated with high impact or twisting loading, can 
lead to damage that predisposes the joint to OA (Buckwalter, 2003). Cartilage lesions are 
generally thought to progress to early OA (Gelber et al., 2000; Anderson et al., 2011). The 
likelihood of this may be affected by other factors such as genetic predisposition and 
obesity (Abramson and Attur, 2009; Sandell, 2012; Zengini et al., 2018).  
The World Health Organization estimates that 9.6% of men and 18.0% of women over 60 
years of age worldwide have significant clinical problems characteristic of symptomatic 
osteoarthritis (WHO, 2016). The United Nations predicted that the number of people aged 
60 years or over is expected to more than double by 2050 (United Nations, 2017). 
Therefore, given that age is a primary risk factor, OA is set to become an increasing 
economic burden to healthcare systems. In addition, the intangible impact upon a patient’s 
quality of life can be significant, with loss of function of the affected joint(s) and associated 
limitations to an individual’s daily activities. This has the potential to result in depression, 




OARSI, 2016). Whilst not life-threatening, OA can have significant impact on physical and 
mental health. It is therefore an increasingly important area for clinical intervention.  
1.1.2. Diagnosis 
Osteoarthritis can usually be diagnosed using a patient’s medical history and a clinical 
examination (Sinusas, 2012). Plain radiography can detect joint space narrowing and 
bone changes including osteophytes, subchondral sclerosis and subchondral cysts, see 
Figure 1-1. The Kellgren-Lawrence scale is commonly used to categorise the disease 
progression from radiographs assigning a grade from 0 to 4, which correlates to increasing 
severity of OA; Grade 0 signifying no presence of OA and Grade 4 signifying severe OA 
(Kohn, Sassoon and Fernando, 2016). Advanced 3D imaging techniques are also used 
to show soft tissue and other local changes.  
Patients commonly present themselves with secondary symptoms (including joint pain 
and a limited and/or painful range of movement in the joint) which occur long after initiation 
of OA. Ordinarily, OA affects joints in an asymmetrical manner; a singular joint can be 
affected but often multiple joints display some degree of degeneration.  
 
Figure 1-1 -The appearance of osteoarthritis.  
(A) Deformities in the joints of the fingers are visible (black arrowheads), (B) narrowing of 
the hip joint space is observed using plain radiography (black arrowhead), (C) MRI shows 
the loss of the cartilage on the medial side of the knee (white arrowhead). (Image adapted 
from Bijlsma et al. 2011). 
1.1.3. Pathological observations 
OA is a disease of synovial joints, with pathological changes seen in the majority of the 
joint tissues including cartilage, subchondral bone, synovium, tendons, and muscles. 
Synovial joints are unique from other joints due to the presence of synovial fluid-filled 
capsules surrounding the joints, which allow for a wide range of movements. 
The most defining feature of OA is the loss of articular cartilage matrix. Hyaline articular 




allow smooth low friction movement of the skeleton, distributing mechanical loads across 
the bone surface. It is a highly organised/structured tissue consisting of macromolecules 
and specialised proteins, which retain water, resulting in high tensile strength and flexibility 
(Gosset et al., 2008).  
 
Figure 1-2 - Schematic of healthy and OA cartilage at early and later stages of 
disease progression. 
Early OA is characterised by the loss of the superficial layer but as disease progresses 
the zonal architecture of the articular cartilage is lost and chondrocyte distribution is 
disrupted (image adapted from Jiang and Tuan, 2015). 
Articular cartilage loss results from the breakdown of matrix proteoglycans and collagen, 
which are degraded by the action of proteolytic enzymes. It is believed that while limited 
pericellular remodelling of cartilage matrix can occur throughout life the extensive 
cartilage loss observed in OA results from a shift to a more catabolic chondrocyte 
phenotype. Alongside the loss of extracellular proteins, changes in chondrocyte 
morphology and spatial distribution can also be seen macroscopically (see Figure 1-2). 
Those in the superficial layer of articular cartilage become clustered, whilst those in the 
deeper and calcified layers undergo apoptosis (Zhang et al., 2016).  
Changes in the bone underlying damaged cartilage also occur, including increased bone 
turnover and remodelling (Figure 1-3) (Li et al., 2013). This has been associated with 
microdamage in the bone, but it remains unclear if microdamage is an initiating event or 
the response to the overlying cartilage degradation (Madry, van Dijk and Mueller-Gerbl, 
2010). Bone marrow oedema-like lesions and subchondral bone cysts are additional 
histopathological alterations in the subchondral bone (Kwoh, 2013; MacKay et al., 2018). 
Bone outgrowths, termed osteophytes, are a pathological feature commonly observed in 
late stage OA. These are present at the margins of the joint in non-weight bearing zones, 




Their presence is thought to be controlled by growth factors elevated in OA, supporting 
the notion that OA is a joint disease, and not simply a disease of the cartilage (Steinberg 
et al., 2018). In addition to growth factors, cytokines and chemokines are also increased 
in OA. These molecules can affect matrix degradation and the repair equilibrium, 
exacerbating disease progression (Fellows et al., 2016). 
  
Figure 1-3 – Schematic describing the tissue changes and degeneration of an 
osteoarthritic knee 
(A) A healthy knee joint with complete covering of articular cartilage and no synovial 
inflammation. (B) Degeneration of articular cartilage, synovial inflammation and bone 
changes are depicted (image adapted from Cibrián Uhalte et al., 2017). 
1.1.4. Current treatment strategies for OA 
A stepped-care approach is the most widely-used treatment strategy for OA (Sinusas, 
2012), focusing on reduction of pain and improved function of affected joints (Zhang et 
al., 2016). A lack of disease modifying-drugs (pharmaceuticals) has led to conservative 
treatments for OA, such as first line analgesics, used to target symptoms, rather than an 
approach aimed at reducing disease progression (Wieland et al., 2005; Driban et al., 
2010). Alongside these pharmacological strategies, physical therapy, bracing and 
splinting of the joint, weight loss, and exercise have been shown to have significant clinical 




As the disease progresses and the effect upon a patient’s daily activities becomes strongly 
apparent, surgical intervention becomes appropriate (ARUK, 2013). Currently the most 
effective procedure is total joint replacement, but other surgical procedures are also used 
as preliminary measures. 
1.1.5. Patient stratification and the need for a new strategy 
One might expect that for effective treatment and the ability to halt disease progression, 
a thorough understanding of the pathological process would be required. In the field of 
musculoskeletal repair, however, this is not the way treatment strategies have classically 
developed. The pathogenesis profile of OA is therefore yet to be fully elucidated.  
The reasons behind this can be strongly associated with the mainstay of OA treatment; 
the joint replacement. Since the 1960s, (Charnley, 1961) this treatment has answered the 
need for a solution to the disabling effects of OA. However, this approach has fundamental 
limitations; it initially masks the symptoms using analgesia and then waits for the condition 
to be ‘bad enough’ to warrant surgery. This has major cost effects, on both patients and 
the healthcare system (Marenah et al., 2018). Additionally, in more recent years the failure 
of this treatment to be curative has become evident. Approximately 5% of patients who 
have a total hip replacement or total knee replacement over the age of 70 years will require 
revision surgery and significantly, this increases to 35 % for men in their early 50s (Bayliss 
et al., 2017). With an ever-increasing life expectancy (resulting from advances in the 
treatment of conditions which were once life-threatening), increasing healthcare costs, 
increasing prevalence of risk factors (e.g., obesity), and growing expectations of patients, 
the need for a more permanent solution to treat OA has become apparent (Driban et al., 
2010).  
Although OA is now accepted to be a heterogeneous disease, it is still unstratified and 
grouped clinically as a single condition with the same common endpoint of joint 
replacement for practically all patients. For improvement in outcomes, it is becoming more 
widely accepted that there is merit in clinically stratifying patients and evolving subset, or 
even personalised, medical approaches, whether these be surgical treatments or the 
development of disease-modifying drugs. 
The best method to stratify OA, however, is unclear. OA is considered highly 
heterogeneous and alongside variables relating to the initiation of OA and genetics, joints 
vary in terms of clinical symptoms and biochemical temporal profiles (Driban et al., 2010; 
Kraus et al., 2015; Mobasheri et al., 2017). Mechanism of onset is perhaps the most 
obvious way to sub-categorise OA. Whilst age related-OA is difficult to predict, patients 
who have an increased risk of secondary OA due to joint trauma or genetical 
predisposition might identify younger patients at an early stage of disease progression 




consider this the demographic most in need of a cure or at minimum a long-term solution, 
as opposed to the current best option of mid-length joint replacement. 
1.2. Trauma Induced Chondral Defects 
Joint trauma, either to the cartilage directly or to the other structures of the joint have been 
shown to substantially increase the risk of OA accounting for 12% of all cases (Gelber et 
al., 2000). These can be either single or repetitive injuries and include any kind of acute 
physical trauma such as a sports injury, vehicle accident or fall. The pathogenesis and 
transition from a chondral defect to established OA is not well-characterised, with limited 
evidence as to which lesions are likely to progress to OA (Punzi et al., 2016). One potential 
route is through changes in biomechanics. Even a small cartilage defect, or change in gait 
due to damage to ligaments, tendons or other joint tissues, has the potential to change 
the biomechanical properties of the joint. This alters the load distribution on the articular 
surface and the strains on the joint tissues (Gomoll et al., 2010). These changes increase 
the likelihood of widespread cartilage degeneration by affecting joint movement, 
mechanical wear and attrition of opposing surfaces as well as the formation of loose 
debris. At the cellular level, the damage of cartilage can be characterised by cell death 
and inflammatory events that can affect the biology of the entire joint compartment (Punzi 
et al., 2016).  
Patients presenting to clinicians with OA that was initiated from a joint trauma injury are 
on average over 10 years younger than those whom progress to OA from an alternative 
aetiology (Gelber et al., 2000). Whilst total joint replacement is effective for established 
degenerated joints, this treatment strategy is not viable for this younger patient group 
before extensive OA changes develop. These patients ideally require a life-long treatment 
to regain full use of their joint and to reduce their risk of progression to OA. This would be 
achieved by re-establishing a normal articular surface (Caldwell and Wang, 2015; Zhang 
et al., 2016). Furthermore, before OA onset these patients have a relatively ‘normal’ joint 
environment compared with a chronic OA joint. It is perhaps then obvious to try and 
intervene at this stage to repair the injured tissue rather than wait and treat a disease of 
the whole joint.  
To summarise, it is widely considered that a less invasive intervention, earlier in disease 
progression, which can regenerate damaged articular cartilage, would be more effective 
in these patients. Importantly, it is in these individuals that one may have the best chance 




1.3. Cartilage Regeneration 
Several approaches are being investigated for the regeneration and long-term repair of 
articular cartilage (Marenah et al., 2018). These include the use of scaffolds and the 
transplantation of cells, with the aim to improve or replace the low innate capacity of 
cartilage to regenerate. Nevertheless, the clear dominance of joint replacements partly 
reflects the difficulties that have been encountered trying to address this need.  
First, it is worth considering what the ideal situation would be. The answer is simple: to 
restore the tissue to its pre-trauma or pre-disease state. Consequently, there would be a 
lack of scar formation following repair, which, for most adult tissues is not achieved by 
endogenous healing. In the case of cartilage, scar formation is particularly problematic as 
it can disrupt the smooth articular surface and lack full integration with the surrounding 
cartilage. This can have detrimental implications, disrupting the mechanical properties 
that allow for even loading of the joint and pain free movement (Tiku and Sabaawy, 2015). 
This has been the primary difficulty in the field; establishing cartilage that displays 
mechanical and functional characteristics that are comparable with native articular 
cartilage and result in pain free movement. 
1.3.1. Basic cartilage biology 
To design new strategies, a good understanding of the tissue of interest is first required. 
Articular cartilage contains a single cell type, the chondrocyte. These cells are individually 
isolated within lacunae surrounded by extracellular matrix (ECM). Relative to the volume 
of the tissue, chondrocytes are sparsely distributed, and rely predominantly on diffusion 
for nutritional support. These cells are responsible for producing, sustaining and 
degrading the ECM (Gosset et al., 2008). The chondrocytes of articular cartilage are 
distinct from chondrocytes located in other cartilaginous tissues, such as the ear and nasal 
septum, in terms of the matrix they produce. The two main macromolecules in articular 
cartilage matrix are produced by these cells: the large proteoglycan aggrecan and type II 
collagen. However, articular cartilage is not homogenous and displays a zonal structure 
with four distinct zones: superficial, transitional (middle), deep, and calcified (Figure 1-4). 
Each zone has unique properties relating to cell density and morphology, collagen fibre 





Figure 1-4 – Schematic describing the architecture of articular cartilage 
Cross-sectional diagram showing the zonal structure of healthy articular cartilage with 
differing cellular (A) and collagen fibre compositions (B) ( image adapted from Fox, Bedi 
and Rodeo, 2009). 
The superficial layer of articular cartilage, which directly apposes the other articular 
surface in the synovial joint, contains cells which are flat in shape and produce large 
amounts of proteoglycans including aggrecan, lubricin and proteoglycan 4 (PRG4) (Tiku 
and Sabaawy, 2015). These glycoproteins maintain the integrity of the superficial zone, 
whilst providing lubrication and resistance to shear stresses. This is fundamental to 
protect and maintain the deeper cartilage layers.  
Below the superficial zone, in the middle zone, chondrocytes are rounder and surrounded 
by randomly organized collagen type I fibrils, whilst in the deep zone these cells are 
ellipsoid and stacked in cell columns parallel to the collagen fibres orientated 
perpendicular to the articular surface. This deep zone has the highest proteoglycan 
content and the lowest water concentration and is believed to provide an important role in 
the distribution of aggrecan and collagen ensuring cartilage can maintain its mechanical 
function. Below this layer, cartilage is calcified acting as a transitional zone by anchoring 
the overlying hyaline cartilage to the subchondral bone. Containing hypertrophic 
chondrocytes, this zone is separated from other layers of cartilage by the ‘tidemark’ 
boundary marking the mineralisation front. 
The ECM of each of these layers is continually remodelled through normal tissue turnover 
with chondrocytes replacing lost macromolecules (Goldring and Marcu, 2009). Whilst 
metabolically active, chondrocytes rarely divide after skeletal growth is complete. Dogma 
has long held that the cartilage lacks a progenitor cell population. In recent years however, 
this has been challenged by multiple research groups and the superficial zone of articular 
cartilage has been reported to contain cells with stem-like properties (Dowthwaite et al., 




that articular cartilage has a resident population of cells with the potential under certain 
circumstances to regenerate the tissue. 
1.3.2. Endogenous repair of defects 
Articular cartilage defects are generally centred on load bearing areas and can be limited 
to the cartilage as chondral defects or extend into the bone when they are termed 
osteochondral defects (Brittberg et al., 1994). It has long been argued that defects solely 
of the cartilage have little capacity to repair, with the characteristics of cartilage suspected 
to be the primary problem. The isolation of individual chondrocytes, with a lack of 
proliferation and migration ability, was first proposed in the 18th century to be the 
compounding factor restricting the ability of the cartilage to heal spontaneously (Marmotti 
et al., 2013a). Articular cartilage has since been considered to have a poor intrinsic 
regeneration potential attributed to its low cellularity, lack of vascularity and the dense, 
hydrated extracellular matrix that inhibits cellular migration in and around the tissue.  
Alongside the identification of chondro-progenitors, there is now evidence that the 
cartilage does attempt some level of repair. Molecular processes such as the expression 
of proteases and the release of growth factors which occur in other wounds do exist (Tiku 
and Sabaawy, 2015). Furthermore, studies in OA have demonstrated an increase in 
matrix synthesis as well as cell proliferation - with clusters of chondrocytes forming at the 
borders of the damaged cartilage. These clusters of six or more chondrocytes residing in 
one large lacuna are considered a hallmark of OA. Seol et al., (2012) published evidence 
that localised chondrocyte death activates clonogenic cells to migrate towards the injury 
boundary (Seol et al., 2012). Importantly, however, it is not yet known if this proliferative 
response is a true attempt at endogenous regeneration by the cells of the cartilage (Lotz 
et al., 2010). As a consequence, it is worth noting that, although it is well reported that 
chondral defects fail to heal, it may simply be that those that successfully heal are not 
clinically investigated.  
Whilst the regenerative capacity of chondral-only defects is unclear, osteochondral 
defects (see Figure 1-5), which bleed on penetration of the underlying subchondral bone, 
are well accepted to generate a level of endogenous repair. If small enough, it is thought 




        
Figure 1-5 – Schematic of osteochondral and chondral defects 
Depiction of the difference in depth of osteochondral and chondral defects. The former 
penetrates through the calcified cartilage into the subchondral bone whereas chondral 
defects only damage the overlying articular cartilage.  
The bone marrow that fills the cavity of the long bones and lies beneath the subchondral 
bone plate is a well-characterised microenvironment. Bone marrow has long been used 
as a source for cellular therapy because it contains an array of different cells; from mature 
differentiated cells, to cells more ‘stem-like’ in nature which harbour multipotent potential. 
These properties make it a primary site for stem cell and tissue regeneration research. 
Cell types include inflammatory cell progenitors, haematopoietic stem cells and vascular 
progenitors all of which are thought to contribute to wound repair. Further, multipotent 
cells capable of differentiating into cartilage and bone are present; mesenchymal 
stem/stromal cells. Which cells of the bone marrow play a role in the endogenous repair 
of osteochondral defects is yet to be fully elucidated, but much research surrounds the 
recruitment, migration and cell therapy usage of this latter cell type into the defect site. 
Unfortunately, unlike the ideal and original hyaline cartilage, the fibrocartilage produced 
by the repair of osteochondral defects lacks the highly organised structure and 
biomechanical properties of healthy hyaline articular cartilage. It can be considered scar 
tissue, lacking some aspects of the biomechanical properties believed necessary for 
durable long-term repair. However, the formation of a scar is an improvement on a wound 
and is considered to be superior to a chondral defect. Surgeons aim to replicate this 
endogenous repair capability using bone marrow stimulation techniques such as 
microdrilling and microfracture. 
1.3.3. Mimicking endogenous repair using the microfracture technique 
Microdrilling was first developed by Pridie in 1959 (Pridie and Gordon, 1959) where 




bore through to the marrow cavity. Pressure within the marrow cavity leads to extrusion 
of blood and bone marrow into the defect site to form a clot. The microfacture technique 
was subsequently developed in the 1980s by Steadman (Steadman et al., 1997) where 
an awl is used rather than a microdrill as used in microdrilling (see Figure 1-6).  
The ultimate intention of bone marrow stimulation techniques is to bring about the 
endogenous repair seen in naturally occurring osteochondral defects. Unfortunately, like 
the naturally-occurring repair tissue, the surgically-induced defects result in the formation 
of fibrocartilage-like repair tissue (Caldwell and Wang, 2015). It is recognised, however, 
that the microfracture technique while beneficial in providing effective short-term 
functional improvement to patients, (Mithoefer et al., 2009) it is not a long-term solution. 
This is due to concerns in the durability of the repair that is thought to be unable to 
withstand the demands of everyday activities resulting in the return of clinical symptoms 
(Fellows et al., 2016).  
Currently this technique is used in patients who are preferably younger than 45 years of 
age, have a body mass index below 30, and have experienced symptoms for less than 
one year. Contraindications include degenerative joint diseases and axial malalignment 
(Steadman, Rodkey and Briggs, 2010). For this reason, microfracture addresses a patient 
stratification category that identifies early trauma-induced cartilage defects, being useful 
as a preventive measure against the development of OA in the affected joint.  
 
Figure 1-6 - Microfracture surgical technique.  
(A) Debridement to generate a clear margin, (B) Removal of calcified cartilage, (C) 
Microfracture penetration within the cartilage defect, (D) Penetration through to the bone 
marrow results in filling of the defect with a mesenchymal blood and bone marrow clot 




1.4. The Relationship between Cartilage and Bone  
Bone marrow stimulation techniques like microfracture disrupt the structure and 
mechanical integrity of subchondral bone. This is believed to play a part in the healing 
response of the osteochondral tissues as bone and cartilage are tightly coupled; the 
disruption of either tissue can have adverse effects on the other. For example, some 
cartilage defects have been linked to changes in the underlying bone, such as in 
osteochondritis dissecans (Gomoll et al., 2010) and malalignment of joints (Li et al., 2013). 
Further, it has been proposed that cross-talk and physical connections between cartilage 
and its underlying bone could be partly responsible for the pathogenesis of OA (Li et al., 
2013). This highlights the important interplay between these two tissues. As the 
understanding of these interactions improves, cartilage defects are being increasingly 
viewed as a problem of the entire osteochondral unit, rather than limited to the surface 
cartilage alone (Gomoll et al., 2010). Here, the development of the bone, the synovial joint 
and articular cartilage will be discussed.  
1.4.1. The development of bone  
Alongside their relationship in the adult skeleton, cartilage and bone also have a close 
connection in terms of developmental biology. Understanding developmental biology is 
considered critical in the field of regenerative medicine, as it is the process a regenerative 
treatment ideally recapitulates. It is therefore worthwhile to briefly overview this process. 
Developmental biology describes the formation of three germ layers during 
embryogenesis; the ectoderm, mesoderm, and endoderm. Individual skeletal segments 
develop through either intramembraneous ossification or endochondral ossification 
(Mackie, Tatarczuch and Mirams, 2011). The flat facial bones develop via the former, 
whereby bone is lain directly onto fibrous connective tissue. Long bones of the skeleton, 
on the other hand, develop by endochondral ossification that differs as a temporary 
cartilage scaffold precedes the formation of bone. This second ossification method will be 
discussed further in section 1.4.2.1 due to its relevance to long bone and bone marrow 
formation. 
1.4.2. Synovial joint and articular cartilage development 
The cartilaginous model (the anlagen) of the appendicular skeleton is formed from the 
lateral plate mesoderm by condensations at the limb bud, forming rod-like structures of a 
temporary cartilage scaffold, sheathed by perichondrium. This is a continuous and 
uninterrupted structure until segmentation occurs where a stripe of mesenchymal tissue 
forms the joint interzone beginning synovial joint formation (Archer, Dowthwaite and 
Francis-West, 2003; Koyama et al., 2008; De Bari, Kurth and Augello, 2010). 




outermost layers contribute to the adult articular cartilage and the inner layer, alongside 
surrounding mesenchyme, contributes to multiple joint tissues including the synovial 
membrane, menisci and ligaments as well as superficial zone chondrocytes. The 
contribution to the adjacent long bone cartilaginous shaft, on the other hand, is negligible.  
 
Figure 1-7 – Synovial joint development 
Schematic representation of synovial joint development that begins by cavitation of the 
mesenchyme limb bud at the interzone. Cells of the interzone subsequently contribute to 
the tissues of the articular cartilage and synovial lining (image from De Bari, Kurth and 
Augello, 2010).  
1.4.2.1. Endochondral ossification 
The formation of the synovial joint occurs simultaneously with the initiation of 
endochondral ossification of the cartilaginous scaffold. Limb bud cells differentiate into 
chondrocytes, proliferate, mature and undergo hypertrophy within each condensation. 
The scaffold structure is then ossified and replaced by bone, a process that is achieved 
by the coordinated action of a number of different cell types (Mackie et al., 2008).  
At the onset of ossification, vasculature invades and tissue mineralises before bone 
remodelling occurs (Sivaraj and Adams, 2016). Remodelling is a process where old bone 
is resorbed by osteoclasts (phagocytic multinucleated cells derived from the monocytic 
haematopoietic lineage) and new bone laid down by osteoblasts (large cuboidal cells 
which are very active protein secretors, derived from the mesenchymal stem cells). As 
this remodelling takes place, large-calibre sinusoid-type blood vessels form and 
haematopoietic progenitors home to this microenvironment leading to the formation of 
bone marrow. 
Bone remodelling continues throughout life to maintain the structural integrity of the 




is complete and concordantly this process repairs ‘wear and tear’ microdamage. 
Furthermore, it is noteworthy that this process of endochondral ossification is an example 
of a developmental process that re-occurs in the adult, during fracture healing where a 
cartilaginous callus forms followed by mineralisation to regenerate the bone (Baron and 
Kneissel, 2013; Sims and Martin, 2014). 
1.5. Mesenchymal Stromal / Stem Cell  
Both chondrocytes, bone forming osteoblasts and other mature cells of bone (osteocytes 
and bone-lining cells) are thought to be derived from a common multipotent progenitor. 
Discovery of the existence of this cell type built momentum in the 1960s. Firstly, Tavassoli 
and Crosby (1968) established that postnatal bone marrow suspensions (devoid of bone) 
has an inherent osteogenic potential. Friedenstein and co-workers followed this with a 
series of seminal studies demonstrating this was associated with a subpopulation of bone 
marrow cells (Friedenstein et al., 1968; Owen and Friedenstein, 1988). Further, these 
cells were able to form ectopic ossicles comprising of multiple skeletal tissues, including 
bone, cartilage and haematopoietic bone marrow when transplanted under the renal 
capsule (Tavassoli and Crosby, 1968). Thus, the hypothesis that these tissues were 
derived from a single progenitor cell population was born. Over time, this progenitor 
population has been refined to describe an adherent non-haematopoietic cell type that is 
capable of self-renewal and demonstrates multipotency – commonly described as a 
Mesenchymal Stromal / Stem Cell (MSC).  
1.5.1. Identifying MSCs  
1.5.1.1. In vitro 
MSCs are now commonly defined by their adherence to plastic, their ability to form 
fibroblastic colony forming units (CFU-F) in vitro (indicative of self-renewal) and their 
osteogenic, chondrogenic and adipogenic in vitro potential (indicative of multi-potency), 
as demonstrated by the production of mineralised, polyanionic, and hydrophobic material 
respectively (Bianco et al., 2013).  
In 2006, the International Society for Cellular Therapy (ISCT) published a seminal paper 
proposing a profile of cell surface markers in an attempt to improve comparability across 
MSC research (Dominici et al., 2006). Surface markers are a modern staple of biology, 
used to help identify and classify cells. However, although many markers have been 
reported to identify MSCs, no single marker is uniquely expressed by these cells. Much 
research has gone into looking for an elusive definitive MSC marker and there is currently 
a whole array under investigation. The ISCT paper defines a minimal criteria for MSCs: 
positive phenotypic expression of surface molecules CD105, CD90 and CD73, whilst 




monocytic (CD14 or CD11b), B cell (CD79a or CD19), and lacking the expression of HLA 
class II (Dominici et al., 2006).  
These criteria have been adopted as best practice and are widely used as a retrospective 
identification strategy of culture expanded cells (De Bari, Kurth and Augello, 2010; da 
Silva Meirelles, Caplan and Nardi, 2008). A key insufficiency of the phenotypic analysis 
conducted in many papers is the reporting of global expression of these markers across 
the cell population under investigation rather than characterisation to the level of the single 
cell. Dominici et al. (2006) suggest that multicolour analysis would be optimal, but little 
has been published as to whether individual cells express the entire set of ICTS markers.  
1.5.1.2. In vivo 
To date most of the work on MSCs has been based in vitro on plastic adherent, culture 
expanded cell populations and a true in vivo correlate of these cells has yet to be 
identified. To understand the in vivo biology of MSCs there is a need for the ability to 
locate and track their role in their native environment. Dominici and colleagues’ (2006) 
focused on ex vivo identification of MSCs and to date the research community has yet to 
find a consensus on in vivo identification. This lies in part down to the lack of a single 
(unique) marker. Markers that have been suggested include leptin receptor and nestin 
(Wang et al., 2014). 
1.5.2. MSC terminology  
The appropriate name for these cells remains controversial. Friedenstein and Owen called 
this cell type an osteogenic stem cell (Friedenstein, Chailakhyan and Gerasimov, 1987)  
and then a bone marrow stromal stem cell (Owen and Friedenstein, 1988). In 1991 Caplan 
coined the term mesenchymal stem cell based on these studies and in vitro evidence that 
these cells could differentiate in vitro into other mesenchymal lineages (Caplan, 1991).  
1.5.2.1. Derived from the mesoderm? 
Whilst bone marrow MSCs can be considered the ‘conventional’ MSC, being the first 
tissue from which these cells were identified (Friedenstein, Chailakhyan and Gerasimov, 
1987). Cells that adhere to plastic, form CFU-Fs and are tri-potent have since been 
isolated from most connective tissues including skeletal muscle (Uccelli, Moretta and 
Pistoia, 2008) and placenta tissue (Talwadekar, Kale and Limaye, 2015). With this ability 
to isolate from these tissues, research have also shown an ability to differentiate MSCs in 
vitro isolated from different tissues down other mesoderm lineages, for example myogenic 
(Drost et al., 2009). One could therefore postulate that the MSC represents a common 
progenitor of all non-epithelial, non-haematopoietic tissues that are developmentally 




In addition to differentiation down mesodermal lineages other than skeletal tissues, 
reports have also been made of differentiation of MSCs to cells classically defined as cells 
of ectodermal origin; such as neurons (Scuteri et al., 2011) and epithelial skin cells 
(Păunescu et al., 2007). One therefore might claim that MSCs are capable of 
differentiation down numerous lineages of all three developmental layers. However, there 
are reasons to be hesitant to reach this conclusion. Namely, culture conditions can 
fundamentally alter cell properties. It is well accepted that in vitro conditions are unable to 
replicate the environment found in a cell’s original anatomical location and in biology 
generally, it is recognised that cells can be induced to undergo differentiation by 
reprogramming in vitro. This leads to experimental artefacts and difficulties in interpreting 
functional assays performed in vitro. 
This same argument can be made against the MSC status of MSCs derived from 
mesodermal tissue other than bone marrow. Bianco and Robey, define MSCs from these 
tissues as being ‘inducible’ rather than ‘determined’ skeletal progenitors (Bianco and 
Robey, 2015). In support, it has been demonstrated that just because a cell can undergo 
tri-lineage differentiation in vitro it does not translate to in vivo potential. Reinisch and 
colleagues, compared MSCs derived from human bone marrow, white adipose tissue, 
umbilical cord, and skin (Reinisch et al., 2015). Whilst the populations have similar 
phenotypic profile matching the ISCT panel and were differentiated down osteogenic, 
chondrogenic and adipogenic lineages in vitro, only the bone marrow derived MSCs were 
able to form a haematopoietic microenvironment consisting of bone through a cartilage 
intermediary structure, in vivo.  
1.5.2.2. Developmental origins? 
In addition to the arguments discussed above, Bianco and Robey strongly dispute that 
cells from connective tissues other than the skeletal tissues are equivalent stating they 
are ‘developmentally distinct from skeletal lineages’. One must consider however, the 
developmental ontogeny of bone marrow and all other prospective MSCs is unclear.  
Based on knowledge of long bone development, it might be expected that the limb bud, 
from which the anlagen forms, contains cells capable of both cartilage and bone formation. 
Mendes et al. (2005) through in vitro characterisation aimed to prove this. They performed 
anatomical mapping and frequency analysis of mesenchymal progenitors by their isolated 
from different tissues, reporting that cells of the limb bud were pre-chondrogenic but 
unable to differentiate down osteogenic or adipogenic lineages in vitro. This disputed 






Figure 1-8 – Schematic of a mouse embryo at E11 
Schematic to illustrate tissues of a mouse embryo 11 days of age. YS, yolk sac; Lb, limb 
bud; H, heart; L, liver; AGM, aorta-gonad-mesonephros; U, umbilical artery; vitelline artery 
(Mendes, Robin and Dzierzak, 2005). 
Like the mesenchymal cells that make up the limb bud, osteoblasts are derived from the 
lateral plate mesoderm as demonstrated by cell tracing using the Hoxb6 gene reporter 
mouse (Isern et al., 2014). The aorta-gonad-mesonephros (agm) region (see Figure 1-8) 
is also derived from the lateral plate mesoderm, and it is in this region that Mendes et al. 
(2005), at the E11 stage of mouse development, solely located cells capable of tri-lineage 
differentiation indicative of MSCs.  
Later developmental time points, on the other hand, located MSCs to primary 
haematopoietic tissues including the liver and bone marrow. MSCs have been found in 
the circulation of mouse embryos between E12 and E14 but disappeared by E17 
(Mendes, Robin and Dzierzak, 2005) and in human foetal blood, liver and bone marrow 
during the first trimester (Campagnoli et al., 2001). If MSCs are derived from the same 
developmental lineage, this could define a potential migratory route for MSCs to reach the 
multitude of tissues from which they have been isolated and could identify a 
developmental relationship between these cells. 
In support of this, much has been made of the similarities between MSCs and pericytes. 
Pericytes are found in all tissues but are not a cell lineage – they are defined 
morphologically based on their location relative to endothelial cells. They are recruited to 
this location from the surrounding tissue during organ development and growth (Bianco 
et al., 2013). Additionally, many markers including Nestin (Ferraro et al., 2011), CD146 
(Sacchetti et al., 2007), and CXCL12 (in the mouse) (Bianco, 2011) used to identify 
putative MSCs in vivo identify cells localised adjacent to blood vessels. Noteworthy, 
however, is that not all pericytes have the unique properties of MSCs and most 




In conclusion, the validity of the term ‘mesenchymal’ in MSC remains contentious. Either 
way, whether MSCs are comparable in adulthood is another question and one that is more 
important to regenerative repair. Importantly, researchers want to be assured that all cells 
studied under the term MSC are equivalent. As discussed, to date the main way in which 
this has been done is by utilisation of the in vitro tri-lineage differentiation assay, but this 
lacks scientific rigour. Nonetheless, this method did receive support in the ISCT position 
paper that defined this as a method to define ‘multipotent differentiation potential’ 
(Dominici et al., 2006).   
1.5.2.3. True stem cells? 
Till and McCulloch (Becker, A. J., McCulloch, E. A. & Till, 1963), were the first to propose 
the concept of a stem cell; a cell capable of self-renewal and multipotency, through their 
work on hematopoietic stem cells using the clonal colony formation assay. Functional 
assays have since become the principle method used to identify all stem cells. True 
haematopoietic stem cells are now identified by long-term reconstitution assays through 
serial transplantation. This in vivo assay provides evidence that the original cell is capable 
of generating fully differentiated tissues – in this case mature cells of the blood – and is 
able to reconstitute cells identical in phenotype and potency to itself. This defines the 
properties of multi-lineage and self-renewal respectively. 
The heterotopic ossicle assay, developed from work by in Tavassoli and Crosby, is 
considered the equivalent assay for an MSC to demonstrate multipotency - the formation 
of a miniature bone organ with the correct histology, architecture and skeletal cell/tissue 
types, driven independently from exogenous, skeletogenic cues. The resulting structure 
is thought to be the progeny of MSCs alone, forming bone, cartilage, adipocytes, 
fibroblasts and haematopoiesis supporting stroma. The ability to generate this ectopic 
ossicle is now considered a more reliable piece of evidence that an MSC is truly a 
multipotent progenitor. Additionally, Bianco (2008) argued that to truly claim a cell is an 
MSC, the progeny of a single cell would need to be evaluated for the formation of multiple 
tissues in vivo. This originates in the widely accepted concept that primary MSC cultures 
are heterogeneous populations, secondary to the heterogeneity observed between tissue 
sources.  
In 2007, Sacchetti, Bianco and colleagues, published the first evidence of self-renewal 
using this assay (Sacchetti et al., 2007). They took single human bone marrow MSCs 
identified by their cell surface phenotype and generated a heterotopic ossicle (using a 
hydroxyapatite carrier). Subsequently, MSCs were harvested from this ossicle, clonally 
grown in vitro and characterised as phenotypically the same as the originally transplanted 




More recent work, by Mendez Ferrer et al. (2010), added further supportive evidence. 
Ceramic porous cubes have been used by multiple groups to demonstrate multi-lineage 
differentiation in vivo as MSCs can form an ossicle around this pro-osteogenic structure. 
By transplanting clonal Nestin positive mesenspheres (aggregates of MSCs cultured 
under non-adherent conditions, which have been shown to be multipotent), the authors, 
demonstrated that enzymatic digest of the ossicle formed, contained cells which were 
able to generate ossicles on a second serial transplantation and directly formed 
osteoblasts (Méndez-Ferrer et al., 2010). 
These two studies (Sacchetti et al., 2007; Méndez-Ferrer et al., 2010) provide evidence 
that MSCs isolated from human bone marrow fulfil the criteria required to claim a cell is a 
stem cell.  
1.5.2.4. The name then is…… 
To summarise, the ‘mesenchymal stem cell’ name has some merit but there are concerns 
in naming all cells that display similar in vitro characteristics as the same population. In 
the ideal world, all MSCs used for experiments on differentiation potential would be 
characterised by their ability to form heterotopic ossicles or ideally, a phenotypic marker 
that identifies a cell capable of this function would be identified. 
The MSCs used in this thesis for in vitro assays are derived from bone marrow. These are 
a heterogenous population and there are likely to be differences between donors. 
Nevertheless, the use of standard isolation strategies and the published literature 
discussed demonstrate that these populations contain multipotent stem cells capable of 
skeletal lineage differentiation in vivo. For these reasons, BMSC is used as an acronym 
of bone marrow (mesenchymal) stem/stromal cells in the studies presented here.  
1.6. Cellular Therapy to Aid Cartilage Repair 
Cell therapy is a platform technology available to achieve a regenerative therapy as such 
it is of clinical utility in the field of cartilage repair and regeneration. 
1.6.1. Chondrocytes 
Autologous chondrocyte implantation (ACI) is the most well-established cell therapy within 
the field of articular cartilage repair and was approved for clinical use in the USA in 1997. 
It requires the isolation of chondrocytes from a non-weight bearing zone, their ex-vivo 
culture and re-implantation into chondral defects. The technique was first trialled in 23 
patients diagnosed with full-thickness articular cartilage defects in 1984, with results 
indicating a clinical benefit (Brittberg et al., 1994); reduced pain and swelling and similar 
macroscopic appearance to surrounding cartilage when observed by a second-look 




Since 2017 the use of ACI has been approved by National Institute of Clinical Excellence 
(NICE) in the UK (NICE, 2017). This suggests the treatment has a positive cost–benefit 
ratio, previously an area of contention, due to the expense and difficulties associated with 
harvesting and culturing procedures. Various studies have been conducted to compare 
the outcomes of ACI versus microfracture. A Cochrane review (Vasiliadis and Wasiak, 
2010) concluded that little difference is observed between the two procedures within the 
first 18 months but ACI repair has better functional results at 3 years. In the UK the 
treatment is indicated for patients with minimal osteoarthritic damage of the knee and 
cartilage defects greater than 2 cm2 in size where symptomatic management has failed, 
but joint replacement is not indicated. 
1.6.2. Stem Cells 
Although the use of mature cells such as chondrocytes has proved beneficial in the field 
of cellular therapy, stem cell research has moved to the forefront of regenerative medicine. 
Endogenously these cells are vital to the natural turnover and repair of various tissues, 
and as a result are thought to be a pool of regenerative cells that could be utilised for 
clinical treatment strategies. Whilst stem cells can differentiate into specific cell types, 
these cells also secrete a variety of growth factors and cytokines that have the potential 
to orchestrate tissue repair and regeneration.  
In recent years, publications using multiple cell populations including stem cell types have 
been published in relation to cartilage regeneration and repair. These included peripheral 
blood mononuclear cells (Hopper et al., 2015), haematopoietic stem cells (Saw et al., 
2013) and chondroprogenitors derived from embryonic stem cells (Cheng et al., 2014). 
MSCs, however, have dominated the research field of cartilage cellular therapy with the 
evidence of their ability to differentiate into chondrocytes and ease of isolation the initial 
driving force behind their use. Relative to chondrocytes they have the clear advantages 
of having a greater in vitro proliferation potential and importantly, the ability to be sourced 
from a choice of different tissues.  
1.6.3. MSCs 
Many studies, including clinical studies, have looked into the benefit of MSCs as a cell 
therapy for regenerative therapy of bone and articular cartilage. However, the cell fate and 
mechanistic action of these cells has been overlooked. As discussed it is well recognised 
that MSCs have the ability to differentiate into cells that make up bone and cartilage tissue, 
representing great potential for regenerative medicine. However, in recent years, there is 
a growing appreciation that MSCs in tissue regeneration and repair may act through a 
trophic role. This suggests that MSCs are acting as an orchestrator of the tissue 





1.6.3.1. Do MSCs contribute directly to repair? 
The heterotopic ossicle model is a clear demonstration of the ability MSCs have to form 
cartilage and bone in vivo. There is good evidence that bone marrow MSCs are able to 
recapitulate this in a regenerative environment. They have been administered clinically 
for the treatment of osteogenesis imperfecta (da Silva Meirelles, Caplan and Nardi, 2008) 
and fracture repair (Thompson et al., 2002; Huang et al., 2015), where they engraft, 
differentiate and contribute to newly formed bone. It may be presumptive, however, to 
assume that they are able to do this in the setting of a synovial joint and the regeneration 
of articular cartilage where the microenvironment conditions may be unfavourable for 
chondrogenic differentiation. 
 
Figure 1-9 – Possible roles of MSCs in tissue repair 
When tissue is damaged MSCs are mobilised to the site where they are thought to have 
two possible roles in tissue repair, acting as a tissue progenitor and differentiating into 
functional cells of the damaged tissue and/or altering the micronenvironment of the repair 
as an orchestrator of tissue repair (image adapted from Wang et al., 2014) 
1.6.3.2. Do MSCs orchestrate repair? 
MSCs are thought to be able to respond to their surrounding microenvironment and 
consequently that of an injury site. As a result, they secrete reparative site-specific factors 
such as paracrine growth factors, cytokines, extracellular vesicles as well as directly 
influencing their neighbouring cells through cell-to-cell interactions. MSCs, therefore, have 
the potential to influence the viability and proliferation of native cells (including tissue-
intrinsic progenitors), induce angiogenesis and reduce apoptosis. Additionally, they are 
thought to reduce inflammation and alter immune cell responses (Németh et al., 2009). 
Further, MSCs produce inhibitors of pro-inflammatory cytokines such as interleukin 1 
receptor antagonist (Ortiz et al., 2007). In models of OA they have been shown to hinder 




for OA unresponsive to conservative treatments, injection of MSCs alone improved MRI 
assessed cartilage quality (Orozco et al., 2013). 
Importantly, MSCs have been reported to localise to sites of injury, through specifically 
broken or inflamed blood vessels (Caplan and Correa, 2011). Furthermore, in vitro work 
has shown they can increase the proliferation and ECM production of the chondrocytes 
(Wu et al., 2012). Through these mechanisms, MSCs are proposed to establish a specific 
microenvironment that aids the regeneration of an injured tissue including articular 
cartilage repair. 
1.6.3.3. A third role? 
Finally, the issue is further complicated by the role that MSCs are believed to play in 
haematopoietic cell biology. Some argue that the ability of bone marrow MSCs to support 
haematopoiesis is their defining feature (Bianco, Robey and Simmons, 2008). In 1977, 
Dexter et al. showed that cells isolated from mouse bone marrow by plastic adherence 
could maintain primitive haematopoietic cells (Dexter, Allen and Lajtha, 1977); this was 
later confirmed in human cell cultures (Gartner and Kaplan, 1980). The interactions of 
haematopoietic stem and progenitor cells with their local microenvironment in the bone 
marrow is an area of significant research output documenting the capability of MSCs to 
be supportive stroma for haematopoietic stem and progenitor cells both in vitro and in 
vivo. What role this interaction has in reverse, i.e. the effect of the interaction on the MSCs 
themselves, has on the other hand, only been minimally explored.  
1.7. The Bone Marrow Niche 
1.7.1. Stem cell niches 
A stem cell niche is a specialised microenvironment that maintains a balance between 
stem cells in an undifferentiated and self-renewable state, against the promotion of their 
differentiation. Within a niche, there is a constant dialogue between the stem cells and 
their surrounding niche cells. Depending on the organism and the stem cell type, these 
niche cells and the physical structure of the niche can vary greatly. A C. elegans 
hermaphrodite gonad, for example, provides a niche for germline stem cells and is made 
up of a single cell, the distal tip cell (Byrd and Kimble, 2009). In mammals, there are 
multiple stem cell niches. For example, paneth cells in the human gut provide essential 
niche signals for the stem cells of the gut epithelium (Sato and Clevers, 2013). The 
haematopoietic bone marrow niche, on the other hand, is a significantly more complex 
highly organised three-dimensional microenvironment, with a plethora of cell types 
thought to be involved. Based on these examples, one might anticipate that all stem cells 




1.7.2. MSC niche 
As discussed previously (section 1.5), bone marrow MSCs have been found to have stem 
cell properties of self-renewal and multipotency in vivo. It is debatable whether MSCs 
require a specific niche. MSCs of the bone marrow, and those from other tissues, have 
been identified in a perivascular location, which perhaps identifies their niche. On the other 
hand, Sacchetti and colleague’s (2007) seminal paper reported that bone marrow MSCs 
cultured in vitro under standard conditions retained their self-renewal and multipotency on 
subsequent transplant in vivo. The maintenance of these properties outside of their native 
microenvironment would suggest that MSCs are more resilient than other types of stem 
cells and depend less on extrinsic signals.  
1.7.3. Haematopoietic stem cell niche 
Haematopoietic stem cells are defined as true stem cells because of their self-renewal 
capacity and multipotency. The classical model of the haematopoietic system has a 
hierarchical structure (see Figure 1-10); haematopoietic stem cells (HSCs) at the top 
which, through an intrinsic network of transcription factors and inputs from the surrounding 
environment undergo progressive lineage restriction. Through asymmetrical cell division, 
HSCs ensure a constant supply of all the mature blood cells, in the process defined as 
haematopoiesis, whilst maintaining their numbers through self-renewal.  
 
 
Figure 1-10 – Classical model of haematopoiesis.  
Through a series of more committed progenitors, a population of multi-potential 
haematopoietic stem cells (HSCs) are able to supply all cells of the haematopoietic 
system. LT-HSC, long term HSC; ST-HSC, short term HSC; MMP, multipotent 
progenitors, CMP, common myeloid progenitor; CLP, common lymphoid progenitor 




The bone marrow niche, termed by Schofield in 1978, provides the microenvironment 
necessary for the survival of haematopoietic stem cells and through intricate signals 
influences the fate decisions of these haematopoietic precursors; to self-renew, proliferate 
or differentiate (Ho et al., 2015). Without this environment, it is thought lifelong 
haematopoiesis would not be possible; all HSCs would commit to lineage differentiation 
(Schofield, 1978). Whilst it may well be the most widely investigated, the components, 
location, and functions of the HSC niche remain elusive. 
1.7.4. BMSCs and their progeny are a significant component of the Bone Marrow 
HSC Niche 
It has been suggested that a supportive cell of the HSC niche should be rare, in physical 
proximity to HSCs and be found to express HSC maintenance genes (Frenette et al., 
2013). Numerous cell types have been investigated including endothelial cells, 
haematopoietic, neurones and skeletal cell types.  
 
Figure 1-11 – The bone marrow haematopoietic stem cell niche 
Haematopoietic stem and progenitors are supported by the microenvironment of the bone 
marrow niche that is comprised of multiple cell types. MSCs are located close to the 
vasculature but are also precursors for osteoblasts, another cell type important for HSC 
maintenance (image from Morrison and Scadden, 2014).  
1.7.4.1. Bone marrow stem/stromal cells 
The lack of an established single marker to mark all BMSCs, makes investigations into 
their niche role complex (Panaroni et al., 2014). It is widely accepted, however, that MSCs 




sinusoids in both humans and mice. In support of a role for BMSCs in the HSC niche, 
cells with a perivascular location in the bone marrow are known to express genes involved 
in the regulation of HSCs such as CXCL12 (Sugiyama et al., 2006) and SCF (Ding et al., 
2012). In mice, studies have been conducted ablating the expression of these molecules 
in cells thought to identify populations of BMSCs. For example, depletion of SCF in Prx1–
cre cells leads to the depletion of HSCs (Greenbaum et al., 2013), whilst ablation of 
CXCL12 expressing cells depleted HSCs as well as impairing the osteogenic and 
adipogenic potential of bone marrow cells (Omatsu et al., 2010).  
Further, transplantation studies into immune-deficient mice of human fluorescently 
labelled BMSCs demonstrated the ability of these cells to contribute to a functioning 
haematopoietic microenvironment in the mouse bone marrow (Muguruma et al., 2006). 
Additionally, human BMSCs are able to generate a haematopoietic environment as shown 
by the ossicle model, which is infiltrated by host (i.e. mouse) haematopoietic stem and 
progenitor cells  (Sacchetti et al., 2007). This demonstrates both the ability of BMSCs to 
generate a haematopoietic niche and be part of it; human BMSCs have been re-isolated 
from this organoid and found by histology to be associated in close proximity to host 
HSCs.  
1.7.4.2. Osteoblasts 
A role of osteoblasts specifically in HSC maintenance and differentiation was proposed 
from evidence demonstrating that these cells could produce cytokines known to play 
important roles in hematopoietic and myeloid development (Taichman and Emerson, 
1994). In vitro they are able to support short-term HSC expansion and haematopoiesis 
(Taichman and Emerson, 1994; Taichman, Reilly and Emerson, 1996) whilst in vivo the 
two cell types are seen to be co-localised at the inner surface of the cavities of trabecular 
bone (Zhang et al., 2003; Calvi et al., 2003). Furthermore, positive correlation between 
osteoblast and HSC number has been observed both by increasing numbers (Calvi et al., 
2003; Zhang et al., 2003) and in conditional osteoblast ablation studies in mice, where 
depletion leads to initiation of extra-medullary haematopoiesis outside of the bone marrow 
(Visnjic et al., 2004). Taken together these results support the notion that committed early 
stage osteoblasts support haematopoiesis. 
1.8. Manipulation of the BM Niche: HSC Mobilising Agents 
1.8.1. Haematopoietic stem cells can leave their niche 
Under basal conditions, the bone marrow niche is the principal location of HSCs and 
prevents their differentiation, apoptosis or activation by other stimuli that might be 
received, to maintain a fixed number of haematopoietic cells in the bone marrow. A small 




marrow is a normal physiological response (Hoggatt and Pelus, 2011). This peripheral 
population can increase in the case of infection, injury or inflammation, whereby HSCs 
are trafficked into the peripheral blood as a response to stress signals. This process is 
known as mobilisation. Thereafter, through differentiation and self-renewal processes, 
these cells and their progeny can help to achieve tissue clearance and reconstruction. To 
drive migration from the niche, interactions between HSCs and their supportive 
microenvironment must be disrupted. This innate mechanism can be manipulated 
pharmacologically with the use of cytokines and/or small molecule inhibitors (Lemoli and 
D’Addio, 2008). 
1.8.2. Interactions of HSCs with their niche 
As with the identification of cell types of the niche, understanding of the dynamic 
interactions is yet to be fully established. Direct cell-to-cell interactions have been 
identified which are thought to be essential in maintaining both HSCs in the niche and 
their stem cell nature (Jung et al., 2008). Adhesion molecules such as angiopoietin-1, 
Annexin II and VCAM-1 have been identified and demonstrated to play a role. Additionally, 
soluble signalling is thought to have a role. One important axis identified is the interaction 
of the chemokine stromal derived factor-1 (SDF-1/CXCL12) and its receptors CXCR4 and 
CXCR7 on HSCs (Bendall and Bradstock, 2014).  
1.8.3. Therapeutic Use of HSC Mobilising Agents 
Autologous or allogenic transplantation of bone marrow cells is the oldest form of anti-
cancer immunotherapy. Transplantation can re-establish the haematopoietic system from 
the top of the hierarchal structure following treatment of haematopoietic malignancies by 
whole blood irradiation. New agents and those currently under development are aimed at 
disrupting the interactions of HSCs with their niche pushing their egress into the peripheral 
blood system. AMD3100 is one such agent that targets the SDF1/CXCR4 interaction by 
specifically and reversibly binding to CXCR4 (Winkler et al., 2012). By targeting niche 
interaction molecules, mobilisation can be achieved within hours of administration of this 
compound. However, whilst this short time span is advantageous the international clinical 
bone marrow mobilisation standard and agent currently most widely used is G-CSF. This 
agent requires 4 to 6 days of administration before sufficient numbers of HSCs are present 
in the periphery harvest (Lowenthal et al., 2007).  
In addition to its clinical use for HSC mobilisation, G-CSF is also given to patients with 
severe neutropenia (low neutrophil numbers) or used for HSC collection and autologous 
transplantation back into patients who have treatment related bone marrow failure, such 
as after high dose chemotherapy (Bendall and Bradstock, 2014). Without such a 
transplantation, a lack of a functioning immune system leaves patients vulnerable to life-




1.8.4. Granulocyte Colony Stimulating Factor  
Granulocyte colony stimulating factor (G-CSF) is an endogenous cytokine, found at low 
to undetectable levels (below 78pg/mL) in the blood of healthy individuals (de Haas et al., 
1994), an observation that is unaffected by age and gender (Kawakami et al., 1990). 
Levels are known to increase in response to physiologic stimuli and primary infections, 
returning to normal levels on recovery (Bendall and Bradstock, 2014; Kawakami et al., 
1990).  
Increased levels of G-CSF results in increased proliferation and activation, whilst inhibiting 
apoptosis, of the haematopoietic myeloid lineage within the bone morrow and 
subsequently their release into the peripheral blood (Bendall and Bradstock, 2014). This 
outcome is a consequence of all cells of this lineage, including committed progenitors, 
expressing the G-CSF receptor; with G-CSF receptor number per cell increasing with cell 
maturity. Other mature and immature cells of the blood system are also reported to display 
the single chain polypeptide receptor, alongside myeloid cells, such as a subset of 
monocytes, NK cells and B cells (see Figure 1-12) (Singh et al., 2012; Eyles et al., 2006). 
 
Figure 1-12 - Cellular effects of G-CSF.  
This endogenous cytokine effects endothelial cells as well as multiple cells of the immune 
system either directly or indirectly. TH2, type 2 T-helper cell; TREG, regulatory T cell. 
(image from Eyles et al. 2006) 
1.8.5. G-CSF’s Cell Mobilisation Mechanism 
Whilst G-CSF has been used for over 30 years, knowledge of its exact mechanisms of 




the interaction between haematopoietic progenitors and their niche. In the last 20 years, 
different research groups have looked further into this and slowly information has been 
added to the field although full understanding of the mechanism remains to be determined. 
When taken together, results suggest that the mechanism though which G-CSF leads to 
mobilisation may include multiple pathways. 
Importantly, G-CSF does not mobilise haematopoietic stem and progenitor cells (HSPCs) 
through a direct influence on the cells themselves. This was shown by Liu and colleagues 
(2000) who demonstrated that in animals lacking the G-CSF receptor on HSPCs (chimeric 
mouse models), these cells were still mobilised with equivalent efficiency as those 
expressing the receptor (Liu, Poursine-Laurent and Link, 2000). However, the lack of the 
G-CSF receptor on all haematopoietic cells prevented G-CSF induced HSC mobilisation.  
One candidate for the key haematopoietic cell type that drives HSC mobilisation are cells 
of the myeloid lineage. These cells can release MMPs which are known to cleave or 
degrade CXCL12 (Levesque et al., 2003) and VCAM-1 (Levesque et al., 2001) disrupting 
these signalling axes. As previously discussed, these molecules are vital for the 
interaction of HSCs and their BM niche.  
Cleavage and degradation of critical niche biomolecules is thought to be a likely 
mechanism linking G-CSF treatment to HSC mobilisation. Genetic animal models 
however have failed to confirm a role for proteases; mice lacking either individual or 
combinations of proteases have demonstrated normal mobilisation (Levesque et al., 
2004). They may nevertheless be part of a cumulative effect of various mechanisms. 
CXCL12/CXCR4 dynamics are particularly thought to have a major role in G-CSF 
mobilisation (Greenbaum and Link, 2011; Semerad et al., 2005); CXCL12 levels decrease 
rapidly with G-CSF administration and are inversely proportional to mobilisation. 
Therefore, the ability of MMPs to degrade CXCL12 is noteworthy.  
Production of both CXCL12 and VCAM-1 would also be affected by a reduction in the 
number of cells synthesising this vital HSC niche homing cytokine such as osteo-lineage 
cells (Singh et al., 2012) which undergo apoptosis with G-CSF administration (Christopher 
and Link, 2008). The reduction of osteoblasts has recently be shown to be through the G-
CSF induced loss of osteoblast supportive monocytes/macrophages (osteomacs), also 
part of the myeloid lineage (Greenbaum and Link, 2011). The importance of these cells in 
G-CSF mobilisation is shown in mice expressing the G-CSF receptor exclusively on 
monocytes, where expected numbers of HSCs are mobilised. Furthermore loss of 
monocytes results in mobilisation under normal conditions (Winkler et al., 2010).  
Finally, the nervous system also has a role in mobilisation, specifically the adrenergic 
sympathetic nervous system; the administration of a β2 adrenergic agonist enhances 




that alone adrenergic nerves activity is insufficient to induce effective mobilisation or that 
a haematopoietic cell type is an intermediary involved in this response pathway, 
supportive of evidence for a key role for monocytes.  
1.9. G-CSF Mobilised Populations for Bone and Cartilage Repair 
The mobilisation of HSCs and increasing the number of total haematopoietic cells in the 
peripheral blood are the most commonly used clinical roles for G-CSF. Most studies using 
G-CSF in musculoskeletal repair collect these cells as a ‘mobilised product’ by apheresis 
and administer it autologously to the site of interest.  
In 2009 Saw et al. began a series of studies reporting that bone marrow aspirate injected 
into the intra-articular space of goats in addition to hyaluronic acid (HA) was able to 
improve the healing of a cartilage defect generated by subchondral drilling (Saw et al., 
2009). Like microfracture, subchondral drilling provides the defect with access to the 
plethora of bone marrow cells both from the drilling through the subchondral bone and the 
post-operational injection. Going forward, however, Saw and colleagues moved away 
from using bone marrow itself, as they translated their findings into the clinical studies, 
utilising G-CSF mobilised apheresis product as an equivalent. This autologous product 
required three daily injects of G-CSF before apheresis harvesting, the product was 
subsequently injected intra-articularly weekly for five weeks from cryopreserved aliquots 
(Saw et al., 2011). This feasibility study (N=5) demonstrated an improvement in the 
hyaline nature of cartilage that developed in the defect.  
With the success of the feasibility study, a subsequent two-armed randomised trial was 
conducted with 25 patients in each of two groups comparing treatments with HA alone 
and HA with autologous mobilised product (Saw et al., 2013). Results indicated improved 
cartilage repair as assessed by MRI and biopsy histology. These outcomes suggest that 
a combination of subchondral drilling, G-CSF treatment and intra-articular injection of 
apheresis product could be a novel treatment strategy for OA repair.  
G-CSF administration has also been trialled for clinical feasibility in patients with non-
union fractures. Whilst Saw and colleagues utilised the whole apheresis product Kuroda 
and colleagues in the following studies isolated (i.e. enriched for) CD34+ cells. This is a 
marker of human haematopoietic stem cells. Initially a case study of an individual patient 
who had failed bone union at nine months post the initial operative procedure was 
reported (Kuroda et al., 2011). Following treatment with G-CSF, CD34+ cells were 
successfully isolated from the apheresis product and added to an atelocollagen gel before 
administration surgically with an autologous bone graft. This treatment resulted in union 
after three months with a return to full weight bearing gait for this patient. Subsequently, 




2014). Five of the patients achieved radiological healing at 12 weeks. Together, these two 
studies demonstrate the feasibility, safety and the potential of this treatment strategy for 
fracture repair in patients with failed bone union.  
1.10. G-CSF as an adjuvant to musculoskeletal surgical techniques 
Saw and Kuroda with their colleagues, utilised G-CSF as a method to enrich the peripheral 
circulation with cells of the bone marrow before apheresis and direct application of the 
product to the trauma site. These procedures are classed as a form of cell therapy. In 
these particular cases, no suggestion was given as to the role of these cells in the 
regeneration of the tissues. These studies support a role for the mobilised product but one 
could also ask the question ‘what role G-CSF treatment alone would have on repair?’  
A number of studies have evaluated the use of G-CSF alone (i.e. no harvest of apheresis 
product) and shown positive outcomes, as detailed in the table below (see Table 1-1). All 
except one of these studies have been carried out on animal models. In all cases, the 
bone defect has been induced including the human trial where an opening-wedge high 
tibial valgus osteotomy was performed to correct malalignment (Marmotti et al., 2013b). 
Of note, the majority of studies have utilised G-CSF as an adjuvant for bone repair rather 
than the repair of cartilage directly. However, the effects of G-CSF could be important for 
the cartilaginous scaffold that forms during the repair of fractures where endochondral 
ossification plays an important role. Further, the results from two studies of where 
osteochondral defects were made in the knees of rats (Okano et al., 2014) and rabbits 
(Sasaki et al., 2017) have shown improved outcomes at early time points. This may well 
suggest the benefits of G-CSF in the early healing process.  
Another point of interest is the method and dosage regime used for G-CSF administration. 
Two studies utilised scaffolds to improve repair and incorporated G-CSF within these 
scaffolds, localising G-CSF administration within the defect itself, here described as peri-
operative administration (Ishida et al., 2010; Minagawa et al., 2014). The remaining 
studies dose subcutaneously but either in the days prior to or after surgery. Depending 
on the mechanism of action, this difference in the time of administration could have effects 
on the repair outcome.  
Multiple suggestions for the mechanism of action of G-CSF to improve the surgical 
procedure outcomes have been suggested by these studies but they focus on four main 
areas; peripheral blood cells (Bozlar et al., 2005; Kaygusuz et al., 2006; Marmotti et al., 
2013b), angiogenesis (Bozlar et al., 2005; Ishida et al., 2010), osteogenesis (Ishida et al., 
2010; Marmotti et al., 2013b; Minagawa et al., 2014) and MSC proliferation (Marmotti et 
al., 2013b; Sasaki et al., 2017). To fully understand these mechanisms in the context of 




through which key cell players can be identified and evaluated. Through this, the value of 
G-CSF as an adjuvant to surgical treatments such as clinical microfracture can be 
assessed.  
Table 1-1 – Published articles of G-CSF administration alongside surgical 
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1.11. Summary 
To summarise, OA is a debilitating condition and a growing healthcare burden, with its 
incidence predicted to increase with the aging population. Trauma induced cartilage 




treat these defects offers an opportunity to delay and possibly prevent the onset of this 
degenerative disease. Bone marrow stimulation techniques, such as microfracture, are 
regenerative strategies thought to restore cartilage by delivering bone marrow cells to the 
defect site. BMSCs are thought to be a key cell type in the repair of bone and cartilage 
tissue initially damaged by these techniques. Their role however remains unclear with 
evidence suggesting they act as both tissue progenitors and coordinators of repair. 
Furthermore, a third role as supportive cells of the bone marrow HSC niche may also have 
consequences for their role in repair.  Understanding the dynamics of these interactions 
during the repair process provides an opportunity to directly target these endogenous cells 
with drug and/or biologic therapeutics to improve the quality and quantity of the newly 
formed tissue.  
G-CSF is a biologic that has been proposed for this use. Its administration disrupts the 
bone marrow niche microenvironment and the interaction between BMSCs and HSCs – 
knowledge gained from haematology research. However, the impact of this disruption on 
BMSCs is not well defined nor is the impact of G-CSF directly on these cells. Interestingly, 
G-CSF has been used in studies of bone and cartilage repair where improved outcomes 
have been reported. The mechanism by which this occurs however is poorly understood. 
Before the translation and clinical utility of G-CSF in this setting, further studies are 
required. 
Large animal models, such as sheep, and smaller animals such as rabbits and rats are 
commonly used for musculoskeletal studies.  However mice offer the opportunity to further 
our understanding of osteochondral repair as they are amenable to genetic manipulation 
which allows for functional molecular studies. Currently a number of models have been 
presented in the literature (Fitzgerald et al., 2008; Eltawil et al., 2009; Matsuoka et al., 
2015) however further refinement is necessary to improve the accuracy and 
reproducibility of these models.  Using such a model will further understanding of the 
contribution of different cell populations to osteochondral repair and provide insight into 
the mechanisms that underlie the structural organisation of the newly formed tissue. 
Furthermore, this model could then be used as a preclinical model for small molecule and 
biological agents, such as G-CSF, when designed to improve osteochondral repair 
outcomes in the context of a surgical therapy.
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2. AIMS AND OBJECTIVES 
The overall aim of this thesis is to extend the present understanding of haematopoietic 
and bone marrow stem/stromal cells in osteochondral repair and the impact of G-CSF on 
the responses of these cells to the injury. To address this overall aim the studies were 
divided into four specific aims for investigation:  
1. Evaluate the consequences of BMSC and HSPC interactions 
BMSCs and HSPCs interact in the bone marrow microenvironment that is 
disrupted during bone marrow stimulation techniques used for cartilage repair. 
Chapter 4 aims to evaluate the consequences of this interaction for 
musculoskeletal repair. To address this, the objectives of this chapter are to 
design and develop and in vitro model of these interactions and assess their 
impact on the differentiation capabilities of BMSCs.  
 
2. Establish a reproducible osteochondral repair model to investigate key cell 
players 
To increase understanding of the cartilage repair process after bone marrow 
stimulation and identify molecular and cellular mechanisms involved in 
osteochondral healing a mouse model is required. Chapter 5 aims to develop a 
mouse osteochondral model by firstly reviewing previously published models, 
trialling different techniques before choosing an appropriate strategy and using 
assessment tools for its evaluation. Finally, the model will be used to identify 
wound healing events and the cells types involved in osteochondral repair.  
 
3. Evaluate the role of BMSCs and G-CSF in osteochondral repair 
BMSCs are thought to be vital for the repair of cartilage defects whilst G-CSF has 
been reported to improve bone and cartilage repair outcomes. Chapter 6 aims to 
evaluate the role of BMSCs and G-CSF in osteochondral repair using the model 
developed in the previous chapter. To answer this the objectives are to determine 
whether BMSCs, marked by nestin in a GFP reporter mouse line, are present in 
the defect at early healing time points and further assess the impact of G-CSF 
administration on BMSCs and haematopoietic cells in vivo.   
 
4. Explore the role of G-CSF on BMSCs directly 
Whilst G-CSF can influence BMSCs cells through changes to the bone marrow 
microenvironment, the aim of chapter 7 is to explore the ability of BMSCs to 
respond to G-CSF directly. This will be address by determining if the G-CSF 
receptor is present and functional in these cells and subsequently the effect of G-









3.1. Cell Culture 
All work was carried out in a Category 2 certified biological safety cabinet, following 
standard aseptic technique. Cell cultures were incubated at 37°C, in a humidified 
atmosphere of 5% CO2, 20% O2. Cell expansion was performed in appropriate basal 
media, as described in Table 3-1, using either Dulbecco's Modified Eagle Medium 
(DMEM, Thermo Fisher Scientific), alpha Modified Eagle Medium (αMEM, Thermo Fisher 
Scientific) or RPMI 1640 (Thermo Fisher Scientific). Unless otherwise stated medium was 
supplemented with 10% (v/v) foetal calf serum (FCS, First Link) and antibiotics at a final 
concentration of 100 units penicillin and 0.1 mg/mL streptomycin (Thermo Fisher 
Scientific). BMSCs and sMSCs (see section 3.2.1 for details) were expanded in 
supplemented αMEM; 25 µg/mL ascorbic acid-2-phosphate (Sigma), 1 ng/mL FGF-2 
(PeproTech) (Narcisi et al., 2015). Medium was changed every 2 to 3 days for culture 
expansion.  
Table 3-1 – Cell populations used 
Name Acquisition Expansion media Used at passage 
Human       
Primary BMSC Lonza  αMEM (+supp) <7 
Primary BMSC Patient bone marrow αMEM (+supp) <4 
Primary sMSCs Patient bone marrow αMEM (+supp) <4 
Peripheral blood MNCs Leukocyte Cone RPMI Fresh 
Mouse       
Primary BM derived cells Mice DMEM Fresh 
D1 ORL UVA cell line ATCC DMEM  
 
Passaging of cells was performed when they reached 70% confluence, using pre-warmed 
Trypsin-EDTA (0.5 g/L porcine trypsin, 0.2 g/L EDTA-4Na in Hank’s Balanced Salt 
Solution with phenol red) (Sigma) or TrypLE Express (Thermo Fisher Scientific). Primary 
cells were used within a certain number of passages as indicated in Table 3-1. Adherent 
cells were plated at a density of 2,300 cells/cm2 in expansion media after counting. 
Counting was performed manually using Glasstic Slide 10 with Grids (Kova International). 
When appropriate, viability was assessed using trypan blue (Thermo Fisher Scientific) 
(1:1 dilution). All cells were recovered from suspension by centrifugation at 300 x g for 
between 5 and 10 minutes unless otherwise stated. 
For long-term storage cells were cryopreserved and stored in liquid nitrogen vapour. For 
this, after detachment from plastic, cells were pelleted by centrifugation and re-suspended 
in cryopreservation medium (FBS, 10% dimethyl sulphoxide (Sigma)). Cryovials were 




nitrogen vapour. Cells were revived by thawing cryovials in a 37°C water bath and 
immediately transferring the contents to a tissue culture flask to which the appropriate 
media added. Cells were left to attach overnight before the medium was changed and 
passaging was continued. All haematopoietic cell fractions were used fresh and not 
cryopreserved before use.  
3.2. Primary and cell lines used 
3.2.1. Human derived cells  
3.2.1.1. Bone marrow mesenchymal stem/stromal cells (BMSCs) 
BMSCs used were either purchased from Lonza or isolated from donors at Addenbrooke’s 
Hospital, Cambridge, UK. Pre-characterised Poetics™ human mesenchymal stem cells 
(Lonza) are confirmed to be positive for BMSC surface antigens by the supplier; CD105, 
CD166, CD29, CD44 and negative for CD14, CD34 and CD45. 
BMSCs were isolated from the femoral or tibial bone marrow of human donors undergoing 
total or hemi knee or hip joint replacement surgery at Addenbrooke’s Hospital, Cambridge, 
UK. These samples were collected under ethical consent obtained from the Cambridge 
Local Research Ethics Committee (No. 06/Q0108/213). Written and informed patient 
consent was obtained for all specimens collected under this ethics. 
Immediately after extraction, marrow was placed into a 50 mL tube containing 5 ml of 400 
μg/ml heparin sulphate solution (Sigma). Bone marrow was then passed through a 70 µm 
filter, using a plunger from a 5 mL syringe. Cells were seeded at a density of approximately 
50,000 nucleated cells/cm2 in supplemented αMEM medium (see section 3.1). After 48 
hours non-adherent cells were washed off and the adherent cells culture in fresh 
supplemented αMEM medium. Whilst human BMSCs used in this thesis were not 
themselves characterised for their phenotypic profile, cells isolated by this method have 
previously been extensively characterised within the laboratory.  
3.2.1.2. Synovial mesenchymal stem/stromal cells (sMSCs) 
sMSCs were isolated from the synovial tissue lining the fat pad of human donors 
undergoing total or hemi knee replacement surgery at Addenbrooke’s Hospital, 
Cambridge, UK. The method of isolation was developed and optimised within the 
laboratory. Fat pad tissue was removed as much as possible from the fibrous synovial 
tissue using a scalpel and subsequently digested in 2 mg/mL solution of collagenase A 
(Sigma) prepared in basic αMEM medium (10% FCS and antibiotics) and incubated 
overnight at 37°C under constant agitation. Cells were then washed in basic αMEM 




αMEM medium (see section 3.1). Cells were passaged once colonies of 70% confluency 
had formed. 
3.2.1.3. Leukocyte Cone Peripheral Blood Mononuclear Cells (PB MNCs) 
Leukocyte cones were purchased from NHS Blood and Transplant, Addenbrooke’s 
Hospital, in accordance with the Human Tissue Act 2004. Leukocyte cones are a waste 
product from the isolation of platelets from healthy donors where leukocytes and other 
mononuclear cells (MNCs) are removed from peripheral blood and remain in the cone. 
The contents of each leukocyte cone were diluted 1 in 10 with dissociation buffer (PBS 
with 3% FCS, and 5 mM EDTA) and layered on Lymphoprep™ solution (STEMCELL 
Technologies) before centrifugation for 20 minutes at 800 x g with a low brake at room 
temperature. This process separates out MNCs which have a lower buoyant density than 
the Lymphoprep™ solution and therefore form a sample/medium interface (i.e. “buffy 
coat”) which can be isolated (first described by Böyum 1968). Erythrocytes and 
polymorphonuclear granulocytes, with a higher density, sediment through the medium to 
the bottom under centrifugation and are separated from the MNC fraction. The MNC-rich 
band was removed and re-suspended in dissociation buffer and spin washed twice, 5 
minutes each. Mononuclear cells were used directly after isolation in the experiments 
described in this thesis. When cultured alone these cells were cultured in RPMI expansion 
medium (10% FCS and antibiotics). 
3.2.2. Mouse derived cells 
3.2.2.1. Primary bone marrow cells 
Primary bone marrow cells used in the first results chapter of this thesis (chapter 4) were 
derived from 8 to 12-week-old female BALB/c mice housed in the local animal facility, 
Phenomics. The exception to this, is the use of bone marrow cells derived from the 
Ubiquitin-GFP reporter mouse line (MGI ID: 3057178) (Schaefer et al., 2001) kindly 
donated post-mortem by the Clatworthy group, University of Cambridge, aged 16 weeks, 
male and female.  
In all cases skinned hind limbs were dissected and transported in PBS. Cell isolation was 
subsequently performed under sterile conditions in a tissue culture cabinet. Hind limbs 
were dissected and as much soft tissue as possible removed to isolate femurs and tibias. 
Bones were then moved to cold dissociation buffer (PBS with 3% FCS, and 5 mM EDTA) 
and crushed using a pestle and mortar (Lo Celso and Scadden, 2007). After pipette 
agitation and washing of bone fragments, the bone marrow suspension was strained 
through a 30 μm cell strainer and cells pelleted by 5 minutes centrifugation before counting 




3.2.2.2. D1 ORL UVA cell line 
D1 ORL UVA (ATCC, CRL-12424) (RRID:CVCL_6495) is a murine stromal cell line that 
was developed in the 1990’s (Patent number US6082364, accepted 04-Jul-2000). The 
cell line was clonally derived from the BALB/c mouse bone marrow after incubation steps 
with and then without monocyte-colony stimulating factor. Evidence detailed in the patent 
filled in 1997 describes that the line is capable of tri-lineage differentiation and when 
transplanted into the tail vein of mouse recipients, the cells home to the bone marrow. 
These cells were cultured as described above in DMEM medium (10% FCS and 
antibiotics). 
3.3. Tri-lineage Differentiation and Staining of BMSCs 
One of the three main criteria for the identification of MSCs is their ability to undergo tri-
lineage differentiation in vitro. Pre-characterised Poetics™ human BMSCs (Lonza) and 
the cell line D1 ORL UVA were both cultured in differentiation media to stimulate and 
assess their osteogenesis, chondrogenesis and adipogenesis potential. Differentiation 
was induced for between 1 and 21 days. Analysis of differentiation was either assessed 
by gene expression analysis after the harvest of RNA (see section 3.11) or by the 
assessment of the production of extracellular matrix by histological staining described 
below. Where differentiation was performed without the exposure of cells to previous 
experimental conditions and in monolayers, cells were plated at 25,000 cells/cm2 density 
and differentiation induced after overnight attachment of cells in the appropriate 
expansion media.  
The effect of G-CSF on the tri-lineage differentiation potential of human BMSCs was 
assessed by the addition G-CSF (PeproTech) at a final concentration of 100 ng/mL to 
differentiation media (Furmento et al., 2014). 
3.3.1. Osteogenesis 
BMSCs can be differentiated into osteoblasts by culturing cells with ascorbic acid, beta-
glycerophosphate and dexamethasone. Cells were grown in basic DMEM medium (10% 
FCS and antibiotics), 50 μg/mL L-ascorbic acid 2-phosphate (Sigma), 10 mM β-glycerol 
phosphate (Sigma) and 10 nM dexamethasone (Sigma). In some experiments StemPro 
Osteogenesis medium (Thermo Fisher Scientific) was used in place of this. In both cases 
medium was changed every 3 to 4 days. 
Mineralisation of BMSC monolayers can be visualised by staining with Alizarin Red S 
(ARS), staining for extracellular calcium-rich deposits produced by osteoblasts during 
mineralisation. The dye forms a complex with calcium in a chelation process, resulting in 




After osteogenic differentiation, cultured cells were washed with PBS, fixed with 10% 
neutral-buffered formalin (Sigma) for 20 to 30 minutes, and again washed with PBS before 
staining. A 2% Alizarin Red solution pH 4.2 (Alfa Aesar) was added to the cells for 2 to 3 
minutes at room temperature and then gently washed with distilled water. Staining was 
then viewed and imaged using phase contrast microscopy and a macroscopic camera 
(see section 3.9).  
Alizarin red staining was quantified using FIJI from macroscopic images of cell culture 
wells. Images were cropped to the size of the well and the green channel selected after 
splitting the channels. An oval was drawn to the shape of the well and the area outside of 
the well cleared. The image was then inverted and a threshold set from 190 to 255 before 
converting to black and white (convert to mask). The number of white pixels was then 
measured as a percentage of the area.   
3.3.2. Chondrogenesis 
Two different methods were used for chondrogenesis assays. Whilst human BMSCs were 
cultured in 3D pellets, D1 ORL UVA cells were differentiated in monolayers. Commonly, 
chondrogenic differentiation is achieved by culturing cells at high density in medium 
containing Transforming Growth Factor-β (TGF-β) and dexamethasone (Johnstone et al., 
1998).  
3.3.2.1. D1 ORL UVA chondrogenic induction  
Chondrogenesis in the D1 ORL UVA cell line was induced using StemPro 
Chondrogenesis medium (Thermo Fisher Scientific) made up as directed by the 
manufacturer’s instructions and supplemented with antibiotics at a final concentration of 
100 units penicillin and 0.1 mg/mL streptomycin (Thermo Fisher Scientific). Medium was 
changed every 2 to 4 days. Subsequently the production of glycosaminoglycans, 
indicative of chondrogenesis, was assessed by histological staining with Alcian blue, a 
cationic dye (Mowry, 1956) , and their presence in cultured media – dimethyl-methylene 
blue (DMMB) assay (Farndale, Buttle and Barrett, 1986).  
For Alcian blue staining of monolayers, cells were washed with PBS, fixed with 10% 
neutral-buffered formalin for 20 to 30 minutes and again washed with PBS before staining. 
A 1% Alcian blue solution (Sigma) diluted in 0.1 M HCl was applied to the cells and left 
overnight at room temperature. The following day cells were washed three times with 0.1M 
HCl and finally with distilled water to neutralise the acidity. Staining was then viewed and 
imaged (see section 3.9). 
Cell culture medium was collected from endpoint cultures at 21 days and used to 
determine the concentration of sulphated glycosaminoglycans present by the DMMB 




Methylene Blue (Sigma), 2.37 g NaCl, 3.04 g glycine and adjusted to pH3) was prepared 
and stored at room temperature. 40 μl of each sample was aliquoted into a 96-well plate 
and 250 μl of the DMMB reagent added to each well. The absorbance was measured 
immediately on a FLUOstar OPTIMA plate reader (BMG Labtech) at 544nm. 
3.3.2.2. Human BMSCs chondrogenic induction 
Human BMSCs were induced to undergo chondrogenic differentiation in 3D 
aggregates/pellets. Chondrogenic medium used for these cultures consisted of DMEM-
high-glucose GlutaMAX+ (Thermo Fisher Scientific), ITS+ (Corning) consisting of insulin, 
transferrin, and selenium diluted 1 in 100, 40 µg/mL L-proline (Sigma), 1 mM sodium 
pyruvate (Thermo Fisher Scientific), 100 nM dexamethasone (Sigma), 10 ng/mL TGFβ1 
(R&D Systems) and antibiotics at a final concentration of 100 units penicillin and 0.1 
mg/mL streptomycin (Thermo Fisher Scientific). To form BMSC cell pellets, BMSCs were 
re-suspended in chondrogenic media at 2.5x106 /mL and 1 mL aliquoted per 15 mL 
polypropylene tube. Cells were then centrifuged at 300 x g for 8 minutes to form pellets. 
After 24 hours, the pellets were loosened from the bottom of the tube by gently tapping. 
Medium was replaced every 2 to 3 days and cultures maintained for up to 21 days.  
Chondrogenic pellets were either used for gene expression analysis by qRT-PCR or 
processed for histological staining. Pellets processed for histology were fixed overnight in 
10% neutral-buffered formalin, washed in PBS and subsequently embedded in 3% 
agarose (Eurogentec) before being processed for paraffin sections (see section 3.13.2.1) 
and staining (see section 3.13.3). Pellets used for gene expression analysis were lysed 
as described in (see section 3.11) however prior to RNA isolation pellets were physically 
dissociated using a cordless motor and disposable pestles (Sigma) in RLT buffer 
(Qiagen).   
3.3.3. Adipogenesis 
During adipogenesis cells accumulate lipid rich vacuoles within their cytoplasm which can 
combine and fill the cytoplasm. (Pittenger et al., 1999) first described an adipogenic 
differentiation media which contained dexamethasone, insulin, isobutyl methyl xanthine 
and indomethacin.  
In this thesis, StemPro Adipogenesis medium (Thermo Fisher Scientific) was used and 
made up as per the manufacturer’s instructions and supplemented with antibiotics at a 
final concentration of 100 units penicillin and 0.1 mg/mL streptomycin (Thermo Fisher 
Scientific). Medium was replaced every 3 to 4 days and cells were then stained with Oil 
red O. This dye is a lipid-soluble, red lysochrome diazo dye which stains triglycerides and 
cholesteryl oleate lipids identifying the lipid filled organelles (Ramírez-Zacarías, Castro-




At 21 days after initiation of adipogenesis, cells were washed with PBS, fixed with 10% 
neutral-buffered formalin for 20 to 30 minutes and again washed with PBS. The monolayer 
was then pre-treated with 60% isopropanol to prevent background Oil red O staining. Prior 
to staining a working staining solution was prepared by 3:2 dilution in distilled water of a 
0.3% Oil red O (Sigma) stock solution (in 99% isopropanol) and left to settle. After 10 
minutes, the working solution was filtered to remove undissolved Oil red O particles. The 
0.18% working solution was then used to stain the cells for 5 minutes before washing with 
PBS. Staining was then viewed and imaged using phase contrast microscopy (see section 
3.9).  
Oil red O staining was quantified using FIJI from three phase contrast images per well. 
The RGB tiff image colour channels were split and the green channel selected for further 
analysis. The image was then grayscale inverted and a threshold set from 190 to 255 
before converting to black and white (“convert to mask”). The number of white pixels was 
then measured as a percentage of the area.   
3.4. Multi-lineage differentiation of haematopoietic progenitors - Colony 
Forming Cell (CFC) Assay 
The Colony Forming Cell assay is the second most rapid method of identifying 
haematopoietic progenitors, second to phenotypic characterisation, but additionally 
provides some functional analysis. The assay assesses the ability of a cell to self-renew 
and differentiate into one or more haematopoietic lineages. The restriction in cellular 
movement using methylcellulose based medium, allows for the formation of individual 
colonies. Furthermore, defined colony shapes form based on the haematopoietic lineage 
and the level of commitment of the original progenitor.  
Cells derived from the bone marrow of mouse long bones were suspended in 4 ml of 
Methocult M3434 (STEMCELL Technologies) at a concentration proportional to 2-3 x 105 
/mL total bone marrow cells. 1.1 mL of this suspension was then plated in a 6-well plate 
and incubated for 10 days prior to the imaging (see section 3.9) and analysis of colonies. 
3.5. Co-culture of primary mouse haematopoietic cells and D1 ORL UVA 
cell line 
D1 OLR UVA cells were seeded in 12-well plates at a density of 1 x 105 cells/well in their 
appropriate expansion media (see Table 3-1) and grown to 90 to 100% confluency in 
DMEM expansion media. Haematopoietic cell fractions isolation from the bone marrow of 
BALB/c mice were then added at concentrations of either 1x103, 1x104 or 1x105 per well, 




3.6. Protein Functionality of the G-CSF R 
To confirm the biological activity of the G-CSF R in human BMSCs, cells were grown to 
60 to 70% confluence while PB MNCs were freshly isolated. Cells were then subjected to 
serum starvation in αMEM with 0.1% bovine serum albumin (BSA) and standard 
antibiotics to minimise baseline activity. After 24 hours 20 μl of each cytokine was added 
at final concentrations of 100 ng/mL G-CSF (PeproTech) and 20 ng/mL IL-6 (PeproTech) 
and cells prepared for protein analysis at 5, 15 and 30 minutes. In some experiments cells 
were exposed to JAK inhibitors after serum starvation for 1 hour prior to the addition of 
cytokines at a final concentration of 0.1% dimethyl sulphoxide (DMSO). Controls were 
exposed to 0.1% DMSO with no inhibitor. JAK inhibitors were either CP 690550 citrate 
(Tocris) at 1 μM or cucurbitacin I (Tocris) at 10 μM. 
3.7. Proliferation Assessment  
3.7.1. xCELLigence assay 
Real time analysis of adherent cell proliferation was conducted using an xCELLigence 
System RTCA DP with E-plates (ACEA biosystems). This device measures electrical 
impedance as cells attach and spread over the E-plate surface covered with a gold 
microelectrode array. The total area of tissue-culture well covered by cells is displayed as 
a dimensionless parameter termed cell-index based on the electrical impedance. Hence, 
the cell-index is directly proportional to the surface of plates covered with cells and can 
measure cell proliferation over time (Ke et al., 2011). 
Plates were blanked on the xCELLigence System with the addition of 50 uL of 
supplemented αMEM expansion medium to provide a reference impedance value. 
BMSCs were then seeded at a density of 2,500 cells/well in the same medium. Cells were 
allowed to settle for 30 minutes at room temperature and then the E-plate was moved to 
the xCELLigence cradle. After 24 hours the medium was removed from all wells and low 
serum media (1% FCS in αMEM) used to wash the wells once, before addition of 135 uL 
per well and the plate replaced in the cradle. After a further 24 hours supplements were 
added to wells (15 uL) to give 1% FCS, 10% FCS and 100 ng/mL G-CSF final 
concentration conditions. Each condition was performed in duplicate. Cell-index values 
were measured at a maximum of every 15 minutes from the addition of cells up to 4 days 
after the addition of supplements. Cell-index values were normalised to the time at which 
supplements were added using the xCELLigence RTCA software (v2.0). 
3.7.2. CyQuant assay 
The CyQUANT Direct Cell Proliferation Assay Kit (Thermo Fisher Scientific) uses a 




cell number. This assay was run alongside the xCELLigence assay described above. 
BMSCs were seeded at a density of 2,500 cells/well (96-well plate) in complete expansion 
medium and left for 24 hours. Wells were then washed with low serum media (1% FCS in 
αMEM) and 135 uL added to each well. Supplements were added after 24 hours in 15 uL 
to generate 1% FCS, 10% FCS and 100 ng/mL G-CSF final concentration conditions. 
After 4 days the CyQuant assay was performed. 
The CyQuant Direct nucleic acid stain and background suppressor were diluted in PBS 
as per the manufacturer’s instructions to prepare a 2X working solution. 150 μL of this 
working solution was added to each well and the plate incubated at 37°C for 60 minutes. 
The fluorescence was subsequently measured at a wavelength of excitation of 480 nm 
and emission of 520 nm using a FluoStar Optima plate reader (BMG Labtech). 
3.8. Cell Phenotyping and Phenotype Isolation 
Different cell types can be identified by specific cell surface phenotypes. Here, antibodies 
attached to both magnetic particles and fluorophores have been used to identify and 
isolate cells based on their cell surface antigens.  
3.8.1. Magnetic-activated Cell Sorting 
Magnetic-activated cell sorting (MACS) (Miltenyi Biotec) is a widely used method for the 
separation of cells based on the expression of a cell surface antigens and uses 50 nm 
superparamagnetic particles that are conjugated to antigen specific antibodies (Miltenyi 
et al., 1990). Once labelled, the cell fraction is applied to a column matrix made up of 
ferromagnetic spheres which when placed within a magnetic field amplify the strength of 
the magnetic field 10,000-fold. Magnetically labelled cells are held in suspension within 
the column whilst unlabelled cells are able to pass through the column and can be 
collected as an antigen negative fraction. The labelled cells can be eluted from the column 
and collected as positive for the antigen of interest. In this thesis, only depletion strategies 
were used on mouse bone marrow derived cells. The kits used are detailed in Table 3-2. 
Table 3-2 - Magnetic-activated cell sorting kits used 
Antigen Code Species  Company 
Lineage depletion kit 130-090-858 anti-mouse Miltenyi Biotec 
CD45 microbeads 130-052-301 anti-mouse Miltenyi Biotec 
 
Cells were re-suspended at a 1x107/mL and incubated with the antibody cocktail, washed 
and then incubated with magnetic beads for lineage depletion CD45 antibodies 
conjugated to magnetic beads. All incubation steps were performed at 4°C in dissociation 
buffer (PBS with 3% FCS, and 5 mM EDTA). Cells were washed again and re-suspended 




Biotec) and applied to a pre-wet LS column (Miltenyi Biotec) mounted in a QuadroMacs 
magnet (Miltenyi Biotec). Columns were rinsed three times with buffer and the elution 
fraction collected and centrifuged before further use. 
3.8.2. Flow Cytometry and Fluorescence-Activated Cell Sorting (FACS) 
Flow cytometry can be used to identify and quantify a range of parameters. In addition to 
fluorescent light emission, flow cytometry uses light scattering properties to determine the 
size (forward scatter) and internal complexities of cells (side scatter) (Brown and Wittwer, 
2000). Fundamentally, a fluidics system it allows each cell to be analysed individually for 
multiple properties using one or many lasers. This makes flow cytometry a powerful 
analysis tool for analysis of complex cell populations.  
Based on the methods described above for flow cytometry, Fluorescence-activated cell 
sorting (FACS) sorts heterogeneous cells into two or more fractions based on their 
individual light scattering and fluorescent characteristics properties.  
Table 3-3 details the antibodies used for flow cytometry analysis and sorting. Antibodies 
were used as per the manufacturer’s instructions. Additionally, cells derived from GFP 
reporter mice were sorted on their GFP fluorescence. The viability dye 7-AAD (Biolegend) 
was used in all cases by the addition of 5 μl per 1x106 cells and all cell suspensions filtered 
through a 30 μm nylon mesh filter (Miltenyi Biotec) prior to analysis. Unstained and isotype 
controls were used to determine auto-fluorescence and non-specific background staining. 
Laser voltages were set with cells below log 10-1. When multiple staining of cells was 
required, compensation controls were run using compensation beads (OneComp eBeads, 
eBioscience) to assess the compensation required for emission spectral overlap.  
For flow cytometry analysis a LSR Fortessa (BD Biosciences) was used and for FACS a 
BD FACSAria III (BD Biosciences) was used, both located at the Cambridge NIHR BRC 
Cell Phenotyping Hub. The data was assessed with Kaluza Analysis Software (Beckman 
Coulter).  
3.8.2.1. Isolation of mouse bone marrow populations 
Primary cells derived from the bone marrow of mice were stained with conjugated 
antibodies detailed in Table 3-3. After isolation of cells, either directly from tissue or after 
magnetic-cell sorting, cells were re-suspended in dissociation buffer at 1x107/mL. 
Antibodies were added and incubated for 30 minutes in the dark at 4°C. Cells were then 
washed twice in 3 mL dissociation buffer before addition of 7-AAD and then flow cytometry 
analysis or sorting was performed. Those cells sorted for co-culture were collected into 
DMEM expansion media before spinning and resuspension into fresh media and addition 




Table 3-3 - Antibodies used for flow cytometry 
Antigen Conjugation Clone Species  Company Dilution 
Un-conjugated primary antibodies 
   
CD11b  M1/70 Rat R&D systems 10 µg/ml 
CD45  30-F11 Rat R&D systems 10 µg/ml 
CD29  265917 Rat R&D systems 10 µg/ml 
CD73  496406 Rat R&D systems 10 µg/ml 
CD105  209701 Rat R&D systems 10 µg/ml 
CD106  112734 Rat R&D systems 10 µg/ml 
Sca-1 (Ly-6A/E)  177228 Rat R&D systems 10 µg/ml 
CD44   Sheep R&D systems 10 µg/ml 
Rat IgG2A isotype control 54447  R&D systems 100 µg/ml 
Rat IgG2B isotype control 141945  R&D systems 100 µg/ml 
Sheep IgG isotype control   R&D systems 100 µg/ml 
Conjugated primary antibodies         
c-Kit (CD117) APC 2B8 Rat Biolegend 1 in 20 
Sca-1 (Ly-6A/E) BV 605 D7 Rat Biolegend 1 in 20 
CD45 APC/Cy7 30-F11 Mouse Biolegend 1 in 80 
CD31 PE 390 Mouse Biolegend 1 in 20 
Secondary antibodies 
    
Anti-rat PE Poly4054 Goat Biolegend 2.5 µg/ml 
Anti-sheep PE HP6017 Mouse Biolegend 2.5 µg/ml 
 
3.8.2.2. D1 ORL UVA phenotypic analysis 
For the phenotypic analysis of the D1 ORL UVA cell line, the cell line was grown to 70% 
confluency prior to staining. Cells were trypsinised, spin washed in DMEM expansion 
media and re-suspended in dissociation buffer (PBS with 3% FCS, and 5 mM EDTA); this 
buffer was used for all the following steps. Cells were then washed a second time and re-
suspended at 1x107/mL. Next, cells were stained with primary antibodies from the R&D 
systems Mouse Mesenchymal Stem Cell Marker Antibody Panel or appropriate isotype 
controls (antibodies detailed in Table 3-3) for 30 minutes at room temperature, one 
antibody per tube. Cells were then washed twice before resuspension in 100 μL per tube 
and addition of either anti-rat or anti-sheep, as appropriate, secondary antibody 
conjugated to APC. Secondary antibody staining was performed at 4°C for 30 minutes in 
the dark. Cells were then washed twice and re-suspended in 1 mL before addition of 7-
AAD (5 μl per 1x106 cells) and flow cytometry analysis.   
3.8.2.3. Separation of co-culture populations 
For the separation via FACS of co-cultures containing ubiquintin-GFP reporter mouse 
cells, cells from 12-well plates were detached by trypsinisation and three replicate wells 
combined in DMEM expansion media before washing twice in dissociation buffer and 
stained for viability. Cells were then sorted into DMEM expansion media to isolate GFP 





Phenotypic analysis of individual human BMSCs was assessed by immunocytochemistry 
(ICC). This technique visualises proteins using antibodies for specific target antigens and 
in addition to flow cytometry allows for the analysis of the site of binding within the cell 
and the cell’s morphology.  
Cells were grown in 0.7 mm2 chamber 8-well Millicell® EZ Slides (Millipore). Cells were 
washed with PBS and fixed with 37°C pre-warmed 4% paraformaldehyde (Sigma), and 
then incubated with PBS containing 0.1% Tween20 (Sigma) (PBS-T) for 5 minutes to 
permeabilise the cells. Cells were then blocked in 10% goat serum ((Vector Laboratories)) 
PBS-T for 30 minutes before the addition of the primary antibody (Table 3-4) diluted in 1% 
goat serum ((Vector Labs)) in PBS-T and incubation overnight at 4°C. . Antibodies were 
used as per the manufacturer’s instructions and the final incubation concentration 
optimised. 
Table 3-4 – Antibodies used for immunocytochemistry 
Antigen Code Species  Company Dilution 
Primary antibodies 
    
G-CSF R ab126167 Rabbit mAb Abcam 1 in 500 
Secondary antibodies 
    
Anti-rabbit Alexa 488 ab150085 Goat Abcam 1 in 250 
 
After washing with PBS, cells were then incubated with an Alexa 488 conjugated 
secondary antibody (Table 3-4) in the dark for 1 hour at room temperature. Additionally 
Phallodin Alexa 555 (Thermo Fisher Scientific) was added with the secondary antibody 
for the visualisation of the actin cytoskeleton. After final wash steps with PBS twice and 
then distilled water, slides were mounted using ProLong Diamond Antifade Mountant with 
DAPI (Thermo Fisher Scientific). 4',6-diamidino-2-phenylindole (DAPI) (Sigma Aldrich) 
was used as a nuclear stain, as it binds to AT-rich regions of DNA within the nucleus. 
Primary and secondary negative wells were prepared alongside to control for non-
specificity and background signals. Cells were imaged by confocal microscopy (see 
section 3.9.2).  
3.9. Cell Culture Imaging Techniques and Analysis 
3.9.1. Standard Microscopy 
Phase contrast imaging used to assess cell morphology, and histological staining of cell 
culture wells, were both viewed using a Leica DM IRB Inverted Brightfield Microscope and 
captured using a MicroPublisher 3.3 RTV Camera (QImaging) and Q Capture Pro 7 




Nikon Eclipse Ti Eclipse with an Orca OSG camera (Nikon, Japan) inverted microscope 
using NIS-Elements Advanced Research.  
3.9.2. Confocal Microscopy 
Confocal microscopy allows for optical sectioning and the acquisition of high resolution 
imaging. Additionally, by acquiring multiple planes it allows the construction of 3D images. 
This technique was used both for immunocytochemistry imaging and the imaging of co-
cultures. Images were taken on a Leica Sp5, an ultra-high speed inverted confocal 
microscope in Cambridge NIHR BRC Cell Phenotyping Hub and analysing using ICY and 
FIJI (de Chaumont et al., 2012; Schindelin et al., 2012). For immunocytochemistry 
imaging, z-stacks were taken and the maximum projection displayed.  
For the analysis of co-cultures, z-stacks were utilised to assess the interaction of the D1 
OLR UVA cell line and bone marrow derived cells from ubiquitin-GFP reporter mice. 
These co-cultures were fixed for 20 minutes with 37°C pre-warmed 4% 
paraformaldehyde, and then incubated with PBS containing 0.1% Tween20 (Sigma) 
(PBS-T) for 5 minutes to permeabilise the cells. Subsequently, Phallodin Alexa 555 
(Thermo Fisher Scientific) was applied to cells for 20 minutes for the visualisation of the 
actin cytoskeleton of D1 ORL UVA cells. Slides were then washed with PBS twice and 
then distilled water, slides were mounted using ProLong Diamond Antifade Mountant with 
DAPI (Thermo Fisher Scientific).  
3.9.3. Macroscopic Images 
Macroscopic images were used to assess Alizarin red histological staining of cell culture 
wells. These were taken with a Canon EOS 1200D at a distance of approximately 20 cm 
away from the plate using a camera stand.  
3.10. Protein Methods 
3.10.1. Protein Isolation 
To isolate total cellular protein from cells, they were first washed with PBS and then lysed 
with protein lysis buffer on ice. This buffer was prepared using RIPA buffer (Millipore) with 
the addition of cOmplete ULTRA protease inhibitor cocktail (Sigma) and PhosSTOP 
phosphatase inhibitor tablets (Sigma). Where protein lysis buffer was added to wells of 6 
well plates, 100 μl per well was added and cells detached with a cell scraper. Suspension 
cells such as PB MNCs were washed through centrifugation and lysis buffer added to the 
cell pellet, 100 μl per <1x107 cells. Lysates were transferred to low-bind Eppendorf’s and 
rotated at 4°C for 30 minutes. Samples were stored at -70°C and before analysis 




3.10.2. Protein Concentration 
Total cellular protein was concentrated for some samples due to low abundance of the 
proteins of interest. Protein lysates were transferred to Amicon Ultra-0.5 30KDa 
centrifugal filter devices (Millipore) and centrifuged for 15 minutes at 14,000 x g. The 
columns were then inverted in new tubes and centrifuged for 2 minutes at 1,000 x g. 
3.10.3. Bicinchoninic (BCA) Assay  
The BCA assay, Pierce™ BCA Protein Assay Kit (Thermo Fisher Scientific), was used to 
quantify total cellular protein. In the presence of peptides comprising of three or more 
residues copper ions are reduced and detected by bicinchoninic acid (BCA) resulting in 
the formation of a purple-coloured product (Smith et al., 1985).  
Protein lysates were compared to known bovine serum albumin (BSA) (Thermo Fisher 
Scientific) protein standards prepared at concentrations ranging from 25 to 2000 ng/mL. 
Protein samples and the BSA standards were diluted 1:8 by the addition of 200 μl of 
working reagent to 25 μL cell lysate or protein standards in a 96-well plate, each in 
triplicate. The working reagent was prepared by diluting CuSO4 pentahydride solution (4 
%) in BCA 1 in 50. Plates were then incubated for 30 minutes at 37°C. The absorbance 
for samples and protein standards was subsequently measured at a wavelength of 562 
nm using a FluoStar Optima plate reader (BMG Labtech). The protein concentrations of 
samples were then estimated using the absorbance of the known BSA standards.  
3.10.4. Western Blotting 
Western blotting is used to detect and analyse proteins based on their molecular weight 
as well as antibody targeting of antigens (Towbin, Staehelin and Gordon, 1979; Burnette, 
1981). Protein lysates were denatured by mixing with 4X NuPAGE sample LDS loading 
buffer (Thermo Fisher Scientific) supplemented with 10X NuPAGE reducing agent 
(Thermo Fisher Scientific) and heating to 75°C for 15 minutes. Quantification from the 
BCA assay was used to ensure consistent amounts of protein were used for each sample. 
3.10.4.1. Electrophoresis 
Proteins were loaded onto mini-PROTEAN TGX pre-cast gels 10-well 4-20% stain free 
gels (BioRad) alongside Chameleon Duo Pre-stained protein ladder (Licor). Samples 
were resolved by electrophoresis in Tris/Glycine/SDS running buffer (BioRad), at 250V 
for 25 minutes. Proteins were then transferred onto 0.2 μm nitrocellulose or 0.45 μm PVDF 
membranes using a Trans-Blot Turbo Transfer Pack (BioRad) in a Trans-Blot Turbo semi-




3.10.4.2. Immuno-Probing and Detection 
Membranes were blocked to prevent non-specific binding of the primary antibody by 
incubation in blocking buffer, prepared by a 1 to 1 dilution of Odyssey blocking solution 
(Licor) in TBS (Fisher Scientific), for 1.5 hours at room temperature. The membrane was 
then probed overnight at 4°C with the primary antibody (see Table 3-5) diluted in blocking 
buffer made using TBS containing 0.1% Tween20 (Sigma) (TBS-T). Antibodies were used 
as per the manufacturer’s instructions and the final incubation concentration optimised. 
Membranes were washed three times in TBS-T for 10 minutes per wash to remove excess 
primary antibody. Subsequently membranes were incubated with secondary antibodies 
diluted in TBS-T blocking buffer for 1.5 hours at room temperature. Membranes were 
washed three times in TBS-T for 10 minutes each.  
Membranes were then imaged using an Odyssey Fc system (Licor) with an exposure time 
of 2 minutes or using a ChemiDoc system (BioRad) with automated exposure settings. 
Both these pieces of equipment detect the fluorescence of the secondary antibody 
conjugated to a fluorophore.  
Table 3-5 – Antibodies used for Western blotting 
Antigen Code Species  Company Dilution 
Primary antibodies 
    
G-CSF R ab126167 Rabbit mAb Abcam 1 in 500 
Phospho-p44/42 (Thr202/Tyr204)  9106 Mouse mAb CST 1 in 2,000 
p44/42  4695 Rabbit mAb CST 1 in 1,000 
Phospho-STAT3 (Y705)  ab76315 Rabbit mAb Abcam 1 in 2,000 
STAT3 9139 Mouse mAb CST 1 in 1,000 
Actin-peroxidase A3854 Mouse mAb Sigma 1 in 25,000 
Secondary antibodies 
    
IRDye800CW Donkey anti-rabbit 925-32213 Donkey Licor 1 in 15,000 
IRDye680CW Donkey anti-mouse 925-68022 Donkey Licor 1 in 15,000 
 
When required, membranes were subsequently incubated with actin-peroxidase in TBS-
T for 20 minutes at room temperature. After a final two wash steps with TBS-T, 10 minutes 
each, membranes were developed by chemiluminescence with Amersham ECL Prime 
Western Blotting Detection Reagent (GE Healthcare). This visualisation technique causes 
the peroxidase conjugated to the primary antibody to catalyse the oxidation of a 
chemiluminescent substrate. As the product of this reaction decays from its excited state 
releasing photons of light at 425nm which are captured. A ChemiDoc system (BioRad) 




3.10.4.3. Protein Quantification 
Protein bands were quantified by densitometry using Image Studio Lite (Licor) for 
Odyssey captured images and Image Lab (BioRad) for ChemiDoc captured images.  
3.11. Gene Expression 
Quantitative real time PCR can be used to assess the gene expression profile of a 
population of cells by determining genes transcribed to messenger RNA. This analysis 
therefore requires the isolation of RNA from cells, its transcription to complementary DNA 
and finally assessment of the quantity of the transcripts of interest. 
3.11.1. RNA extraction 
Prior to RNA extraction, surfaces and designated RNA pipettes were cleaned with 
RNaseZAP (Thermo Fisher Scientific) to eliminate any environmental RNase and sterile 
filter tips used.  
RNeasy (QIAGEN) uses a silica-based membrane to which RNA binds after it is released 
by the lysis of cells. Using a denaturing guanidine-isothiocyanate lysis buffer, RNA is kept 
intact by the inactivation of RNases. The addition of ethanol provides the appropriate 
conditions for RNA to bind to a spin column, which can subsequently be washed with 
various buffers to remove contaminants, before elution of harvested RNA in water.  
Cells cultured for gene expression analysis were first washed with PBS before cell lysis 
by the addition of RLT buffer (QIAGEN) to which 1% β-mercaptoethanol (BME) (Sigma) 
had been added. Cells isolated from co-cultures and then sorted by FACS were sorted 
into DMEM expansion media and subsequently spin washed twice with PBS (300 x g for 
5 minutes) before the addition of RLT buffer with BME. Cells from the spinal vertebrae of 
mice on the other hand, were sorted directly into RLT buffer. All samples were stored at -
70°C after lysis until required.  
The RNeasy protocol was followed as per the manufacturer’s instructions described here. 
Where necessary, for example from 7 day osteogenesis assays, cells were homogenised 
using a Qiashredder (QIAGEN). For this, samples were added to QIAshredder columns 
and centrifuged for 2 minutes at 14,000 x g and the flow though retrieved. Cell lysates 
were combined 1:1 with 70% ethanol, and added to an RNEasy column, which was 
centrifuged for 20 seconds at 14,000 x g. The flow-through was discarded and 700 μL of 
RW1 buffer added to the column, before centrifuging again for 20 seconds at 14,000 x g. 
The column was washed twice with 500 μL of RPE wash buffer under the same 
centrifugation conditions, and the flow-through discarded. Spin columns were then 
transferred to clean 2 mL tubes, and centrifuged for 2 minutes at 14,000 x g to remove 




transferred to clean 1.5 mL Eppendorfs and 30 μL of RNase/DNase-free water added to 
each column. RNA was eluted by centrifuging for 1 minute at 14,000 x g, and the tubes 
immediately placed on ice. 
RNA concentration and quality was quantified using UV-spectrometry - Nanodrop ND-
2000 Spectrophotometer (Thermo Fisher Scientific). Purity was assessed based on 
260/280 nm wavelength ratios and a ratio of ~2.0 was accepted as suitable for cDNA 
synthesis. RNA was stored at -70°C until required. 
3.11.2. cDNA Synthesis 
Double-stranded complementary DNA (cDNA) is required for qRT-PCR and was 
synthesised from the extracted RNA using reverse transcriptase. RNA was reverse-
transcribed using a QuantiTect Reverse Transcription Kit (QIAGEN), as per the 
manufacturer’s instructions (concentrations of kit contents not provided), alongside 
reverse transcriptase enzyme negative controls.  
RNA was diluted to <1000 ng in 12 μL with RNase/DNase-free water and combined with 
2 μL ‘gDNase Wipeout Buffer’. This was incubated for 2 minutes at 42°C and then placed 
on ice. 6 μL of a prepared mastermix solution containing dNTPs, reverse transcriptase 
and RT buffer was added to each sample and incubated at 42°C for 30 minutes. 
Subsequently samples were transferred to 95°C for 3 minutes to denature the reverse 
transcriptase. cDNA was stored at -20°C until required. The total amount of cDNA was 
considered 1:1 with the quantity of RNA used in the reaction. 
3.11.3. Quantitative Real Time PCR 
qRT-PCR can determine relative amounts of a specific mRNA transcripts present between 
two or more samples using the amplification products synthesised by reverse 
transcription, thus enabling an understanding of gene expression differences between 
samples. As with traditional PCR, the amplicon is amplified but the addition of a 
fluorescent dye such as Sybr Green allows for the quantity of an amplicon to be gauged. 
Sybr Green binds to the double-stranded DNA generated during the amplification step of 
PCR at which point fluorescence is registered by a detector.  
As the amplicon numbers increase with each cycle the fluorescent signal should increase 
proportionally if the reaction is 100% efficient (Wittwer et al., 1997; Schneeberger et al., 
1995). Assessing the efficiency of the reaction is therefore vital before quantification of 
experimental samples. This was done for all in-house designed primers (see section 
3.11.5).  
The number of PCR cycles required to detect a real signal exceeding background 




relative gene expression between samples can be calculated (Schmittgen and Livak, 
2008). The use of a stable housekeeping gene ensures that varying levels of starting 
material and quality of RNA is accounted for by subtracting the gene of interest CT from 
that of the housekeeping gene. A fold-change is then calculated to determine relative 
gene expression between samples. 
HPRT was validated as a suitable housekeeping gene for the experiments performed in 
this thesis. This was based on the analysis of several housekeeping genes for both human 
(HPRT, GAPDH and B2M) and mouse (HPRT and GAPDH) cells and the housekeeping 
gene selected using the NormFinder Software (Andersen, Jensen and Ørntoft, 2004). 
HPRT was selected as the best compromise between "stability" and "standard error” for 
human BMSCs (Appendix 10.2).  
3.11.4. qRT-PCR assay 
Reaction volumes of 12 uL were used combining 2X QuantiFast SYBR Green PCR Kit 
(QIAGEN), a final concentration of 10 mM for both forward and reverse primers and 2 uL 
of 5 ng/ul cDNA. Reactions were run on a StepOnePlus instrument (Applied Biosystems). 
Thermocycling conditions of 95°C for 5 minutes followed by 40 cycles of 95°C for 10 
seconds and 62°C for 30 seconds were used for all primer pairs.  
CT values were quantified in triplicate for each gene and normalised to HPRT 
housekeeping control. The cDNA template negative controls were run for each primer mix 
prepared. Analysis of experimental samples was performed by relative quantification 
using the comparative Ct (2-ΔΔ CT) method, normalising to the housekeeping gene 
HPRT. 
The following equations were used for the comparative CT method:  
ΔCT = CT GOI – CT HK  
(where GOI is Gene Of Interest and HK= Housekeeping gene)  
ΔΔCT = ΔCT sample – CT calibrator  
Relative quantification = 2–ΔΔCT 
3.11.5. qRT-PCR primer design  
Primers were either purchased pre-designed from Sigma or Qiagen or primer sequences 
were taken from published literature and checked using NCBI PrimerBlast / 
NucleotideBlast. Primers were validated for amplification efficiencies between 0.4ng and 
100ng of cDNA per reaction above using RNA from appropriate cell types. Primer 
performance was determined through slope, efficiency and R2 in StepOne software 
(Appendix 10.3). Primers with efficiencies between 90 and 110% (with the exception of 




samples. Melt curves were assessed to ensure no primer dimers formed between primer 
pairs or off target amplification.  
3.12. In Vivo Models 
3.12.1. Animal Husbandry 
All surgery was performed in accordance with the regulations laid out in the Animals 
(Scientific Procedures) Act 1986. Mice were housed in the Phenomics animal facility, 
University of Cambridge, according to Home Office requirements under project license 
70/8635. All animals were housed in individually ventilated cages under a 12h dark 12h 
light cycle and fed a standard diet.  
3.12.2. Animals Used 
Two stains of mice were used for in vivo studies in this thesis; wild type C57BL/6 mice, 
supplied by Charles River and transgenic Nestin-GFP reporter mice (MGI ID: 5523870) 
(Mignone et al., 2004) kindly donated as a gift from the Mendez-Ferrer group, University 
of Cambridge. Mice were used between 8 and 12 weeks of age and ear notching 
conducted for the identification of animals.  
3.12.3. Genotyping 
Genotyping of transgenic mice was performed to confirm the expression of GFP under 
the Nestin promotor. Ear biopsies of 2 mm diameter from identification ear notching were 
collected and genotyped. Biopsies were stored at -20°C until required. 
Biopsies were incubated in 100 μL Direct PCR Lysis Regent Ear (Viagen Biotech) 
containing 0.5 mg/mL Proteinase K (Bioquote) at 55°C overnight. After inactivation at 
85°C for 45 minutes, PCR was performed directly on lysate.  
PCR reaction mixture (21 μL) consisted of the following components: 2 μl of ear biopsy 
lysate, 4 μL of 5X Green GoTaq Reaction Buffer (Promega), 0.2 μL of GoTaq G2 DNA 
Polymerase (Promega), and 2 μL dNTPs (Thermo Scientific) to final concentration of 0.2 
μM. Additionally, 0.5 μM of each primer (1 μL each) was added to each reaction; Nestin 
Primer: 5′ GGAGCTGCACACAACCCATTGCC 3', GFP Primer: 5′ 
GATCACTCTCGGCATGGACGAGC 3′ (Mignone et al., 2004).  
A gradient PCR was run initially to determine the best annealing temperature conditions 
using a Veriti 96-Well Thermal Cycler (Applied Biosystems). Thermocycling conditions of 
94°C for 5 minutes; 30 cycles of 94°C for 30 seconds, an annealing temperature of 67°C 
for 30 seconds, 72°C for 45 seconds and 72°C for 5 minutes, were subsequently used for 




gel prepared in TAE buffer (4.84 mg/mL Tris base, 0.3 mg/mL EDTA made up to pH 8 
with glacial acetic acid) containing 0.01% SYBR Safe DNA Gel Stain (Thermo Fisher 
Scientific) alongside a 100 base pair ladder (New England Biolabs), at 100V, 400mA for 
1.5 hours. Gels were imaged under UV light (Syngene inGenius system). 
3.12.4. Agent Dose and Delivery 
G-CSF is a biologic agent sold for clinical use under the generic name Filgrastim. G-CSF 
is cross species reactive and therefore clinical grade Filgrastim (Zarzio) was used for 
animal studies. However, the solution was diluted in 5% glucose (Aqupharm No3, 
Animalcare) to 10 µg/mL and dosed at 250 µg/kg/day subcutaneously consistent with 
published literature (Semerad et al., 2005; Christopher and Link, 2008) for 3 days.  
3.12.5. Animal Surgery 
Mice were acclimatised to the animal facility for a minimum of 7 days and health checked 
and weighed before surgery. The basic surgical procedure was performed under strict 
asepsis by a single surgeon. General anaesthesia was induced by exposure to 4% 
isoflurane and then maintained at 1.5-2%. All mice were given pre-operative analgesia of 
subcutaneous 1 mg/kg buprenorphine. 
The hair over the left knee was clipped, the skin disinfected and the animal placed under 
a surgical microscope in a dorsal recumbent position on a heat pad. The left leg was bent 
over a 2.5 mL syringe barrel and the foot taped into place to achieve a right angle at the 
knee joint. The animal was then draped exposing the knee joint. A small (0.5 to 1 cm) 
medial para-patellar skin incision was made, the joint capsule opened by blunt dissection 
and the patella luxated laterally to expose the patella groove articular surface. 
Osteochondral defects within the patella groove were created using a 26 G needle with 
0.6 mm of the tip exposed by the use of a fixed plastic cylinder   acting as a depth guard.  
This instrument was sterilised using ethylene oxide gas sterilisation. Trials with other size 
needles were performed on euthanised cadavers using the same method of patella 
groove exposure.  
After creation of the osteochondral defect the patella groove was washed with sterile 
saline and a drop of 0.25% bupivacaine applied to the defect before repositioning the 
patella. The joint capsule was close with two 7-0 absorbable sutures (Ethicon), one above 
and one below the patella. Finally, three to four 6-0 sutures (Ethicon) were used to close 
the skin.  
The mice were moved to a clean cage in a warm Incubator to recover, with checks every 
15 minutes for the first hour. After this time mice were fully weight bearing and showed no 




post-operative checks carried out by skilled technical staff every day for the first 7 days 
post-surgery.  
3.12.6. Necropsy 
Animals were humanely sacrificed post-operatively by carbon dioxide asphyxiation and 
tissue samples harvested at various time points between 24 hours and 8 weeks post-
surgery. The operated left hind and contralateral right hind limb were both harvested from 
all animals. Additionally, from transgenic mice, spleens and spinal columns were 
harvested and peripheral blood samples were taken via cardiac puncture.  
3.12.6.1. Hind Limbs 
The skin was removed from the hind limbs of mice. On the operated left hind of some 
animals the patella groove was visualised by luxation of the patella and photographs taken 
of the osteochondral defect surface using a 20x macro lens. The femur and tibia of all 
limbs were cut to 0.5 cm away from the knee joint. Samples were then moved to 10% 
neutral buffered formalin for 24 to 48 hrs at 4°C before preparation for histology (see 
section 3.13).  
3.12.6.2. Peripheral Blood - Cardiac Puncture 
Immediately after carbon dioxide asphyxiation, blood was collected by cardiac puncture 
using a 23G needle and a 2.5 mL syringe. Blood samples were then transfer into 1.3 mL 
heparin micro tubes. Cells were stained and analysed by flow cytometry as detailed in 
section 3.8.2. 
3.12.6.3. Spleen 
Spleens were harvested and transferred to 10% neutral-buffered formalin (Sigma) for 24 
hours fixation. Spleens were then processed for paraffin sectioning (see section 
3.133.13.2.1).  
3.12.6.4. Spinal Vertebrae 
The spinal columns were dissected, and soft tissue removed using a scalpel and Kimtech 
tissue. The spinal column was broken into pieces of approximately 1 cm. Segments were 
processed for paraffin or cryo-sectioning (see section 3.13) or segments from Nestin-GFP 
reporter mice were additionally used for the isolation of bone marrow CD45-GFP+ cells. 
Segments used for histology were moved to 10% neutral-buffered formalin for 24 hours 
fixation at 4°C before further processing.  
Where segments were used for isolation of cells, the spinal cord was removed to minimise 
the contamination of spinal cord derived cells. This was done at dissection by carefully 




buffer (PBS with 3% FBS, and 5 mM EDTA). Bones were then crushed using a pestle and 
mortar. After pipette agitation and washing of bone fragments, the bone marrow 
suspension was strained through a 30 μm cell strainer and cells pelleted at 300 x g. Cells 
were sorted first by immune-magnetic depletion of CD45+ cells and subsequently re-
suspended in dissociation buffer and sorted by FACS (see section 3.8). FACS sorted cells 
were eluted directly into RLT lysis buffer for the isolation of RNA (see section 3.11).  
3.13. Histological Sectioning 
Tissue samples were processed for histological analysis. Sections were generated by 
either paraffin- or cryo- sectioning. In both cases tissues containing bone were de-calcified 
before embedding (hind limbs and vertebrae samples).  
3.13.1. De-Calcification of Bone 
By its nature, bone contains a high proportion of mineralised calcium (hydroxyapatite) and 
the increased density relative to embedding media makes routine histology challenging 
and causes numerous tissue artefacts. Samples were decalcified by one of two methods; 
incubation in acid or Ethylenediaminetetraacetic acid (EDTA). Unless stated samples 
were decalcified with EDTA. 
3.13.1.1. EDTA 
EDTA is a chelating agent, which captures calcium ions from the surface of apatite 
crystals, slowly reducing their size. This process is very slow but very gentle maintaining 
tissue morphology and preserving epitopes for molecular techniques such as 
immunohistochemistry. 
After fixation, samples were washed in distilled water for 30 minutes and then transferred 
to a decalcification solution of 14% EDTA (Sigma) solution (adjusted to pH 8 using NaOH 
pellets). Samples were incubated at room temperature, on a rocker and the EDTA solution 
replaced 2 to 3 times a week. Hind limbs and vertebrae for cyro-sectioning were 
decalcified for 1 week whereas those for paraffin-sectioning were decalcified for 2 to 3 
weeks. The completion of decalcification of samples for paraffin sectioning was confirmed 
by a lack of resistance on penetration of the tibia with a 27 G needle. In both cases 
samples were washed in distilled water for 30 minutes before processing and embedding 
as appropriate. 
3.13.1.2. Formic Acid and Hydrochloric Acid Mix 
Acid decalcification occurs more quickly than decalcification using EDTA (Skinner et al., 
1997). Acid decalcification was used here for the processing of tissues quickly when the 




water for 30 minutes and then transferred to a decalcification solution of 4% formic acid 
and 4% hydrochloric acid, ensuring the samples were submerged. Samples were left in 
the acid mix for 4 to 5 hours on a rocker at room temperature.  
Samples were then removed and rinsed in distilled water for 5 minutes before the addition 
of 5 drops of 10% ammonia hydroxide solution (Sigma) to approximately 100 mL of 
distilled water. Samples were left for 30 minutes to neutralise the acidity before rinsing 
them in running tap water for 30 minutes before processing and embedding in paraffin. 
3.13.2. Embedding and Sectioning 
Embedding tissues in different media offers the possibility to analyse different histological 
characteristics. Paraffin embedding best preserves the structure of the tissue, whilst cryo-
sectioning used here preserves the fluorescence present in the GFP transgenic line. All 
hind limbs were embedded for sagittal sectioning.  
3.13.2.1. Paraffin Embedded Sections 
Decalcified (bone) and un-decalcified (spleen and chondrogenic cell pellet) samples were 
transferred to 50% ethanol after washing in distilled water. Samples were then moved to 
a Leica TP1020 Tissue Processor. This machine moves samples through a series of 
reagents to allow paraffin infiltration throughout the tissue. First samples are incubated 
through a series of increasing concentrations of ethanol (50%, 70%, 80%, 95% for 1 hour 
each and three 100% changes 1 hour each), before immersion in two sequential xylene 
steps (2 hours each). Finally, samples are moved into 60°C melted paraffin, each bath for 
2 hours. All these steps were performed under vacuum. Samples were then orientated as 
appropriate and embedded in paraffin using Leica HistoCore Arcadia H Embedding 
Station. Samples were stored at 4°C until required for sectioning.  
Samples were sectioned at 5 µm using a Leica BM2255 Microtome and dried onto 
Superfrost Plus Slides (Thermo Fisher Scientific). Slides were then stored at room 
temperature or 4°C.  
3.13.2.2. Cryo- Embedded Sections 
After washing decalcified samples in distilled water, they were then incubated in an 
increasing gradient of sucrose solutions to equilibrate the tissue to the embedding media; 
15% sucrose at 4°C until the tissue sunk (approximately 3 to 4 hrs) and then 30% sucrose 
overnight. Samples were embedded in OCT compound (Tissue-Tek) in cryo-moulds and 
placed into liquid nitrogen vapour for 3 to 5 minutes to snap freeze. Samples were kept at 
-70°C for long-term storage. 
Sections were cut in a cryostat (Bright Instruments) using a tungsten carbide tipped knife 




acclimatise the tissue. Sections were made at 15 µm either using Kawamoto tape 
(Kawamoto and Kawamoto, 2014) or direct transfer onto Superfrost Plus Slides (Thermo 
Fisher Scientific). Slides were then air-dried and transferred to -20°C for storage.  
3.13.3. Histological Stains and Counter Stains 
Paraffin tissue sections were rehydrated prior to commencing the staining procedures as 
outlined below. First, sections were warmed on at hot plate at 60°C for 10 minutes before 
transfer to xylene for 10 minutes, following by a second xylene bath for 10 minutes. Slides 
were then incubated in decreasing concentrations of ethanol for 5 minutes each (100%, 
100%, 95%, 80%, 70%, 50%, 30%), followed by two washes in distilled water for 5 
minutes each.  
3.13.3.1. DAB Immunohistochemistry of Paraffin Sections 
Diaminobenzidine (DAB) is oxidized in the presence of peroxidase and hydrogen peroxide 
resulting in the deposition of a brown, alcohol-insoluble precipitate at the site of enzymatic 
activity. By applying antibodies (tagged with horseradish peroxidase) against epitopes of 
interest, DAB precipitation can be used to identify the location of proteins.  
After rehydration to water, samples were treated to unmask antigens through an antigen 
retrieval procedure. For the identification of collagen proteins, samples were incubated at 
37°C in 0.1% hyaluronidase (Sigma) for 50 minutes before washing in PBS for 5 minutes 
and continuing to the blocking step. Other samples were incubated in 10 mM sodium 
citrate (Sigma) buffer adjusted to pH 6 containing 0.05% Tween (Sigma). This method 
was optimised and a final procedure of incubating slides in the buffer at 78°C to 83°C was 
utilised to help prevent tissue detachment from the slides. After this, slides were left under 
cold running tap water for 10 min and then blocked. 
Slides were blocked for 90 minutes at room temperature in 10% goat serum (Vector 
Laboratories) diluted in blocking buffer; PBS containing 0.1% Tween20 (Sigma) (PBS-T). 
Primary antibodies were diluted in blocking buffer at concentrations indicated in Table 3-6 
and applied to sections before incubation overnight at 4°C.  
The following day slides were washed in PBS four times for 5 minutes each before 
incubation in 3% hydrogen peroxide (Sigma) for 15 minutes. All incubation steps on the 
second day were performed at room temperature. Slides were washed three times the 
host species of the primary antibody used, either an anti-rabbit kit (Rabbit Specific 
HRP/DAB (ABC) Detection IHC kit, Abcam) was used or an HRP-conjugated secondary 
antibody (see Table 3-6). 
When using the anti-rabbit kit the manufacturer’s instructions were followed. Briefly, 




times in PBS (5 minutes each) and incubated with the streptavidin peroxidase solution for 
10 minutes. Otherwise when using an HRP-conjugated secondary, the antibody was 
diluted in 1% BSA and slides incubated for 1 hour.  
After secondary antibody incubation or the streptavidin peroxidase incubation (for the kit 
samples) slides were washed four times in TBS, 5 minutes each. Samples were then 
incubated with DAB substrate for the time quoted in Table 3-6 before stopping the enzyme 
reaction by submersion of the slide in PBS. Finally, samples were counterstained with 
methyl green (see below). 
Table 3-6 – Antibodies used for immunohistochemistry 
Antigen Code Species  Company Dilution DAB incubation 
Primary antibodies 
     
Type II Collagen ab34712 Rabbit pAb Abcam 1 in 100 5 minutes 
Type IV Collagen ab6588 Rabbit pAb Abcam 1 in 400 3 minutes 
NIMP (neutophil) ab2557 Rat mAb Abcam 1 in 100 6 minutes 
CD68 ab125212 Rabbit pAb Abcam 1 in 100 3 minutes 
Ki67 12202 Rabbit mAb CST 1 in 400 10 minutes 
Secondary antibodies 
     
HRP-conjugated anti-rat  ab205720 Goat Abcam 1 in 2,500   
 
3.13.3.2. Methyl green staining 
Methyl green is a nuclear stain that is used as a counterstain to DAB 
immunohistochemistry staining. After completion of IHC, slides were washed in distilled 
water for 5 minutes before transfer to preheated (60°C) methyl green (Vector 
Laboratories) solution for 5 minutes. Slides were then transferred to tap water (three 
changes) and the slides left for 1 minute in the third tap water change. Slides were then 
dipped into acetone containing 0.05% acetic acid 6 to 8 times. Sections were then 
dehydrated through 95% and 100% ethanol (one change, 5 minutes each) and then 
cleared with xylene (2 changes, 5 minutes each) before mounting in DPX medium. 
3.13.3.3. Alcian Blue 
Alcian blue stains proteoglycan components of the extracellular matrix. After 
deparaffinisation and rehydration, sections were stained with a solution of 1% Alcian blue 
(Sigma) diluted in 0.1 M HCl overnight. Sections were subsequently dehydrated through 
95% and 100% ethanol (one change, 5 minutes each) and then cleared with xylene (2 
changes, 1 minutes each) before mounting in DPX medium. 
3.13.3.4. Haematoxylin / Eosin  
Haematoxylin stains basophilic substances such as DNA and RNA in nuclei while eosin 
colours eosinophilic structures in various shades of red, pink and orange (Schmitz et al., 




solution (Cell Signalling Technologies) for 5 minutes and then rinsed in running tap water 
until clear. Slides were then dipped into 2% acetic acid 10 times, followed by 10 dips into 
tap water before transfer into a bluing solution of 0.2% ammonium hydroxide in 70% 
ethanol for 1 minute. Next, slides were dipped 10 times in tap water before incubation in 
Eosin Y (Sigma) for 30 seconds. Sections were subsequently dehydrated through 95% 
and 100% ethanol (one change, 5 minutes each) and then cleared with xylene (2 changes, 
5 minutes each) before mounting in DPX medium. 
3.13.3.5. Safranin O / Fast Green / Weigert’s iron haematoxylin 
Safranin O staining is a cationic dye that stains acidic proteoglycans orange to red. Fast 
green acts as a counterstain, staining background tissue and cell cytoplasm green whilst 
Weigert’s iron haematoxylin stains nuclei black (Schmitz et al., 2010).  
After deparaffinisation and rehydration, sections were stained with Weigert’s iron 
haematoxylin (Sigma) working solution for 10 minutes, followed by washing under running 
tap water for 10 minutes. Slides were then transferred to 0.1% Fast Green FCF (Sigma) 
for 5 minutes, before transferred to 1% acetic acid for 10 to 15 seconds. Subsequently 
slides were stained in 0.1% Safranin O (Sigma) solution for 5 minutes. Sections were then 
dehydrated through 100% ethanol (2 changes, 5 minutes), cleared with xylene (2 
changes, 5 minutes each) and mounted using DPX mounting medium. 
3.13.3.6. Pico-Sirius Red 
Pico-Sirius Red stains connective tissue and can be used for the visualisation of type I 
and III collagen fibres that when viewed under polarised light results in birefringence 
(Schmitz et al., 2010). After deparaffinisation and rehydration, sections were stained with 
Pico-Sirius Red solution (Abcam) for 1 hour and then rinsed in 0.5% acetic acid solution. 
Sections were then dehydrated through 100% ethanol, cleared with xylene (2 changes, 5 
minutes each) and mounted using DPX mounting medium. 
3.13.3.7. Thionin 
Thionin is a metachromatic dye that binds to negatively charged glycosaminoglycans 
indicative of cartilage matrix (Narcisi et al., 2015). After deparaffinisation and rehydration, 
sections were stained with 0.5% thionin acetate salt (Sigma) solution for 2 minutes before 
rinsing with distilled water. Sections were then dehydrated through 100% ethanol, cleared 
with xylene (2 changes, 5 minutes each) and mounted using DPX mounting medium. 
3.13.3.8. Toluidine blue / Fast Green 
Toluidine blue, like Safranin O, is a cationic dye that stains proteoglycans and additionally 
stains acidic nucleic acids (Schmitz et al., 2010). The dye is a metachromatic stain and 
its staining properties are altered depending upon the pH of the solution. Fast green was 




After bringing slides to water, they were stained for 10 minutes in 0.04% Toluidine blue 
(Sigma) made in 0.1 M sodium acetate buffer at pH 4. Slides were then washed in three 
changes of distilled water (30 seconds each). Counterstaining was carried out in 0.02% 
Fast Green for 3 minutes before two water washes (30 seconds each). Finally, slides were 
dehydrated through three changes of 95% ethanol and two changes of 100% ethanol and 
two changes of xylene before DPX mounting.  
3.14. Histological Section Imaging Techniques and Analysis 
3.14.1. Standard and Polarised Light Microscopy 
Bright field imaging of histological sections was performed using one of two microscopes. 
Either a Leica DM RXA2 Microscope with images captured using a MicroPublisher 3.3 
RTV Camera (QImaging) and Q Capture Pro 7 software or a M8 microscope and scanner 
(PreciPoint) using ViewPoint software. Polarised light images were taken with the former 
with the addition of a polarising filter.  
3.14.2. Confocal Microscopy 
Cryo-sectioned histology images were taken on a Leica Sp5 or Leica SPE ultra-high 
speed inverted confocal microscopes in Cambridge NIHR BRC Cell Phenotyping Hub. 
Prior to imaging samples were removed for storage at -20 and washed in distilled water 
before mounting using ProLong Diamond Antifade Mountant with DAPI (Thermo Fisher 
Scientific). Z-stacks were taken and analysed using ICY and FIJI (de Chaumont et al., 
2012; Schindelin et al., 2012).  
3.15. Articular Cartilage Repair Scoring 
To assess the level of cartilage repair in the pre-clinical osteochondral imaging model, a 
modified Pineda scoring system was used (Pineda et al., 1992). Histological sections 
stained with Safranin O / Fast Green / Weigert’s iron haematoxylin were scored blindly by 










Table 3-7 - Histological scoring system based on Pineda et al. (1992) 







Reconstruction of osteochondral junction   
Yes 0 
Almost 1 
Not close 2 
Matrix staining (bone & cartilage)   
Normal  0 
Reduced staining  1 
Significantly reduced staining 2 
Faint staining 3 
No stain 4 
Cell morphology   
Normal Reduced staining  0 
Most hyaline and fibrocartilage 1 
Mostly fibrocartilage 2 
Some fibrocartilage, but mostly nonchondrocytic cells 3 
Nonchondrocytic cells only 4 
3.16. Statistical Analysis 
The number of replicates for each experiment are detailed in the figure legends. Points 
on graphs represent the mean, and error bars show standard deviation unless specified. 
Analysis was performed using GraphPad Prism 6 to produce graphs/histograms and 
perform statistical analysis using analysis of variance (ANOVA) or other statistical tests 
as specified in the figure legends. Tukey and Dunnett’s tests were performed as post-hoc 
analysis to identify differences between experimental groups. Statistical analysis was 
performed when data from a minimum of three replicates was available. 
   
63 
 
4. RESULTS: HAEMATOPOIETIC PROGENITORS HAVE A DIRECT 
EFFECT ON STROMAL CELL FUNCTION 
4.1. Background and Rationale 
Granulocyte colony stimulating factor (G-CSF) is a commonly used agent in the field of 
haematological disorders and has a principle action of increasing myeloid lineage cell 
numbers systemically as well as haematopoietic progenitors and stem cells (HSPCs). The 
therapeutic use of G-CSF has been reported in several papers to improve the outcomes 
of a number of surgical approaches for bone and cartilage repair (see section 1.10). 
However, these reports have lacked comment on the biological mechanism(s) through 
which this cytokine brings about these effects.  
HSPCs commonly reside in the bone marrow of long bones where they are maintained 
for life long haematopoiesis by the specialised microenvironment of the bone marrow 
niche. Cells of the bone marrow niche involved in HSPC homeostasis also are of 
relevance to musculoskeletal repair such as mesenchymal stem/stromal cells (BMSCs). 
Furthermore, research groups have shown that co-culture of BMSCs and haematopoietic 
progenitor populations in vitro provides a dynamic model in which to study the interactions 
of these cell types (Jing et al., 2010). 
Most of the work studying the interactions of cells within the bone marrow niche has 
focused on the haematopoietic lineage cells, in an attempt to further understanding of the 
haematopoietic supportive capacity of the niche microenvironment (Bianco, 2011). There 
is however evidence of crosstalk between HSPCs and the other cells in the surrounding 
niche and it is through this action that the HSPCs can regulate the microenvironment itself 
(Durand, Charbord and Jaffredo, 2018) .  
4.2. Aim and objectives 
The aim of this chapter is to further understand the influence of HSPC-MSC niche 
interactions on BMSC fate. To investigate this question, the first objective was to establish 
a co-culture system that allowed the interaction of murine HSPCs and BMSCs to be 
studied in vitro. This model was then used to characterise specific haematopoietic 
progenitor subpopulations that influence the differentiation potential of BMSCs. It was 
hypothesised that BMSC differentiation would be altered by the presence of HSPCs within 
the surrounding microenvironment.  
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4.3. The evaluation of D1 ORL UVA cells as murine BMSC model 
D1 ORL UVA (ATCC, CRL-12424) (RRID:CVCL_6495) is a murine stromal cell line that 
was developed in the 1990’s and patented in 1997 (Patent number US6082364, accepted 
04-Jul-2000). The patent describes evidence that the cell line is capable of tri-lineage 
differentiation (osteogenesis, chondrogenesis and adipogenesis) and that when 
transplanted into the tail vein of mouse recipients, the cells home to the bone marrow. 
The cell line was derived from the non-adherent fraction of BALB/c mouse bone marrow 
through incubation steps with and then without monocyte-colony stimulating factor. The 
cell line was subsequently derived clonally from the remaining adherent fraction. Several 
published papers have utilised the D1 ORL UVA cell line as a model of murine BMSCs 
(Mussano et al., 2010; Phinney et al., 2006).  
Prior to utilising this cell line, multiple attempts had been made to isolate primary murine 
MSCs by plastic adherence, however expanded cell numbers were not large enough to 
move forward to co-culture systems (data not shown). For this reason, an established and 
stable cell line was used in subsequent experiments. After purchase and expansion, the 
cell line was assessed for its BMSC properties. 
4.3.1. Morphological appearance 
Morphologically the cell line exhibits characteristics of adherent fibroblastic-like cells, with 
a stellate form when cultured on plastic (Figure 4-1).   
   
Figure 4-1 – Phase light microscopy image of D1 ORL UVA cell line.  
D1 ORL UVA cells were grown on tissue culture plastic and imaged using a 10x objective. 
Scale bar indicates 200 µm. 
4.3.2. Differentiation potential 
Differentiation potential is the defining feature of cells described as BMSCs and D1 ORL 
UVA cells were assessed for their ability to differentiate into osteoblasts, chondrocytes 




and adipocytes. Firstly, the cells were evaluated for their ability to form extracellular matrix 
(ECM) indicative of differentiation down each of these lineages and secondly for the 
expression of genes related to each lineage over 10 days. 
D1 ORL UVA cells were cultured as monolayers for 21 days under osteogenic, adipogenic 
and chondrogenic conditions. At 7 days morphological changes were seen relative to 
control media (Figure 4-2). Notably, adipogenic differentiation media led to the formation 
of phase bright lipid vacuoles within cells (Figure 4-2 C i). After 21 days, tri-lineage 
differentiation was confirmed by evaluation of biological staining using a light microscope. 
The matrix staining shown in Figure 4-2 confirmed the potential of these cells to generate 
the three forms of ECM. Osteogenic differentiation was confirmed by the presence of 
mineralising matrix and aggregates stained with alizarin red (Figure 4-2 A ii), 
chondrogenic differentiation by staining for polyanionic matrix with alcian blue (Figure 
4-2 A ii), and adipogenic differentiation by the presence of hydrophobic lipid vacuoles 
stained with oil red O (Figure 4-2 A ii).  
Further to the endpoint assessment of the ECM production, gene expression analysis by 
qRT-PCR was used to elucidate the dynamics of the differentiation process by 
assessment at multiple timepoints, day 1, 3, 7 and 10 (Figure 4-3). Under osteogenic 
conditions D1 ORL UVA cells increased the transcription of genes associated with both 
early and late osteogenic differentiation. For example, between 1 day and 3 days of 
osteogenic induction the expression of two key  transcription factors, Runx2 and Sp7 
(osterix)  both increased over 10-fold at these early time points (Figure 4-3 A). Osterix 
continued to increase over the timecourse to over 250-fold at 10 days. Between 1 day and 
10 days of induction, transcription of key matrix proteins was upregulated. Bglap is the 
gene transcript for osteocalcin, a protein produced soley by osteoblasts, and mRNA levels 
increased  >9,500 fold over this time.  
All adipogenic genes assessed showed a rapid increase between day 1 and day 3 (Figure 
4-3 C) at which point they remained high and stable up until the final timepoint of day 10. 
These include the nuclear receptor Pparγ gene which is known to activate genes that 
stimulate lipid uptake and adipogenesis.  
Following chondrogenic induction, D1 ORL UVA cells showed a steady increase in 
abundance of Sox9, Tgfβ and Col2a transcripts up until day 7 (Figure 4-3 B).  At day 10 
the levels of these chondrogenic genes began to fall in these highly dense monolayer 
cultures. 




Figure 4-2 - Histological staining of tri-lineage differentiation of the murine cell line 
D1 ORL UVA.  
D1 ORL UVA were differentiated down the osteogenic, chondrogenic and adipogenic 
lineages (N=3). After 7 days cells were visualised and imaged by light microscopy (20x 
objective). After 21 days cells were visualised and imaged by light microscopy (10x 
objective) after histological staining with alizarin red (osteogenesis), alcian blue 
(chondrogenesis) and oil red O (adipogenesis). Arrowheads indicate lipid vacuoles at 7 
days (C i) and at 21 days stained with oil red O (C ii). Scale bars indicate 200 µm. 
  





Figure 4-3 – Gene expression analysis of D1 ORL UVA tri-lineage differentiation. 
D1 ORL UVA were differentiated down the osteogenic (A), chondrogenic (B) and 
adipogenic (C) lineages. Cells were harvested at day 1, day 3, day 7 and day 10 and 
analysed for genes specific for each pathway. Bars indicate the expression of mRNA for 
each gene normalised to Hprt. Error bars indicate the standard deviation of the mean for 
technical replicates for qRT-PCR run in triplicate (N=1). 
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4.3.3. Phenotypic Evaluation 
Several cell surface antigens have been published as markers of murine MSCs. Using 
the ‘R&D Systems Mouse Mesenchymal Stem Cell Marker Antibody Panel’ a selection of 
these markers were used to assess the phenotypic profile of the D1 ORL UVA cell line by 
flow cytometry (Figure 4-4).  
The cells were grown to 70% confluency in expansion media and stained with one of the 
eight antibodies or one of three isotype controls (rat IgG2A or IgG2B and sheep IgG). For 
each sample between 43,000 and 46,000 single cells were recorded and analysed. The 
appropriate isotype controls were used to set the gates and thus determine the true 
expression of cell surface markers as a percentage of total single cells.  
As expected, the cells demonstrated negativity for haematopoietic markers such as CD45 
and CD11b, with less than 2% of cells being positive. With regard to MSC markers, over 
90% of cells were positive for CD29, CD44 and CD73 and the majority of cells were 
positive for CD106 (86.5%), but only 6.3% of cells were positive for CD105. Interestingly, 
the Sca-1 antigen showed a wide spread in expression indicating its expression is highly 
variable.  
Based on the evidence presented here, confirming the tri-lineage differentiation potential 
and a phenotypic profile known to represent murine BMSCs, D1 ORL UVA cells were 
used as a model of murine BMSCs for the co-culture experiments described below.  





Figure 4-4 – Phenotypic analysis of D1 ORL UVA cells for eight murine MSC 
markers. 
Analysis of the expression of CD29, CD44, CD73, CD106, Sca-1, CD105, CD45 and 
CD11b on D1 ORL UVA cells by flow cytometry. (A) Scatter plots of (i) forward versus 
side scatter area used to identify cells and (ii) forward scatter area versus forward scatter 
width used to eliminate cell doublets. (B) Logarithmic histograms showing the appropriate 
isotype control (all except CD44 are IgG2A whist CD44 is IgG2B) in white, used to set the 
gating, with the stained cells overlaid in grey. (C) Graph summarising the percentage of 
positive cells for each antigen. Secondary antibody was conjugated to APC.  
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4.4. The lineage negative fraction of primary bone marrow contains 
haematopoietic stem and progenitor cells 
4.4.1. Haematopoietic progenitors 
Haematopoietic stem and early progenitors differ phenotypically from more mature cells 
of the haematopoietic hierarchy as they are negative for mature haematopoietic lineage 
markers.  To isolate a fraction enriched for these early progenitors, bone marrow was 
harvested from the hind limb long bones of mice by crushing to liberate a single cell 
suspension and subsequent depletion of mature haematopoietic cells by immune-
magnetic separation using a lineage antibody cocktail. 
The presence of HSPCs within this population was confirmed by the colony-forming unit 
cell (CFU-C) assay, Figure 4-5. Culture in methylcellulose restricts the movement of cells 
and allows for the identification of non-adherent colonies from single progenitors. Based 
on the morphology of individual cells and the colony itself, the progenitor subtype can be 
determined. Colonies of the erythroid and macrophage lineage were identified alongside 
colony forming unit-granulocyte, macrophage, erythroid and megakaryocyte (CFU-
GEMM) colonies. The latter is the earliest lineage identifiable by this assay. The results 
from this assay in Figure 4-5 therefore confirm the ability to isolate primary haematopoietic 
progenitors from murine bone marrow by lineage depletion.  
 
Figure 4-5 – Lineage negative bone marrow cells form haematopoietic colony 
forming units. 
Lineage negative bone marrow cells were cultured in methylcellulose for 14 days cells 
and then were visualised by light microscopy. Different colony morphologies identify 
different haematopoietic lineages of the haematopoietic progenitors. (A) CFU-M, a 
macrophage colony, (B) CFU-E, erythroid based colony, (C) BFU-E, burst forming 
erythroid colony, (D) CFU-GEMM, granulocyte, macrophage, erythroid and 
megakaryocyte colony. Images were taken at 10x magnification. Scale bar indicates 100 
µm. 




4.5. Immuno-depleted bone marrow contains haematopoietic stem cells 
defined as Lineage negative, Sca-1 and c-Kit positive 
Mouse haematopoietic stem cells (HSCs) can be identified more specifically using 
phenotypic markers. The most basic phenotypic profile for HSCs is positivity for Sca-1 
and c-Kit in addition to being negative for mature haematopoietic markers. This is termed 
the LSK+ fraction (Peng et al., 2012). 
Cells that were isolated from the bone marrow of BALB/c mouse hind limbs and immune-
magnetically lineage depleted were subsequently stained with Sca-1 and c-Kit antibodies 
as well as a viability dye and a lineage marker antibody cocktail. Figure 4-6 illustrates the 
gating strategy used based on the fluorescence of unstained cells. Firstly, single cells 
were gated and selected for their negativity for the viability dye 7-AAD, and their negativity 
for the lineage cocktail. These double negative cells were then analysed for c-Kit and Sca-
1 expression (Figure 4-6 D).   
 
Figure 4-6 – Gating strategy for the identification of LSK+ cells by flow cytometry.  
Primary mouse bone marrow cells were isolated and depleted of mature lineage positive 
haematopoietic cells by immune-magnetic sorting. Enriched lineage negative cells were 
analysed for the expression of Sca-1 and c-Kit and the absence of lineage markers. (A) 
Cells were identified based on forward versus side scatter area and (B) single cells by 
forward scatter area versus forward scatter width. (C) Logarithmic scatter plot used to 
gate viable lineage negative cells and (D) serial gating for Sca-1 and c-Kit antigens. Gates 
set against unstained controls.    
Figure 4-6 confirms the presence of LSK+ in the lineage negative fraction. Further, Figure 
4-7 shows a comparison between cells of the whole bone marrow isolate against those 
depleted of mature haematopoietic lineages by immune-magnetic sorting. Cells were 
stained with 7-AAD, Sca-1 and c-Kit antibodies and a lineage marker antibody cocktail 
before flow cytometry analysis recording 100,000 events. Figure 4-7 B shows the success 
of the depletion strategy as the proportion of lineage negative cells increases from 66.7 
to 92.5% whilst the number of LSK+ cells increases by 3.4-fold to 1.2%. Additionally, the 
proportion of the haematopoietic progenitors defined by their phenotype of lineage 
negative, Sca-1- and c-Kit+ (L-S-K+) also increases from 7.06% to 37.4%, an increase of 
5.3-fold. The double negative for Sca-1 and c-Kit does not change whilst the Sca-1+, c-Kit- 
cells decreases in proportion by half. In summary, the depletion of lineage positive cells 
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from mouse bone marrow increases the concentration of haematopoietic stem and 
progenitors within the total cell fraction.  
 
Figure 4-7 – Comparison of lineage negative, Sca-1 and c-kit populations before 
and after lineage depletion of bone marrow.  
Mouse bone marrow cells were analysed by flow cytometry for the expression Sca-1 and 
c-Kit with and without the previous depletion of mature haematopoietic cells by immune-
magnetic cell sorting. (A) Logarithmic scatter plots for Sca-1 and c-Kit after gating for 
viable lineage negative single cells, (i) total bone marrow, (ii) immuno-magnetic lineage 
depleted bone marrow. (B) The percentage of each population as a proportion of total 
viable cells. Gates set against unstained controls. 100,000 total events recorded for each 
sample.  
4.6. Lineage negative Bone Marrow Cells Regulate Stromal Cell Fate 
With the confirmation of BMSC properties of the cell line D1 ORL UVA and the ability to 
isolate a bone marrow fraction enriched for haematopoietic stem and progenitor cells, co-
culture experiments of the two populations were set up. The objective of this series of 
experiments was to determine whether interaction between the adherent cell line D1 ORL 
UVA and primary haematopoietic stem and progenitor enriched fraction of lineage 
negative cells had a downstream effect on stromal cell differentiation.   
Firstly, the two cells types were co-cultured with either 1x104 or 1x105 lineage negative 
cells added to 12 well plates in which D1 ORL UVA cells had been grown to 90-100% 
confluency. Co-cultures were cultured under control media for 3 days before media 
removal and the addition of differentiation inducing media. 




4.6.1. Reduction in matrix production 
4.6.1.1. Osteogenesis 
After 3 days of co-culture followed by 21 days of osteogenic differentiation, alizarin red 
staining for mineralised matrix was performed to assess whether differentiation was 
altered by the presence of lineage negative cells. The addition of 1x104 lineage negative 
cells showed islands where staining was absent, whilst the osteogenesis of the cell line 
alone led to complete staining of the wells (Figure 4-8). However, when quantified by FIJI 
contrast analysis no significant difference was seen. On the other hand, a 10-fold increase 
in lineage negative cells (1x105) led to a further reduction in the amount of mineralised 
matrix and resulted in a significant decrease in alizarin red staining relative to the 
monoculture of the D1 ORL UVA cell line.  
Microscopy analysis using a 10x objective showed that these stain-free regions with a 
lack of calcium deposits were not devoid of cells but in fact had abundant cells growing 
but without surrounding calcium deposits. This indicates a lack of matrix production by the 
cells in these isolated areas and a reduction in osteogenesis.  
4.6.1.2. Chondrogenesis 
This lack of matrix production was also seen when cells were exposed to chondrogenic 
stimuli. After 3 days of co-culture with 1x105 lineage negative cells, chondrogenic 
differentiation led to islands where cells did not form a 3D structure of cells pilling up 
(Figure 4-9 A). These observations were supported quantitatively by assessment of the 
production and secretion of proteoglycans in to the media as assessed by the DMMB 
assay (Figure 4-9 B). This assay showed a significant reduction in proteoglycans not only 
in the 1x105 co-culture but also in the 1x104 co-culture.   
4.6.1.3. Adipogenesis 
Whilst matrix production was significantly affected in osteogenic and chondrogenic 
differentiation assays by the co-culture with HSPC, the effect upon adipogenesis was not 
clear when assessed by oil red O staining. The images in Figure 4-10 A are representative 
for each condition, and alongside a further three images from three wells per condition 









Figure 4-8 - Histological staining and quantification of osteogenic differentiation 
after co-culture. 
D1 ORL UVA cells were grown to confluency in 12-well plates and then cultured either 
alone or with 1x104 or 1x105 bone marrow lineage negative cells (Lin-) isolated by 
immuno-magnetic depletion in control media. After 3 days media was replaced with osteo-
inductive media. 21 days after osteogenic induction, cells were stained with alizarin red 
and imaged both macroscopically (A) and microscopically (B). (C) Alizarin red staining 
was quantified using macroscopic images (N=3). Scale bar indicates 200 µm. Statistical 
significance was calculated using a one-way ANOVA with Tukey’s test for multiple 
comparisons, with *** indicating a p<0.001. 





Figure 4-9 - Histological staining and quantification of chondrogenic differentiation 
after co-culture.  
D1 ORL UVA cells were grown to confluency in 12-well plates and then cultured either 
alone or with 1x104 or 1x105 bone marrow lineage negative (Lin-) cells isolated by 
immuno-magnetic depletion in control media. After 3 days media was replaced chondro-
inductive media. 21 days after chondrogenic induction, cells were stained with alcian blue 
and imaged microscopically (A) and media removed for the analysis of proteoglycan 
content using the DMMB assay (B) (N=3). Scale bar indicates 200 µm. Statistical 
significance was calculated using a one-way ANOVA with Tukey’s test for multiple 
comparisons, with * indicating a p<0.1. 
 




Figure 4-10 - Histological staining and quantification of adipogenic differentiation 
after co-culture. 
D1 ORL UVA cells were grown to confluency in 12-well plates and then cultured either 
alone or with 1x104 or 1x105 bone marrow lineage negative (Lin-) cells isolated by 
immuno-magnetic depletion in control media. After 3 days media was replaced chondro-
inductive media. 21 days after osteogenic induction, cells were stained with alizarin red 
and imaged microscopically (A). (C) Oil red O staining was quantified using microscopic 
images (N=9). Scale bar indicates 200 µm. Statistical significance was calculated using a 
one-way ANOVA, no significance.  
4.6.2. Change in gene expression at 7 days 
As matrix production was seen to be altered in both osteogenesis and chondrogenesis 
matrix assays when using 1x105 lineage negative cells, gene expression studies were 
used to support these findings. Rather than allowing differentiation to continue to 21 days, 
as for matrix assessment, RNA was harvested at 7 days after initiating differentiation of 
the co-culture. This time point was chosen based on the results from earlier studies 
(Figure 4-3) where the expression of differentiation genes was induced. 
In support of the histological staining results at 21 days, qRT-PCR at 7 days showed no 
significant change in the expression of adipogenic genes between the two groups (Figure 
4-11 C) whilst all osteogenic genes tested decreased (Figure 4-11 B). Chondrogenic gene 
expression showed a decrease in the transcription factor Sox9 and the chondrogenic 
promoting growth factor Tgfβ. Type II collagen (Col2a), on the other hand was increased 
by nearly 4-fold (Figure 4-11 C). 




   
Figure 4-11 - Gene expression analysis of D1 ORL UVA tri-lineage differentiation 
after co-culture 
D1 ORL UVA cells were grown to confluency in 12-well plates and then cultured either 
alone or with 1x104 or 1x105 bone marrow lineage negative cells isolated by immuno-
magnetic depletion in control media. After 3 days media was replaced differentiation 
inductive media - osteogenic (A), chondrogenic (B) or adipogenic (C). After 7 days in 
differentiation media cells were harvested and analysed for genes specific for each 
pathway. Bars indicate the expression of mRNA for each gene normalised to Hprt. Error 
bars indicate the standard deviation of the mean for technical replicates for qRT-PCR run 
in triplicate (N=1). 
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4.7. Lineage negative cells integrate into the stromal monolayer and are 
maintained for 7 days 
With the assumption that direct cell-to-cell contact was required for the decrease in D1 
ORL UVA osteogenic differentiation after co-culture, confocal microscopy was performed 
to explore the dynamics of the lineage negative bone marrow cells interaction with the cell 
line. For this experiment, the haematopoietic fraction was isolated by immune-magnetic 
depletion from mice expressing GFP under the ubiquitin promoter. The primary cells 
isolated therefore expressed GFP (Schaefer et al., 2001).  
After 3 days of co-culture, cells were fixed and stained with phalloidin, to visualise the 
actin filaments of the cytoskeleton, and DAPI before confocal imaging. Z-stack projection 
(Figure 4-12) shows localisation of the GFP positive lineage negative bone marrow cells 
at both the surface of the D1 ORL UVA stromal layer and beneath. This demonstrates 
that the two cell populations have a strong interaction with the haematopoietic population 
incorporating into and beneath the D1 ORL UVA cell layer. 
  
Figure 4-12 – Interaction of bone marrow lineage negative cells and D1 ORL UVA 
monolayer.  
D1 ORL UVA cells were grown to confluency in 0.7 mm2 wells of glass slide chambers. 
Bone marrow lineage negative cells isolated by immuno-magnetic depletion from 
ubiquitin-GFP reported mice were added to the wells in control media. After 3 days media 
was removed and the cells fixed and imaged by confocal microscopy (A) (63x objective). 
Actin filaments, red; nucleus, blue; bone marrow lineage negative cells, green. Scale bar 
indicates 40 µm.  




Gene expression analysis at 3 days showed that the cells interacting with the monolayer 
were haematopoietic lineage cells (Figure 4-13). The expression of Ptprc (CD45 protein), 
a classical marker of haematopoietic cells, and Cfsr3 (G-CSF receptor) were over 100 
times greater in co-cultures than the stromal D1 ORL UVA cells alone. The expression of 
these genes remained significantly higher than monocultures at 7 days indicating the 
haematopoietic cells were maintained in the co-culture. Interestingly, genes specific to 
haematopoietic progenitors, Flt3 and Hck decreased between 3 days and 7 days 
suggesting a loss of progenitor phenotype.  
 
Figure 4-13 – Haematopoietic gene analysis after co-culture. 
D1 ORL UVA cells were grown to confluency in 12-well plates and then cultured in control 
media either alone or with 1x105 bone marrow lineage negative (Lin-) cells isolated by 
immuno-magnetic depletion. After 3 days cells were either harvested or media was 
replaced with fresh control media. After a further 7 days cells were harvested from the 
remaining wells. All harvested cells were analysed for the expression of haematopoietic 
genes. Bars indicate the expression of mRNA for each gene normalised to Hprt. Error 
bars indicate the standard deviation of the mean for technical replicates for qRT-PCR run 
in triplicate (N=1). 
4.8. Altered levels of osteogenic gene expression in D1 ORL UVA cells 
following co-culture with lineage negative cells  
Due to the continued presence of lineage negative derived cells at 10 days of co-culture, 
an assessment was made to determine their specific influence on D1 ORL UVA 
expression of genes representing osteogenic differentiation. To perform these studies, 
GFP lineage negative cells from GFP ubiquitin promoter mice were used. After co-culture 
for 3 days followed by 7 days of osteogenic differentiation, the cells were detached by 
trypsinisation and separated by fluorescence activated cell sorting. This removed GFP 
expressing cells and allowed isolation of the GFP negative D1 ORL UVA cells only.  
Phase contrast microscopy merged with fluorescent imaging of the GFP channel (Figure 
4-14 A), illustrates the presence of GFP cells in the co-culture after 7 days of osteogenic 
induction. Flow cytometry plots show that as expected in the D1 ORL UVA only culture 
no GFP cells were detected, whereas in the co-culture, 5.2% of the total cells were GFP 
positive (Figure 4-14).  
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Gene expression analysis of unsorted co-cultures showed a decrease in the expression 
of osteogenic genes, by approximately half, as previously demonstrated in Figure 4-11 
(although on this occasion no change in Runx2 transcript levels were observed). This 
difference was maintained in GFP- D1 ORL UVA cells isolated by FACS where GFP+ 
haematopoietic cells had been removed. This confirms that the analysis of osteogenic 
gene expression in these co-cultures is not skewed by the presence of haematopoietic 
cell RNA.  
4.9. Haematopoietic progenitor fraction (Lin-Sca1-cKit+) is predominantly 
responsible for the reduction in D1 ORL UVA osteogenesis  
Having demonstrated that primary lineage negative bone marrow cells reduce the 
osteogenesis of the stromal cell line D1 ORL UVA, the next step was to investigate which 
cells of the lineage negative fraction were exerting this effect.   
Firstly, the lineage negative population was divided in two based on Sca-1 and c-Kit 
expression. Figure 4-15 A shows the serial gating strategy used to isolate single viable 
lineage negative cells and the selection of cells positive for both Sca-1 and c-Kit (LSK+ 
fraction). The remaining cells, gated as single viable lineage negative cells, were also 
collected and named the LSK- fraction. As previously described for other experiments, 
these cells were added to confluent layers of D1 ORL UVA cells and cultured for 3 days 
after which osteogenic induction media was added. However, a limited number of LSK+ 
cells were isolated and numbers equivalent to those of lineage negative and LSK- 
populations were not available (1x105/well). Therefore 1x103 LSK+ cells were added per 
well. 
At 7 days, cells were harvested for mRNA gene expression analysis. In Figure 4-15 the 
expression of two osteogenic genes, Bglap and Sp7, is shown for multiple replicates of 
this experiment. As seen previously the expression of both genes was reduced in all 
replicates for the co-culture of lineage negative cells with D1 ORL UVA cells (Figure 4-15 
B), although this was not significant across all experimental replicates. This trend however 
was maintained for the co-culture with the LSK- FACS isolated fraction. The LSK+ fraction, 
on the other hand, led to variable results for both genes.  
 





Figure 4-14 - Isolation by FACS and gene expression analysis of D1 ORL UVA GFP- 
cells after co-culture.  
D1 ORL UVA cells were grown to confluency in 12-well plates. Bone marrow lineage 
negative (Lin-) cells isolated by immuno-magnetic depletion from ubiquitin-GFP reported 
mice were added to the wells in control media. After 3 days media was replaced with 
osteo-inductive media for 7 days and then imaged. (A) Phase contrast with GFP overlay 
of co-culture. (B) For three wells per condition cells were detached by typsinisation, 
combined and sorted by FACS for GFP negative cells, (i) D1 ORL UVA alone, (ii) co-
culture. Cells were identified based on forward versus side scatter area and then gated 
for single cells by forward scatter area versus forward scatter width. (C) Subsequently, 
GFP negative cells were gated and isolated for osteogenic gene expression analysis (i). 
Gene expression analysis was also conducted for unsorted cultures where RNA was 
isolated directly from the wells including lineage negative cells (ii). Bars indicate the 
expression of mRNA for each gene normalised to Hprt. (N=1).  




Figure 4-15 –Osteogenic differentiation of D1 ORL UVA after co-culture with lineage 
negative subpopulations. 
Primary mouse bone marrow cells were isolated and depleted of mature lineage positive 
haematopoietic cells by immune-magnetic sorting. Enriched lineage negative cells were 
used directly or sub-divided into subpopulations by FACS based on the expression of 
Sca-1 and c-Kit (A). (i) Cells were identified based on forward versus side scatter area 
and (ii) single cells by forward scatter area versus forward scatter width. (iii) Logarithmic 
scatter plot used to gate viable lineage negative cells and (iv) serial gating for Sca-1 and 
c-Kit antigens. Viable lineage negative cells were sorted into two populations - cells 
positive for Sca-1 and c-Kit (LSK+) and those lineage negative cells remaining. Gates set 
against unstained controls. The primary cell populations were added to D1 ORL UVA cells 
grown to confluency in 12-well plates. After 3 days media was replaced with osteo-
inductive media. After 7 days in differentiation media, cells were harvested and analysed 
for the expression of two osteogenic genes (B) (i) Bglap and (ii) Sp7. Bars indicate the 
expression of mRNA for each gene normalised to Hprt. Error bars indicate the standard 
deviation of the mean for biological replicates across 4 experiments (N=9 or 12). No 




significance difference calculated using a one-way ANOVA. In other replicate wells, after 
21 days osteo-induction, cells were stained with alizarin red and imaged macroscopically 
(C). (D) Alizarin red staining was quantified using macroscopic images (N=3, single 
experiment). Statistical significance was calculated using a one-way ANOVA with a 
Dunnett test for multiple comparisons, ****  p<0.0001. Scale bar indicates 200 µm.  
 
Figure 4-16 - Osteogenic differentiation of D1 ORL UVA after co-culture with lineage 
negative subpopulations. 
Primary mouse bone marrow cells were isolated and depleted of mature lineage positive 
haematopoietic cells by immune-magnetic sorting. Enriched lineage negative cells were 
used directly or sub-divided into subpopulations by FACS based on the expression of 
Sca-1 and c-Kit (A). (i) Cells were identified based on forward versus side scatter area 
and (ii) single cells by forward scatter area versus forward scatter width. (iii) Logarithmic 
scatter plot used to gate viable lineage negative cells and (iv) serial gating for Sca-1 and 
c-Kit antigens. Viable lineage negative cells were sorted into four populations 1. Sca-1- 
and c-Kit+ (LS-K+), 2. Sca-1- and c-Kit- (LS-K-), 3. Sca-1+ and c-Kit- (LS+K-) and 4. Sca-1+ 
and c-Kit+ (LS+K+). Gates set against unstained controls. The primary cell populations 
were added to D1 ORL UVA cells grown to confluency in 12-well plates. After 3 days 
media was replaced with osteo-inductive media. After 7 days in differentiation media, cells 
were harvested and analysed for the expression of osteogenic genes (B). (i) Runx2, (ii) 
Bglap, (iii) Sp7 and (iv) Col1a. Bars indicate the expression of mRNA for each gene 
normalised to Hprt. Error bars indicate the standard deviation of the mean for biological 
replicates of a single experiment (N=3). Statistical significance was calculated using a 
one-way ANOVA with Tukey’s test for multiple comparisons ****  p<0.0001, ** p<0.01 and 
* p<0.1. 




Figure 4-17 – CD45 and CD31 analysis of LS-K+ cells by flow cytometry. 
Primary mouse bone marrow cells were isolated and depleted of mature lineage positive 
haematopoietic cells by immune-magnetic sorting. (A) Cells were identified based on 
forward versus side scatter area and (B) single cells by forward scatter area versus 
forward scatter width. (C) Logarithmic scatter plot used to gate viable lineage negative 
cells and (D) serial gating for Sca-1 and c-Kit antigens. Cells determined to be Sca-1- and 
c-Kit+ were analysed for the expression of CD45 and CD31 on a logarithmic scatter plot.  
With the potential to reduce D1 ORL UVA osteogenesis predominantly ascribed to the 
LSK- fraction, this population was further sub-divided as illustrated in the quadrants of the 
Sca-1 c-Kit flow cytometry plot (Figure 4-16 A iv). The cells were co-cultured as previously 
described and analysed for osteogenic gene expression. Results for the total lineage 
negative fraction were consistent with preceding experiments, demonstrating significance, 
except for Col1a. Interesting the only fraction that maintained the reduction in gene 
expression was the Sca-1 negative, c-Kit positive (LS-K+) fraction of the lineage negative 
cells. The other two fractions had equivalent transcript levels to D1 ORL UVA cells alone. 
Furthermore, for the genes Runx2, Bglap and Sp7, the expression was significantly lower 
than that for the total lineage negative fraction. Noteworthy, Col1a did not show a 
decreased expression in any of the conditions but did increase in co-cultures with the 
lineage negative, Sca-1, c-Kit negative (LS+K-) cells 
4.9.1. The LS-K+ cell fraction contains CD45highCD31+ and CD45lowCD31- 
subpopulations 
To identify what cell types the LS-K+ fraction contains, the cells were additionally stained 
for CD45 and CD31. In Figure 4-17 E, flow cytometry showed that there were two sub-
populations within this fraction, most clearly separated by their expression for CD31. 
CD45 expression was also different between the two populations with Population 1 having 
a slightly lower abundance of this antigen relative to Population 2. 
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4.10. Discussion  
The aim of this chapter was to investigate the direct influence of haematopoietic stem and 
progenitor cells (HSPCs) on the differentiation of bone marrow stem/stromal cells 
(BMSCs). BMSCs are a key cell type widely studied within the field of musculoskeletal 
science due to their ability to differentiate into the mesenchymal lineages of bone, 
cartilage and adipose tissue, as well as a having a trophic role influencing other cell types 
in the surrounding microenvironment. The BMSC population is thought of as a 
heterogeneous population within which individual cells have different phenotypes with 
some cells exhibiting different levels of commitment to particular cell lineages. The ability 
to drive endogenous BMSC in vivo to a particular phenotype could be of benefit in a clinical 
setting. As HSPC numbers increase after G-CSF treatment, understanding the impact of 
the interaction between HSPCs and BMSCs in the haematopoietic niche will provide 
mechanistic insight into the use of G-CSF in skeletal repair strategies.   
4.10.1. In vitro co-culture as a model of the BM niche 
Monolayers of feeder cells have been used for many years as a method to maintain the 
multi-potency of HSCs in vitro (Dexter, Allen and Lajtha, 1977). By mimicking some of the 
interplay that occurs in vivo, these cultures have allowed researchers to study the role of 
the microenvironment in controlling the fate of HSCs. Commonly cell lines have been used 
as the feeder cells and have often been grown out from adherent bone marrow cells. 
Whilst mostly not defined more specifically than this, these cells are likely to be BMSCs 
by their most simple definition of plastic adherent bone marrow cells. 
In this chapter, the BALB/c mouse bone marrow derived stromal cell line D1 ORL UVA 
was used to model mouse BMSC activity. To support the use of this cell line the cells were 
first characterised to confirm their tri-lineage differentiation capability and phenotypic 
profile of the population. As with human BMSCs, a single marker for mouse BMSCs has 
not been identified but several markers have been described in the literature (Morikawa 
et al., 2009; Zhou et al., 2014; Méndez-Ferrer et al., 2010). By using a panel of markers, 
data presented here shows that the D1 ORL UVA cell line expresses markers such as 
CD73 and CD44, and lacks haematopoietic markers, supporting previous phenotypic 
analysis of the cell line (Mussano et al., 2010). It is important to note than unlike primary 
BMSCs that represent the diversity of BMSC phenotypes, this cell line is likely to represent 
only an isolated phenotype and therefore a discrete/distinct population of BMSCs. In ideal 
circumstances primary BMSCs would have been used, however, attempts to reproducibly 
isolate sufficient numbers of phenotypically similar cell populations were unsuccessful. 
Further experiments to support the observations made in this chapter could be performed 
using primary murine cultures, but perhaps more relevantly could be performed using 
human derived cell populations.  
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HSPCs and BMSCs reside in close physical association in the bone marrow, making 
direct co-cultures an important tool in mimicking cell-to-cell niche dynamics and according 
direct cell-to-cell culture were used here. To begin this series of experiments, the lineage 
negative fraction of bone marrow enriched for HSPCs was added to the D1 ORL UVA 
stromal cell line and strong interactions between the two cells populations formed as 
lineage negative cells integrated into the stromal cell layer. Jing and colleagues (2010) 
observed similar in vitro dynamics between human BMSCs and HSPCs in direct cultures. 
The authors investigated further and found that BMSCs could act as a physical boundary 
between distinct compartments of HSPCs – progenitors that are more quiescent were 
found to migrate below the MSC monolayer, forming a three-dimensional 
microenvironment (Jing et al., 2010). This supports the conclusion that the co-culture 
model used in the studies presented here likely represents interactions present in the in 
vivo bone marrow niche.  
4.10.2. HSPC enriched fraction reduces osteogenic differentiation 
The in vitro co-culture model was used first to evaluate the effect of co-culture on the 
differentiation of the stromal cell line down osteogenic, chondrogenic and adipogenic 
pathways.  Adipogenic differentiation of the stromal cell line was unaffected by co-culture 
whilst both osteogenic and chondrogenic differentiation were seen to be reduced.  
Osteogenic differentiation was assessed by studying early gene expression levels at 
7 days after induction of differentiation and matrix deposition of calcium as a late marker 
of osteoblastic extracellular matrix mineralisation. Since cell populations were not 
separated following co-culture, gene expression was assessed in RNA isolated from all 
cells in the co-culture system raising the possibility of lineage negative cell transcripts 
influencing observations of the stromal cell lines differentiation. Runx2, for example, is a 
gene upregulated early in osteogenic differentiation (Xu et al., 2015) but is also expressed 
by HSPCs (de Bruijn and Dzierzak, 2017). To try to decipher the contribution of lineage 
negative cells to the gene expression profile, separation of the two population was 
performed by FACS prior to analysis. Whilst HPSCs will have contributed to the transcript 
levels of the housekeeping genes used for normalisation, the evaluation conducted 
demonstrated that their impact upon relative osteogenic gene transcript levels was 
minimal. Consequently, further evaluations were made based on total co-culture 
transcripts.  
Through further enrichment steps, the population within the lineage negative bone marrow 
fraction determined to be responsible for the decreased osteogenesis potential of co-
cultures was the lineage negative, Sca-1 negative, c-Kit positive fraction. This phenotype 
is known to be that of HPCs including multipotent progenitors and common myeloid 
progenitors that express high levels of c-Kit whilst having low expression of the cell 
surface the antigen Sca-1. In the C57BL/6 strain of mice the expression of Sca-1 can 
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differentiate between HSCs and HPCs, unfortunately however, the use of bone marrow 
fractions derived from BALB/c mice here prevents differentiation between these two 
populations.  
The BALB/c mouse strain was chosen in order to maintain strain species between the two 
cell populations, as the D1 ORL UVA cell line was original derived from this strain. 
Unfortunately, the identification of HSCs from Balb/c mice based on LSK+ expression is 
not regarded as very effective, as this strain has a lack of Sca-1 expression (Spangrude 
and Brooks., 1993). This provides an explanation as to why a limited number of LSK+ cells 
(HSCs) were isolated from these mice leading to an inability to add equivalent numbers 
of LSK+ cells to co-cultures relative to the other populations studied. For this reason the 
specific effect of HSCs alone on the culture system was not assessed comparably with 
the other lineage negative fractions and furthermore HSCs were likely to have been sorted 
into the LS-K+ fraction. Therefore, whilst it can be concluded that the HSPC population 
reduced the subsequent osteogenesis of the stromal cell line, it is not possible to 
distinguish between the influence of HSCs or HPCs within the HSPC enriched fraction. 
Other published studies have used the C57BL/6 strain as a source of LSK+ and observed 
a different response after co-culture. Liao et al. (2011) conducted direct co-cultures of 
LSK populations with primary mouse BMSCs that were pre-conditioned with 
dexamethasone prior to establishment of co-cultures. The authors’ results demonstrated 
that the addition of LSK+ cells led to enhanced calcium deposition whereas removal of 
dexamethasone from the co-culture reduced deposition (Liao et al., 2011). Significantly, 
the areas where deposition was reduced were where HSPCs were localised, correlating 
with the data gathered in the work presented here. This data suggests that the interplay 
between BMSCs and HSPCs in driving BMSC osteogenesis is influenced by the strength 
of the osteogenic cues. Moreover, a more osteogenic (endosteal-like) niche is generated 
under culture with dexamethasone. In addition to the strong pro-osteogenic effects of this 
steroid, it can also act upon HSPCs directly and increase the quiescence of 
haematopoietic stem cells (Kim et al., 2008). Through this action dexamethasone might 
drive enhance osteogenesis to BMSC culture alone. 
Overall, these observations indicate that the dynamics of the bone marrow niche are 
complex and that BMSCs and HSPCs have a reciprocal relationship in regulating one 
another. Additionally, they suggest that BMSC osteogenic differentiation is dependent on 
both HSPC numbers and osteogenic cues which are likely relevant to G-CSF and bone 
inducing regenerative therapies.  
4.10.3. HSPCs promote and maintain a supporting stromal cell niche 
Commonly in musculoskeletal research, the aim is to improve the differentiation potential 
of BMSCs, for example by adding pro-osteogenic scaffolds (Perez et al., 2018). In 
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contrast, in these studies HSPCs reduced the deposition of calcium by BMSCs in co-
culture. Interestingly, both BMSCs and osteoblasts are known to be key components of 
the bone marrow niche and therefore the promotion of either phenotype by HSPCs may 
indicate the potential for dynamic modulation of the niche environment by these 
haematopoietic cells.  
The relationship between HSPCs and BMSCs is believed to be dependent on in vivo 
location within the bone marrow niche, for example the endosteal or vascular regions. As 
discussed, the co-cultures established here are likely to include higher numbers of HPCs 
relative to HSCs. The endosteal niche, where osteoblasts are the key cell type, is thought 
to maintain the quiescence of more primitive HSCs (Lambertsen and Weiss, 1984). The 
vascular niche, on the other hand, is thought to maintain more mature progenitors, being 
closer to the vasculature where HPCs are poised to enter the blood stream (Bianco, 
2011). BMSCs are considered part of the vascular niche. One might therefore hypothesise 
that the high numbers of HPCs in the co-culture may lead to the preferential maintenance 
of BMSCs that make up their vascular stromal compartment rather than promote their 
differentiation.  
Additionally, the experiments conducted in this chapter were performed under normoxic 
conditions. Although the bone marrow as a whole is considered a hypoxic environment 
relative to general systemic oxygen levels, within the niche itself there is an oxygen 
gradient (Parmar et al., 2007). The reduced vasculature of the endosteal niche makes this 
environment more hypoxic. In the future, it would be worthwhile to assess the effect of 
oxygen tension on the differentiation of the co-culture. If the decrease in osteogenic 
differentiation is due to HPSCs and the maintenance of BMSCs in a vascular niche-like 
culture system, perhaps under hypoxia a more endosteal niche would develop with 
increased osteogenic differentiation.  
4.10.4. Are the trophic/immunomodulatory roles of BMSCs influenced by HSPCs? 
Importantly, data collected in the current study demonstrates that LS-K+ cells influence 
stromal cells with BMSC properties. Whilst differentiation has been focused on in this 
work, the multiple actions of BMSCs mean that other BMSC properties should also be 
considered e.g. immunomodulatory potential. If interactions between these HSPCs and 
BMSCs alter the secretome of BMSCs, this may have consequences if BMSCs encounter 
inflammation or trauma in their surrounding environment. The immunomodulatory ability 
of the D1 ORL UVA cell line has not been evaluated here nor in published literature, and 
may worth investigation. 
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4.10.5. G-CSF and the model 
The bone marrow niche is a complex multi-cell environment whereas this co-culture model 
represents a simplistic version of in vivo conditions. Whilst G-CSF treatment of patients 
increases the number of HSPCs, and other haematopoietic cells, this is only one way 
G-CSF might affect the activity of BMSC during tissue repair events. This cytokine is seen 
to cause changes in numerous cell types, from osteoblasts to mature haematopoietic 
cells, within the bone marrow altering the biology of this complex microenvironment.  
To begin to establish the influence of G-CSF within this environment the cytokine could 
be added to the co-culture model and experimental assessments made as conducted 
here to understand the cytokines influence on the cross talk between the cell populations. 
In addition to increasing the number of HSPCs in the bone marrow, G-CSF also alters the 
transcription profile of these cells (Schuettpelz et al., 2014). When administered in vivo, 
G-CSF can be considered to lead to haematopoietic stress inducing sudden changes in 
the haematopoietic system.   
Jung et al. (2008) isolated HSCs from animals that were haematopoietically stressed 
either by bleeding to remove 20 to 30% of their blood volume or 5-fluorouracil treatment 
(another HSC mobilising agent, which is also used as a chemotherapeutic drug). The 
authors present data showing that in transwell culture HSCs isolated from haematopoietic 
stressed mice increase osteogenesis of BMSCs through the production of bone 
morphogenetic proteins (BMP-2 and BMP-6) (Jung et al., 2008). Investigation in to 
whether G-CSF causes similar changes in HSCs or HSPC populations could add insight 
into the effect of G-CSF on BMSC function. Furthermore, surgical procedures, such as 
those used in orthopaedic procedures, that lead to blood loss may additionally exacerbate 
these effects.   
4.10.6. Future directions 
Future work could attempt to unpick the cell type responsible for the decrease in 
osteogenesis of D1 ORL UVA cells. As discussed, the first objective could be to determine 
whether HSCs or HPCs are responsible but this would require the use of an alternative 
strain of mice for haematopoietic cell isolation rather than BALB/c mice in order to recover 
cells based on Sca-1 expression. Additionally, the final experiment conducted in this 
series of work demonstrated that the lineage negative, Sca-1 negative, c-Kit positive 
fraction contained two populations identifiable by differences in the expression of CD31 
and CD45. CD31 or Platelet Endothelial Cell Adhesion Molecule-1 is commonly used to 
identify endothelial cells but these cells are negative for CD45. To a lesser extent, CD31 
is expressed on myeloid progenitors (Bronte et al., 2000) which as discussed have the 
L-S-K+ phenotype. Initially, the two populations based on CD31 and CD45 of L-S-K+ cells  
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could be evaluated but to define a specific population such as myeloid progenitors a 
specific isolation strategy would be required such as CD11b+/Gr-1+/CD31+.  
Another line of development could be the translation of this model with the use of human 
derived cells. Initial attempts for this were made here (data not shown) by isolation BMSCs 
and CD34+CD38- HSCs from human bone marrow. Constraints to the use of this model 
were a lack of HSC numbers. Perhaps other sources of HSCs could be useful in 
developing a human model system such as using umbilical cord derived or apheresis 
product CD34+CD38- cells. The advantage of using primary BMSCs human cells would 
allow the analysis of different differentiation pathways and immunomodulatory effects of 
HSCs on the stromal bone marrow component using techniques already established 
within the laboratory.   
Finally, as previously mentioned analysis of the effect of G-CSF on bone marrow niche 
dynamics may provide insight into the effect of G-CSF upon this microenvironment and 
whether it primes BMSCs to a particular lineage prior to their exposure to differentiation 
stimuli.  
4.10.7. Summary 
This work has identified that HSPCs and BMSCs have a dynamic reciprocal relationship, 
which influences the differentiation potential of stromal cells when exposed to osteogenic 
stimulating cues. The influence of G-CSF on these interactions remains to be explored.  
However, purely on the basis that HSPCs increase in the bone marrow after G-CSF 
administration, one could hypothesise that osteogenic differentiation is suppressed. If 
trauma is induced at this time, where osteogenesis is required for repair, it may occur at 
a lower rate, though cessation of G-CSF treatment has further consequences (see chapter 
6 and section 6.6.3). Importantly, it is recognised that the in vivo bone marrow niche is a 
complex microenvironment and G-CSF will have effects on other cells and interactions 
within the bone marrow, making this perhaps a simplistic view.
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5. RESULTS: OSTEOCHONDRAL DEFECT MODEL IN C57BL/6 
MICE ILLUSTRATES TEMPORAL AND SPATIAL CELL 
DYNAMICS DURING REPAIR 
5.1. Background and Rationale 
Traumatic articular cartilage injuries in adult patients are reported to have limited capacity 
to repair and consequently predispose affected joints to further cartilage degeneration and 
increased likelihood of osteoarthritis (OA) (Punzi et al., 2016). Treatments for these 
defects are limited and commonly patients are required to wait for significant OA 
progression to warrant surgical intervention such as total joint replacement. Intervening 
earlier, with treatments such as microfracture and autologous chondrocyte implantation 
(ACI), has the potential to hinder or halt the progression of joint degeneration as well as 
treating the acute problem. Unfortunately, the outcomes of these techniques are variable 
(Fellows et al., 2016).  
Whilst articular cartilage is reported to have limited repair potential, spontaneous healing 
has been described in humans as well as animal models. Importantly, spontaneous 
healing is particularly associated with full-thickness cartilage defects that penetrate the 
subchondral bone over cartilage only defects (Lydon, Getgood and Henson, 2017; 
Dell’accio and Vincent, 2010). This is hypothesised to be due to the access of a full-
thickness lesion to the bone marrow below the subchondral bone plate, which contains 
multiple stem and progenitor cell types. Recapitulation of this using the microfracture 
technique in human patients has positive outcomes but often leads to the formation of 
fibrocartilage lacking the properties of the original hyaline cartilage (Caldwell and Wang, 
2015). By elucidating the cartilage repair process and understanding the molecular and 
cellular mechanisms leading to repair tissue, therapeutic targets may be identified to 
improve these outcomes and encourage intrinsic hyaline cartilage healing.  
To both aid understanding of the repair process and to trial potential therapeutics in vivo, 
an optimised animal model is required. Large animal models are commonly used for 
cartilage repair studies due to the similarity in structure and mechanical loading relative 
to humans (Kuyinu et al., 2016). However, for early pre-clinical investigations smaller 
animals are more useful due to their low cost, ease of maintenance and relatively short 
regeneration time. Many studies using osteochondral defects have been conducted in 
rabbits and rats, but mice offer a further advantage, their amenability to genetic 
manipulation (Eltawil et al., 2009).  
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5.2. Aim and objectives 
This chapter describes the development and evaluation of an osteochondral model in 
mice. Further insights into the repair process were gained by examining the contribution 
of different cell types at different stages of repair.  
To achieve this, an overview of the currently published models in mice was conducted 
and an optimised technique established by trialling different methods to generate an 
osteochondral defect. Once achieved, a time course study was conducted and specimens 
analysed by histology and immunohistochemistry, firstly to assess the reproducibility and 
consistency of the defect and secondly to identify different cell types in and around the 
repair tissue across different time points.  
5.3. Literature review of published osteochondral mouse models 
Several osteochondral models had previously been described in the literature prior to 
beginning this work. A summary of the key features from these publications is described 
in Table 5-1.  The published studies had various aims with the earlier published articles 
looking first to establish a model and then address specific questions using it (Fitzgerald 
et al., 2008; Eltawil et al., 2009; Martinez et al., 2015). Later articles then reference the 
Eltawil et al. (2009) paper for its methodology (Matsuoka et al., 2015; Mak et al., 2015). 
Whilst some insight has been made into the cell dynamics within these models limited 
time points have left scope for an in depth analysis of defect healing over time. 
Based on the information gathered by analysis of the published literature, decisions were 
made for experimental parameters. Firstly, across all studies detailed in Table 5-1 the 
C57BL/6 strain of mice was used (excluding Martinez et al., 2015). This strain is well 
characterised to have a poor healing ability and is reported in all cases to fail to fully heal 
the cartilage injury by 8 weeks. This provides an opportunity to analyse the process by 
which the defect attempts to repair with the potential to adapt the process and quantify 
any improved repair that occurs through intervention. Importantly, C57BL/6 mice are the 
most popular strain of genetically manipulated mice and therefore it is worthwhile 
establishing a repair model in these mice in the first instance.  
Secondly, the age of the mice is a key feature. Eltawil et al. (2009) and Matsuoka et al. 
(2015) aimed to assess the differences in the repair between mice of different ages, 
finding that younger mice showed improved repair. Importantly, all the studies 
documented used skeletally mature animals of 8 weeks of age as a standard reference 
(excluding Martinez et al., 2015, where 15 weeks was used).  
Finally, the method of inducing a defect is detailed in Table 5-1. All studies made the 
defect in the distal femur within the patella (or trochlear) groove and, barring Mak et al., 




the patella was dislocated laterally before the defect was made using a needle between 
25G and 27G. The type of the defect, on the other hand, falls into one of two types; either 
a cylindrical defect made by rotation of the needle, or a scratch produced by passing the 
needle along the length of the patella groove.  
The papers all claim to form osteochondral defects and in the simplest of cases this was 
confirmed during surgery by the appearance of blood to confirm penetration of the 
subchondral bone. Eltawil et al. (2009), Matsuoka et al. (2015) and Mak et al. (2015) all 
attempted to control the depth of the defect by modifying the needle, with either a glass 
bead or a 21G needle sheathing the smaller needle to prevent deeper penetration of the 
defect into the marrow cavity.  
Table 5-1 – Review of published patella groove osteochondral defect studies  
Fitzgerald et 
al., 2008 






Mak et al., 
2015 
Age of mice: 8 weeks  8 weeks or 8 
months 
15 weeks 3 weeks, 4 
weeks and 8 
weeks 
4 to 6 weeks 
Sex: Male and 
female 
Male Female Not defined Not defined 
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5.4. Model development  
Using the key features from the published studies discussed above, certain parameters 
were defined before beginning model optimisation. Female, C57BL/6 strain mice were 
chosen between 8-10 weeks of age with the aim to generate a cylindrical osteochondral 
defect within the patella groove of the distal femur. A cylindrical defect was chosen to 
ensure production of an osteochondral defect by a more controllable pushing motion 
rather than a sweeping scratch. Firstly, experimental trials were conducted on ex vivo 
cadavers of mice to gain practice and insight into the practicalities of the technique.  
Once a method was established to access the joint by lateral displacement of the patella, 
different needle sizes were compared. Needles were selected of sizes similar to those 
used in the published studies discussed above (section 5.3). The largest needle trialled 
was 21G. This was found to be large relative to the patella groove, which led to difficulties 
in needle placement and regularly led to breakage of the ridge of the femoral condyles. 
Similar difficulties were found with the 23G needle. The smallest size trial was 27G. These 
were found to be fragile and susceptible to bending when pushed against the surface of 
the joint. Optimal needle size to maintain the needle integrity and generate a defect with 
minimal damage to the surrounding joint structure was as a result determined to be 26G.   
Histological sections were generated from these trials and can be seen in Figure 5-1 and 
highlight the need to consider further the needle placement. Whilst establishing that the 
defect should be located centrally within the patella grove, the length of the groove meant 
optimal placement for a cylindrical defect needed to be determined. As shown in Figure 
5-1 (21G, 23G, 25G and 27G), histological analysis revealed that in initial attempts defects 
were made relatively posteriorly/low in the groove, a location which has limited articular 
cartilage as this site is non-loading bearing and encounters minimal friction. This meant 
the defect needed to be positioned more superiorly in the patella groove. However, the 
depth must be limited as the presence of an open growth plate in mice means the top of 
the patella groove is a vulnerable location to breakage of the epiphysis. Furthermore, as 
shown in Figure 5-1 (26G) the defect can also penetrate through the epiphyseal growth 
plate of the femur. A compromise is therefore required and the defect must be positioned 
centrally along the length of the patella groove.  
In line with three of the published protocols, a method with which to establish a controlled 
depth was investigated. Whilst the methodology of Matsuoka and colleagues’ (2015) 
using a larger needle to sheath a smaller one sounded promising, fabrication of the 
sheathed needle and its use for defect generation encountered difficulties. Firstly, cutting 
of larger 21G needles with which to sheath the 26G needle led to compression of the 
metal and meant the hollow cylinder was regularly no longer fully open so that the smaller 
needle could not be inserted. Further, on trial of metal sheath needles on mouse cadavers, 
the edge of the sheath caused damage to the ridge of the femoral condyles due to its 




sharp nature. This was a cause for concern as the aim was to make a defect with sharp 
intact cartilage borders. 
 
Figure 5-1 – Trial of different gauge needles to generate an osteochondral defect  
Mice cadavers were used for the trial of needles ranging from 21G to 27G to determine 
the optimal size for use going forward. The placement of the defect was observed relative 
to the articular cartilage and femoral epiphyseal growth plate highlighted in dark blue. 
Sagittal sections stained with Toluidine blue / Fast Green. Sections decalcified under acid 
conditions. Scale bar indicates 1 mm.   
Subsequently, this led to trial of other sheathing materials. Whilst, Eltawil et al. (2009) and 
Mak et al. (2015) utilised beads attached with resin glue, it was decided to adopt the idea 
of sheathing the needle to help ensure that the needle entered at a perpendicular angle. 
A method using small green plastic collars was developed. This had the advantage of 
controlling the depth whilst avoiding damage to the femoral condyles on rotation of the 
needle.  




Figure 5-2 – Generation of an osteochondral defect in the patella groove  
(A) Schematic representation of the sagittal cross-sectional view of the middle of the 
patella groove after generation of an osteochondral defect within the articular cartilage. 
(B) Toluidine blue / Fast Green staining of a sagittal histological section from a mouse 24 
hours after generation of the defect. (C) The devise used to generate the defect - a 26G 
needle with 0.06 mm of its tip exposed, denoted by 0.6 mm line. (D) The left hind of two 
mice during surgery. A 1 cm skin incision was made over the left knee joint, and the patella 
groove exposed by lateral dislocation of the patella, and an osteochondral defect made 
by pressure and rotation of the device. Some defects bleed after penetration (i) whilst 
others remained hollow (ii). The patella was replaced and sutured in place before skin 
suturing. P, patella; AC, articular cartilage; D, osteochondral defect; GP, growth plate; FP, 
fat pad. Scale bar indicates 1 mm. 




5.5. Generation of an osteochondral defect  
Figure 5-2 A shows a schematic of the cross-sectional view across the centre of the 
patella groove and the optimal positioning of the osteochondral defect under the patella 
within the articulating cartilage, penetrating the bone. Figure 5-2 B shows the histology of 
an animal at 24 hours post-surgery and an osteochondral defect positioned as intended. 
Figure 5-2 C shows the device used to produce this defect – a 26G needle with 0.6mm of 
the tip expose by the positioning of a green plastic collar.  A full description of the final 
surgical procedure can be found in the methods section (see section 3.12.5). Figure 5-2 
D shows images of two mice during the surgical procedure before realignment of the 
patella. This demonstrates that not all osteochondral defects bled during surgery.  
5.6. Reproducibility and consistency of creating the model 
osteochondral defect  
At 24 hours post-surgery, animals were sacrificed and the patella groove re-exposed for 
photography and macroscopic assessment of the defect. Figure 5-3 A shows the defect 
for 8 mice at this time point. In all animals the defect had infilled with tissue. In some 
animals this tissue was bloodier in appearance (Figure 5-3 A i to iii) whereas in others the 
boundaries were more difficult to assess (vi to viii). Black dotted lines denote the femoral 
condyles and demonstrate that the defect was located centrally within the patella groove. 
Figure 5-3 B shows the ratio of the defect relative to the width of the femoral condyles. 
This data indicates that the defect expands across 43% of the groove (N=8).  
To further assess the reproducibility and consistency of the osteochondral defect 
generated across different individual mice, histomorphometric measurements were made 
from sagittal histological sections of these mice. Figure 5-3 C shows sections from a single 
mouse at 150 μm intervals moving from the medial to lateral side stained with 
Safranin O / Fast Green which were used for these measurements. Firstly, the histology 
sections demonstrate the change in morphology of the joint across the patella groove. On 
the first section (Figure 5-3 C i), the distal femur is at it’s largest, articulating directly 
against the proximal tibia with mensci visible in the joint space. The femoral growth plate, 
stained red by the Safranin O stain, has a wave morphology. 150 μm further (Figure 5-3 
C ii) the morphology is similar, but the wave of the femoral growth plate is slightly flatter. 
At this point the edge of the osteochondral defect can also be identified. The next section 
(Figure 5-3 C iii) is from within the patella groove. This can be identified by several 
anatomical features aside from the presence of the osteochondral defect. Firstly, the 
femoral growth plate is now almost flat and secondly the joint space is wider as the femoral 
and tibial surface no longer directly articulate, instead, the cruciate ligaments can be seen 
in this space.  
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Using serial sections from three mice, measurements were taken for the cross-sectional 
width, depth and area of the defect. Figure 5-3 D presents values for the width of the 
defect at intervals of a maximum of 50 µm. With the maximum width centred on 0 µm, the 
shape of the defect was cylindrical and similar across the three animals shown. 
Furthermore, the maximum width, depth and area were consistent and highly reproducible 
(Figure 5-3 E) with the coefficient of variation of these measurements and the defect to 
patella groove width ratio all between 4.5 and 6.5% (Table 5-2).  
 
Figure 5-3 – Reproducibility and consistency of the osteochondral defect 
Osteochondral defects were generated in eight mice and after animal euthanasia at 24 
hours the defect imaged (A). (B) Graph shows the ratio of measurements taken for the 
width of the defect to the width of the patella groove (N=8). Joints were prepared and 
sagittal sections prepared. Safranin O (red) staining of the femoral growth plate provides 
a landmark for histology preparation (C). Counterstained with Fast Green and 
haematoxylin. Scale bar indicates 1 mm.  Measurements for histomorphometric analysis 
of the defect (width, depth and area) were taken from these sections. (D) Width of the 
defect across serial sections, maximum 50 µm apart. 0 represent the centre of the defect 
– the largest width. Polynomial regression, r squared value between 0.84 and 0.90 for 
each animal. The maximum measurement for (i) width, depth and (ii) area. All the values 
are expressed as mean ± standard deviation (N=3).  




Table 5-2 – The mean, the standard deviation (SD) and coefficient of variation (CV) 
of histomorphometric measurements 
  








Mean 41.64 729.0 µm 1205 µm 626.3 mm2 
SD ±2.48 ±41.62 ±58.58 ±39.50 
CV 5.88% 5.71% 4.87% 6.31% 
 
5.7. Analysis of osteochondral repair over 8 weeks 
A time course analysis was conducted over 8 weeks post-surgery, eight mice per group. 
Mice were scarified at 24 hours, 1 week, 2 weeks, 4 weeks and 8 weeks post-surgery. All 
operations were performed without incident. All animals recovered and were weight 
bearing within the 30 minutes of removal from anaesthesia. Due to time constraints, only 
three or four animals from each group were sectioned and used for further analysis.   
5.7.1. Early healing osteochondral defects have distinct repair regions 
Figure 5-4, Figure 5-5, and Figure 5-6, show Toluidine Blue / Fast Green staining of the 
distal femur of mice at 24 hours, 1 week and 2 weeks respectively after generation of the 
osteochondral defect. Toluidine blue is a basic dye and stains nuclei and denotes areas 
of acidic proteoglycans such as the articular cartilage and femoral growth plate whilst Fast 
Green is used here as a counterstain.  
At all of the time points, a clear boundary between the intact articular cartilage and the 
borders of the defect is clearly seen (except for one mouse at 2 weeks where articular 
cartilage crosses over the defect). However, the deeper margins of the defect become 
less clear over time. Whilst clear at 24 hours, and definable at 1 week, by 2 weeks the 
repair of the tissue makes it difficult to determine the borders of the defect.  
Cellular organization was observed by higher 40x magnification of the defects. For the 
purposes of description, the defect can be considered in three regions: top middle and 
bottom. At 24 hours, the patella-articulating surface of the defect shows the presence of 
an overlying cap of fibres orientated across the defect. Beneath this a less dense fibrous 
network is seen in which cells are widely dispersed. One animal (Figure 5-4 B I top) had 
a large cluster of red blood cells in this tissue whilst the other two animals had red blood 
cell clusters and nucleated cells distributed throughout the top and middle regions. By 1 
week, the top of the defect has become significantly denser in structure with lateral fibrous 
structures continuing to cap the articular surface. Red blood cells are still present but in 
smaller in clusters below this fibrous cap. At 2 weeks on the other hand, these cells are 
no longer present and the matrix structure of this top section of the defect has significantly 
changed. Most obvious is the overall increase in positive staining with toluidine blue and 
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specifically its strong staining of lacunae within which cells sit. This is suggestive of the 
presence of chondrocytes that are depositing a proteoglycan rich matrix. Interestingly 
these cells are not at the level of the articulating surface but 50 μm below, extending down 
to 300 μm and within the centre of the defect rather than at the side edges. In one animal 
at 1 week, these histological observations of chondrogenesis are also seen deeper, in the 
middle region of the defect. 
In the defects at 24 hours and 1 week, blue/purple stained material is identifiable in all 
animals, although there is variability. Furthermore, in one animal per time point there was 
clear disruption of the distal femoral growth plate. Debris from the growth plate was not 
significant in the 2-week animals, except two animals where there was a chondrogenic 
island at the very base of the defect.   
Most notable at 2 weeks was the re-establishment of bone marrow architecture at the 
base of the defect. Additionally, bone structures appear to be re-forming with Fast Green 
staining intensity similar to the undamaged surrounding bone. This differs from the earlier 
time points where the Fast Green staining was less intense and bone appeared more 
fragmented. Furthermore, at 2 weeks cell nuclei were also visible in the bone tissue within 
the defect identifying osteocytes whilst absent at earlier time points and osteoblasts are 
visible on the surface of bone fragments.  






Figure 5-4 – Osteochondral defect histology at 24 hours post-surgery.  
Toluidine blue / Fast Green staining of sagittal sections of the patella groove 24 hours 
after the generation of an osteochondral defect. 8.5x images (A) and 40x images (B) of 
three mice (i, ii and iii) showing the top, middle and bottom regions of the defects. Red 
star indicates damage to the femoral growth plate. Black arrowheads indicate toluidine 
blue stained tissue within the defect. Orange arrowheads indicate red blood cell clusters. 
Scale bars indicate 500 µm (A) and 100 µm (B). 




Figure 5-5 – Osteochondral defect histology at 1 week post-surgery.  
Toluidine blue / Fast Green staining of sagittal sections of the patella groove 1 week after 
the generation of an osteochondral defect. 8.5x images (A) and 40x images (B) of three 
mice (i, ii and iii) showing the top, middle and bottom regions of the defects. Red star 
indicates damage to the femoral growth plate. Black arrowheads indicate toluidine blue 
stained tissue within the defect. Orange arrowheads indicate red blood cell clusters. Scale 
bars indicate 500 µm (A) and 100 µm (B). 





Figure 5-6 – Osteochondral defect histology at 2 weeks post-surgery.  
Toluidine blue / Fast Green staining of sagittal sections of the patella groove 2 weeks after 
the generation of an osteochondral defect. 8.5x images (A) and 40x images (B) of three 
mice (i, ii and iii) showing the top, middle and bottom regions of the defects. Red star 
indicates damage to the femoral growth plate. Black arrowheads indicate toluidine blue 
stained tissue within the defect. Yellow arrowheads indicate osteoblasts on, and red 
arrowheads osteocytes in, bone fragments within the defect site. Scale bars indicate 
500 µm (A) and 100 µm (B). 
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5.7.2. C57BL/6 osteochondral defects can regenerate articular cartilage 
By 4 weeks after injury (Figure 5-7) there was evidence, by toluidine staining, of 
proteoglycan content across the entire defect at the articular surface in two of the three 
animals. However, the margin of the original defect with the surrounding articular cartilage 
was still identifiable. This was mostly apparent because of the increased thickness of 
cartilage at these locations and overgrowth of the repair tissue above the level of the 
surrounding articular cartilage. Interestingly, in the animal with the poorest level of healing 
(Figure 5-7 iii), there was an absence of any chondrogenesis, relative to that observed in 
the 2-week animals. The defect surface in this animal was highly cellular and more fibrous 
in appearance. In comparison, the base of the defect was well healed with bone and bone 
marrow tissue like the other animals in the group. This is most notable in the Safranin O / 
Fast Green / Haematoxylin stained sections. Like Toluidine Blue, Safranin O stains 
proteoglycans red and nuclei are counterstained with haematoxylin.  
 
Figure 5-7 – Osteochondral defect histology at 4 weeks post-surgery.  
Sagittal sections of the patella groove 4 weeks after the generation of an osteochondral 
defect. 8.5x images Toluidine blue / Fast Green (A). 40x images Toluidine blue / Fast 
Green and Safranin O /Fast Green staining (B) showing the top regions of the defects. 
Scale bars indicate 1 mm (A) and 100 µm (B). 
 





Figure 5-8 – Osteochondral defect histology at 8 weeks post-surgery.  
Sagittal sections of the patella groove 8 weeks after the generation of an osteochondral 
defect. 8.5x images Toluidine blue / Fast Green (A). 40x images Toluidine blue / Fast 
Green and Safranin O /Fast Green staining (B) showing the top regions of the defects. 
Scale bars indicate 500 µm (A) and 100 µm (B). 
In Figure 5-8 the 8-week animals are shown. The histological observations between the 
different animals were contrasting. The animal with the best level of healing (Figure 5-8 i) 
exhibited histological morphology similar to that seen in two animals at 4 weeks with 
toluidine blue staining across the defect with overgrowth of proteoglycan negative tissue 
above the intact articular cartilage level. The second animal (Figure 5-8 ii) had a 
proteoglycan rich matrix partially covering the injury starting from the distal side of the 
defect. On the proximal side, a dense highly nucleated area of tissue is observed. The 
third animal at this time point (Figure 5-8 iii) had toluidine positive matrix at the distal and 
proximal edges of the defect but minimal staining at the centre. The haematoxylin staining 
showed cells present in this central region but they do not have the appearance of 
chondrocytes as they lack the defining lacunae.  
5.7.3. Quality and variability of repair 
A modified Pineda scoring system was used to quantify articular cartilage repair. This 
system is composed of four parameters: (1) filling of the defect, (2) reconstitution of the 
osteochondral junction, (3) matrix staining, and (4) cell morphology. Together these 
scores result in an overall score that ranges from 0 (complete regeneration) to 14 points 
RESULTS: OSTEOCHONDRAL DEFECT MODEL ILLUSTRATES CELL DYNAMICS DURING REPAIR 
106 
 
(no repair) while maximum point values for single parameters range between 2 and 4. 
Scoring of Safranin O / Fast Green / haematoxylin stained sections is shown in Figure 
5-9. All animals scored the maximum of 14 points at 24 hours and at 1 week all defects 
improved to a score of 10. At 2 weeks there was a variation in the repair scores with the 
standard deviation increasing from ±0 to ±3.11 (Table 5-3), although as seen in Figure 
5-9 a single outlier animal skewed the score with a lower level healing.  This variation 
however remained in the 4 week animals with Pineda scores ranging from 3 for the best 
healed animal to 9. These observations illustrate the increased variability between 
animals at later time points.  
 
Figure 5-9 – Articular cartilage repair scores across time after generation of an 
osteochondral defect. 
Mice were sacrificed at various time points post-surgery. Safranin O / Fast Green / 
haematoxylin stained representative sections from the centre of the defect were scored 
using the Pineda scoring system (N=4). 
Table 5-3 – Scores for individual parameters of the Pineda score 
  










24 hours 4 (±0) 2 (±0) 4 (±0) 4 (±0) 14 (±0) 
1 week 0 (±0) 2 (±0) 4 (±0) 4 (±0) 10 (±0) 
2 weeks 1 (±2) 1.75 (±0.5) 3.75 (±0.5) 3 (±0.82) 9.5 (±3.11) 
4 weeks 0.5 (±0.58) 1 (±0.82) 2.25 (±1.5) 2 (±1.15) 5.75 (±2.75) 
5.7.4. Matrix remodelling  
To further assess the healing at each time point histological sections were immunostained 
for type II collagen and type VI collagen. Type II collagen is an important structural 
component of healthy articular cartilage and was seen to increase overtime within the 
defect region. At 1 week staining was present and strong in discrete areas consistent with 
the toluidine staining seen in Figure 5-5. By 2 weeks positive staining was seen centrally 
within the defect just below the articular cartilage level whilst at 4 weeks the staining had 




moved up to the articular surface. There is a lack of any real difference in the type and 
organisation of repair tissue between the 4 and 8 weeks time-points. In the better healed 
animals, the intensity of staining matched the staining of the undamaged surrounding 
cartilage.  
 
Figure 5-10 – Type II collagen staining of osteochondral defects 
Sagittal sections of the patella groove at 1 week, 2 week, 4 weeks and 8 weeks after the 
generation of an osteochondral defect stained by immunohistochemistry for type II 
collagen (brown). Nuclei are counterstained with methyl green. Scale bars indicate 500 
µm. 
Type VI collagen is another extracellular protein present in healthy articular cartilage, 
although in contrast to collagen type II, the staining is mainly concentrated in the 
pericellular matrix. Additionally, the staining had a higher intensity in the superficial layer 
of articular cartilage relative to deeper layers. At 1 week, this protein was localised to the 
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top half of the defect clearly marking the boundary between defect and surrounding bone. 
At later time points the staining continued to be localised to the top of the defect and 
remained stronger than the surrounding undamaged cartilage. In the most well healed 
animals the staining was localised to the superficial area of repaired articular cartilage 
extending over the level of the defect neighbouring undamaged cartilage.  
 
Figure 5-11 – Type VI collagen staining of osteochondral defects 
Sagittal sections of the patella groove at 1 week, 2 week, 4 weeks and 8 weeks after the 
generation of an osteochondral defect stained by immunohistochemistry for type VI 
collagen (brown). Nuclei are counterstained with methyl green. Scale bars indicate 500 
µm. 
Picrosirius red stained histological sections were imaged under polarised light resulting in 
enhancement of the natural birefringence of the collagen fibres. This allowed comparison 
across the time points of the cartilage and bone tissue organisation as well as the 
assessment of bone remodelling. 




At 24 hours within the defect there was a lack of birefringent material (Figure 5-12). 
However, broken fragments of bone were identifiable at the boundary of the defect. 
Additionally, the upper edge of the defect was clear due to the strong birefringence of the 
neighbouring undamaged cartilage and bone. This clear boundary remained at 1 week 
whilst at 2 weeks the border was less clear as collagen fibres were synthesised and laid 
down within the repair material. Furthermore, at 2 weeks there was evidence of bone 
remodelling within the repair tissue as lamellar bone was found within the lower portion of 
the defect site. At 4 weeks parallel bundles of collagen perpendicular to the articular 
surface were identifiable as well as superficial fibres, similar to undamaged cartilage, in 
line with the surface. In the 8 weeks sample there was some evidence of integration with 
the neighbouring tissue as fibres curved and crossed the wound interface.  
 
Figure 5-12 – Polarised light imaging of osteochondral defects stained with 
Picrosirius red.  
Sagittal sections of the patella groove at 1 week, 2 week, 4 weeks and 8 weeks after the 
generation of an osteochondral defect were stained with Picrosirius red and imaged under 
polarised light. 5x images (A) and 40x images (B); (i) at the articular surface and (ii) 
relatively deeper as indicated by the white boxes in (A). Scale bars indicate 100 µm. 
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5.7.5. Cell Dynamics during osteochondral injury repair 
5.7.5.1. Proliferation of cells 
Ki67 is present during all active phases of the cell cycle (G1, S, G2, and mitosis), but is 
absent from resting cells (G0). At 24 hours there is limited positive staining within the 
defect region (Figure 5-13). By 1 week post-surgery a number of Ki67 positive cells are 
present within the defect site, indicated by black arrowheads in Figure 5-14 B. 
Interestingly, there is a large increase in proliferating cells in the bone marrow cavities in 
the surrounding bone marrow relative to the 24 hour animals. At 2 weeks there is still 
positive staining in the neighbouring bone marrow, however, less proliferation is identified 
in the defect area relative to 1 week samples (Figure 5-15). Noteworthy, no positive 
staining is seen in the articular cartilage boarding the defect at any time point. 
 
Figure 5-13 – Ki67 staining of osteochondral defects at 24 hours 
Sagittal sections of the patella groove at 24 hours after the generation of an osteochondral 
defect stained by immunohistochemistry for Ki67. 5x images (A) and 40x images (B) of 
three mice (i, ii and iii) showing the top region of the defect and an area of neighbouring 
bone marrow cavity. Brown DAB staining identifies positively stained cells. Nuclei are 
counterstained with methyl green. Black arrowheads indicate positive staining in the top 
region. Scale bars indicate 500 µm (A) and 100 µm (B). 





Figure 5-14  – Ki67 staining of osteochondral defects at 1 week 
Sagittal sections of the patella groove at 1 week after the generation of an osteochondral 
defect stained by immunohistochemistry for Ki67. 5x images (A) and 40x images (B) of 
three mice (i, ii and iii) showing the top region of the defect and an area of neighbouring 
bone marrow cavity. Brown DAB staining identifies positively stained cells. Nuclei are 
counterstained with methyl green. Black arrowheads indicate positive staining (B Top). 












Figure 5-15 – Ki67 staining of osteochondral defects at 2 weeks 
Sagittal sections of the patella groove at 2 weeks after the generation of an osteochondral 
defect stained by immunohistochemistry for Ki67. 5x images (A) and 40x images (B) of 
three mice (i, ii and iii) showing the top region of the defect and an area of neighbouring 
bone marrow cavity. Brown DAB staining identifies positively stained cells. Nuclei are 
counterstained with methyl green. Black arrowheads indicate positive staining (B Top). 











5.7.5.2. Identification of neutrophils and monocytes 
Neutrophils were identified using a NIMP antibody that is highly specific for murine Ly-6G 
and Ly-6C proteins. These cells were observed within the defect at 24 hours after surgery 
but were not present in 1 and 2 week specimens (Figure 5-16).  
The protein CD68 is highly expressed by cells in the monocyte lineage. Using an antibody 
against CD68, monocytes were identified in the repair tissue of the osteochondral defects 
at 1 week and 2 weeks throughout the defect tissue (Figure 5-17. Minimal staining 
however was detected at 24 hours after surgery.  
 
Figure 5-16 – NIMP staining of osteochondral defects for the identification of 
neutrophils 
Sagittal sections of the patella groove at 24 hours, 1 week and 2 weeks after the 
generation of an osteochondral defect stained by immunohistochemistry for NIMP. 
Representative image shown from three mice per time point. Brown DAB staining 
identifies positively stained cells. Nuclei are counterstained with methyl green. Scale bars 
indicate 500 µm (A) and 100 µm (B). 
 




Figure 5-17 – CD68 staining of osteochondral defects for the identification of 
monocytes 
Sagittal sections of the patella groove at 24 hours, 1 week and 2 weeks after the 
generation of an osteochondral defect stained by immunohistochemistry for CD68. Brown 
DAB staining identifies positively stained cells. Nuclei are counterstained with methyl 
green. Images of three mice per time point (A, B and C). Scale bars indicate 500 µm.




Traumatic articular cartilage lesions can lead to pain and the development of osteoarthritis 
(OA). Bone marrow stimulation techniques such as microfracture are used clinically in an 
attempt to repair cartilage damage and delay the onset of OA. This technique however 
does not have consistent outcomes and commonly forms a repair tissue lacking the 
properties of the original hyaline cartilage. The therapeutic development of microfracture 
to improve the quality and quantity of repair tissue is currently hindered by a lack of robust 
models for the analysis of the molecular pathways involved. Furthermore, the mechanism 
and key cells types involved in osteochondral repair are not well understood.  
5.8.1. Development of an osteochondral surgical defect model 
Pre-clinical animal models are an important stage in the testing of novel therapeutics and 
treatment strategies. Whilst larger animals are more comparable to humans regarding 
joint size and articular cartilage thickness, smaller animals offer the advantage of more 
reproducible changes though higher throughput. Mice in particular offer the opportunity 
for detailed molecular and mechanistic studies, through the use of genetically manipulated 
animals. 
The model developed here was designed to be a full thickness osteochondral defect 
penetrating into the bone marrow of the distal femur. By developing a reliable device to 
create the surgical defect with a stopper to control the depth, a consistent size of defect 
was generated as seen by analysis of specimens at the 24 hour time point. Serial 
histological sections were quantified for the cross-sectional width, depth and area of the 
defect and the maximum value for each parameter recorded. These values showed 
consistency with coefficients of variation (CVs) all less than 7%.  
The defects occupied on average 43% of the patella groove and by routine observation 
of the articular cartilage surface appeared to be located centrally within the groove. 
However, whilst centrally located, the angulation of the defect was not initially controllable. 
An additional confounding factor was the technical difficulty encountered to orientate 
samples at an angle so that they were cut on exactly the vertical sagittal plane. In one 
animal at 24 hours and another at 1 week it can be observed that the growth plate is not 
flat, an anatomical feature which is seen at the midline of the patella groove suggesting 
true vertical sectioning was not achieved. These challenges were acknowledged during 
sample processing and although they may have influenced measurements of the defect 
size, by measuring across serial sections this should have been limited. 
A histological scoring system, the modified Pineda score, was used to quantify the repair 
of the defect and demonstrated the formation of new tissue over time. Improvements in 
the repair score were seen up to 4 weeks although variation between animals was 
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apparent. Previously, Fitzgerald et al. (2008) noted a decrease in cartilage repair scores 
between 6 and 12 week after creation of an osteochondral defect in female MRL/MpJ 
mice. Interestingly, this might suggest that whilst repair is achieved initially, the cartilage 
is not maintained long term. This lack of long-term integrity is a feature seen in human 
patients after microfracture surgery (Bark et al., 2014). Studies following mouse 
osteochondral defects to a later time point are required to confirm whether osteochondral 
repair tissue in this model significantly deteriorates as the mice age further. Nonetheless, 
the model may provide an opportunity to understand why human microfracture fails to 
generate articular cartilage with long-term durability and further aid the development of 
therapeutics to improve outcomes.  
The Pineda scoring system also highlights the increase in variability in repair at later time 
points. Whilst the bone and bone marrow repair appears consistent across animals, 
articular cartilage repair varies. One feature that could lead to variation in healing between 
animals is the level of defect bleeding that occurred during surgery, as some defects 
visibly bleed whilst others did not. The clinical microfracture technique uses an awl to push 
down into the subchondral bone, and like the needle used here, this results in the 
compaction of bone. Unlike drilling, the use of an awl, or needle here, leads to the 
compaction of bone lining the defect potentially limiting or blocking the supply of blood 
and access to the bone marrow compartments, as seen by Chen et al. (2009) in a rabbit 
model. When it is considered that cells of the bone marrow are thought to be the key to 
successful repair, the blocking off of this tissue may be a contributing factor to some 
defects healing better than others.  
A depth of 0.6 mm was chosen during model development for the defect depth. This depth 
was deemed suitably deep to penetrate through the articular cartilage, through the 
subchondral bone plate and into the bone marrow cavity. However, measurements of 
defect depth demonstrate that in fact defects were over 1 mm deep. This highlights a 
potential discrepancy in the needle stopper design. Either the stopper was place too high 
on the needles exposing a large proportion than intended or the stopper may have slipped 
during the curing of the glue after fixation to the needle. Whilst deeper than intended the 
coefficient of variation between the three animals measured at 24 hours was less than 5% 
indicating consistency in the depth.  
Even though consistent, the increase in depth from that intended led to the disruption of 
the femoral ephyseal growth plate in several animals. It should also be noted that this 
might have been exacerbated by the inability to control the angle at which the needle 
entered the patella groove. The growth plate contains proliferative and hypertrophic 
chondrocytes and is vital for bone growth during development. By disrupting this structure 
it is possible that cells from the growth plate were liberated and played a role in the repair 
tissue. Interestingly, looking at the specimens regeneration of the broken growth plate 
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was not observed, an observation seen in patients who suffer growth plate fractures whilst 
children (Chung and Xian, 2014). This results in the diaphysis and ephyseal bone marrow 
compartments remaining linked and, as well as the cells of the growth plate, this could 
alter the repair mechanism and most importantly its success. One should note however 
that in the patient population who acquire a cartilage lesion the growth plate is already 
closed and replaced with bone.  
Further, a number of factors mean that the osteochondral defect generated here is not a 
directly comparable model of the microfracture technique. Firstly, a cartilage lesion 
through traumatic injury will likely induce a level of inflammation in the joint (Lieberthal, 
Sambamurthy and Scanzello, 2015). Here, defects were generated in wild type mice with 
previously healthy joints and no underlying level of inflammation.  Secondly, whilst the 
patella groove offers a location of relatively easy access and uniform thickness to induce 
an osteochondral defect, this location is not the classical location at which osteochondral 
defects can usually be found in patients. Commonly they occur in the femoral condyles 
an anatomical area too small in mice for the creation of a defect using this method. There 
is a clear difference between these two anatomical locations in terms of the loading forces 
that they are exposed to. Mechanical load and shear forces are thought to be significant 
contributing factors to the repair potential of clinical defects. For example in joint 
distraction, where articulating surfaces are separated removing direct mechanical loading, 
cartilage repair is reported to improve (van der Woude et al., 2017). For these reasons, 
the repair of the osteochondral defects generated here are not absolutely equivalent to 
microfracture treatment in a clinical setting. Nonetheless, the model may provide insights 
into the key cellular players and biological mechanisms in the repair process.  
5.8.2. Wound healing pattern 
By understanding the healing of osteochondral defects and the cells involved in the repair 
process, it is hoped that insight into potential therapeutic targets can be obtained. The 
healing of wounds is known to follow a series of coordinated biological events and the 
sequence is best characterised in the repair of the skin. The process of osteochondral 
healing is less well defined but it is probable that it follows a series of defined steps. The 
first stage of wound repair irrespective of the tissue is the formation of a blood clot 
following the damage of local blood vessels. This results in a haematoma composed of a 
fibrin plug that traps proteins and cells and acts as a temporary scaffold to allow migratory 
cells to move in and around the wound.  
5.8.2.1. Inflammatory cells 
At 24 hours the osteochondral defect in this study is seen to have the open fibrous 
structure, indicative of a haematoma, through which cells are spatially distributed and 
clusters of red blood cells are seen trapped. Through immunohistochemistry staining, 
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neutrophils were confirmed to be a predominant cell type. These cells are known to arrive 
at sites of damage within the first hour where they phagocytose debris and secrete 
proteases to break down damaged tissue. Subsequently neutrophils die via apoptosis at 
around 2 days and consistent with this there is a loss of neutrophil staining at 1 week, at 
which time macrophages are observed to become a predominant cell type. These early 
stages follow the sequence of events previously described in other tissues (Shah et al., 
2012).  
Damaged tissue within the defect created in this study included fragments of bone and 
cartilage, which were seen clearly at 24 hours and 1 week. The pieces of proteoglycan 
rich matrix within the defect are likely to originate from the articular surface or the broken 
growth plate. These fragments were absent however in the 2 week samples. This could 
indicate the clearance of tissue debris by phagocytic cells such as macrophages.   
In addition to this role, macrophages are thought to have a vital role in wound healing by 
inducing other reparative processes such as the induction of angiogenesis and the laying 
down of new ECM. Furthermore, these cells are highly plastic and can change phenotype 
influencing the inflammatory status of their surrounding microenvironment depending on 
exogenous or endogenous stimuli to which they are exposed. A more reparative 
phenotype, commonly referred to as M2 macrophages, is thought to facilitate proliferation 
and angiogenesis within tissues where as a more inflammatory phenotype, M1, is thought 
to exacerbate inflammation and classically have a role in the response to pathogens. 
Whilst the results here demonstrate that macrophages are present in osteochondral repair 
tissue, the inflammatory status has not been investigated. It is likely that there is a 
temporal change in the phenotypes of macrophages, a hypothesis supported by 
observations in the analysis of fracture repair in long bones. Schlundt and co-workers. 
(2015) demonstrated that inflammatory M1 macrophages are present during the initial 
healing but that they are replaced by M2 macrophages when repair tissue is formed 
(Schlundt et al., 2018). This switch is important as prolonged inflammation and 
unsuccessful healing are associated with prolonged presence of pro-inflammatory 
macrophages (Claes, Recknagel and Ignatius, 2012).  
Previous studies of osteochondral repair models in mice have compared super-healing 
strains, such as MRL/MpJ mice to the poor healing strain used here, C57BL/6 (Fitzgerald 
et al., 2008; Mak et al., 2015). These studies have shown that the super-healing strain 
has better outcomes and these has been partly explained by an impaired inflammatory 
response in this strain. Whether this correlates to the balance of M1 and M2 macrophages 
during the repair process and the relative levels of pro- and anti-inflammatory factors 
released by these cells is yet to be explored. Therefore, the mouse model described in 
this chapter provides the opportunity for investigation in this area and the potential of 
therapeutics to drive specific macrophage phenotypes.  




Classically the next stage of wound repair after the inflammatory phase is defined as the 
proliferative stage. During the proliferative stage endothelial cells are attracted to the 
wound site by chemotaxis in response to the release of angiogenic factors by other cells. 
This leads to the tissue being interspersed with small blood vessels. From morphological 
analysis of toluidine blue / fast green staining, at 1 week red blood cells can be identified 
within the repair tissue at the defect site but whether these are remnants of the 
haematoma or the formation of new blood vessels would require endothelial localisation 
by immunohistochemistry. Attempts were made to stain for blood vessels using antibodies 
against CD34 and CD31 (data not shown), however further optimisation of the staining 
process using other antibodies is required.  
Surprisingly, high levels of proliferation did not appear at any of the time points assessed 
within the defect site, as assessed by Ki67 staining which marks all cells except those in 
resting G0 phase.  This may suggest that within the defect there is minimal expansion of 
cell populations and rather that cells migrate into the defect from the surrounding area. 
This is supported by positive staining for increased proliferation in the bone marrow 
cavities surrounding the defect at 1 and 2 weeks, suggesting that the immune cells 
neighbouring the defect proliferate in response to the neighbouring trauma. 
There is evidence from published in vitro and in vivo studies that demonstrates that 
chondro-progenitors in the superficial cartilage zone can rapidly proliferate and migrate 
over an injured cartilage surface (Seol et al., 2012). In this study some animals did show 
extension of neighbouring articular cartilage across the defect. On the other hand, another 
explanation could be that this cartilage is actually the original articular cartilage that was 
not sufficiently removed during surgery. The relatively blunt needle used to generate the 
defect here may have been insufficient in making a clean cut at the cartilage boundary in 
some animals. Furthermore, no proliferation (marked by Ki67 staining) was identified in 
chondrocytes of the intact articular cartilage neighbouring the defect created in this study. 
This discrepancy with previous literature where activation of chondrocytes proliferation 
was observed could be due to differences in the type and extent of cartilage trauma. For 
example, Seol et al., 2012 saw the proliferation and migration of chondrocytes after 
impaction damage to cartilage whereas bone marrow stimulation trauma, leads to a lack 
in response by neighbouring chondrocytes as seen here or in other studies (Shapiro, 
Koide and Glimcher, 1993; Eltawil et al., 2009).  
A further argument against the hypothesis of chondrocytes initiating the repair of articular 
cartilage from the intact boundaries is the lack of integration seen in the defects. This is 
regarded as one of the biggest limitations of therapies such as microfracture. It is thought 
that defects fail as the lack of a smooth and seamless integration between the two articular 
cartilage interfaces is lacking and collagen fibres do not cross the boundary. Polarised 
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light imaging in the work presented here identifies collagen fibres perpendicular to the 
surface within the defect region at 4 weeks. As only one animal was analysed by this 
method, further work is required to examine if collagen fibres cross the boundary.  
5.8.2.3. Changes in the extracellular matrix 
The extracellular matrix of the defect changes overtime as cells remodel the defect site. 
As discussed, a fibrin scaffold is initially formed as blood and bone marrow clot within the 
defect. Collagen is subsequently deposited forming a fibrous network around which new 
tissue formation occurs. To this end, it has been proposed that the quality of the initial clot 
formed, may define how successfully the process progresses (Paletta, Arnoczky and 
Warren, 1992). In this study, a significant amount of matrix remodelling took place within 
the first 4 weeks of osteochondral defect repair.  
One extracellular protein that is laid down early in wound repair is type VI collagen (Oono 
et al., 1993). In the osteochondral defect generated here, this form of collagen is already 
present at 1 week (not assessed at 24 hours). Type VI collagen is a non-fibrillar collagen 
which encourages the attachment of osteoblasts (Izu et al., 2016) and proliferation, 
integrity and attachment of chondrocytes (Smeriglio et al., 2015). This collagen protein 
therefore has an important role in the normal homeostasis of osteochondral tissues as 
well as their repair. The deletion of this protein in mice has been shown to lead to an 
accelerated development of age-related osteoarthritic joint degeneration, reduced bone 
mineral density and altered mechanical properties of the chondrocyte pericellular matrix 
(Alexopoulos et al., 2009). The cells responsible for laying down this protein have not 
been identified, however, the importance of this protein would make them a target for 
therapeutic intervention to improve repair outcomes.  
Later in the healing of osteochondral defects, collagens specific to bone and cartilage 
tissue, type I collagen and type II collagen respectively, are laid down. Here, collagen type 
II was assessed by immunohistochemistry. Commonly this assessment is used to define 
the quality of the repair tissue as 90% of articular cartilage is made up of this protein. 
Interestingly, at 2 weeks type II collagen was identified in the central portion of the defect 
below the articular surface. Alongside the observation of cells isolated in lacunae, this 
suggests the presence of active chondrocytes secreting ECM proteins. Future 
investigations into the origin of these cells could potential answer a longstanding question 
within the field of whether bone marrow stromal/stem cells (BMSCs) differentiate to repair 
bone and cartilage or if another cell population is responsible such as cells derived from 
the synovium, as proposed by De Bari and colleagues (Roelofs et al., 2017). Furthermore, 
whether this population of chondrocytes arises from a single cell or multiple cells 
undergoing differentiation in parallel could be addressed.  
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Intriguingly, whilst type II collagen was identified in the central and upper regions of the 
defect during repair, at no time points was this protein identified in the lower portion of the 
defect. Furthermore, this deeper region appears to reform its original architecture of bone 
and bone marrow more quickly than the tissue closer to the articular surface. Either this 
could indicate that chondrocytes at this location were missed between time points or it 
could suggest a different pattern of repair takes place at this location. 
5.8.3. Endochondral or Intramembranous Ossification 
As described in the introduction to this thesis (section 1.4), bone forms through two 
different ossification processes during development, either in the presence or the absence 
of a cartilaginous scaffold. Although the long bones of the limbs form by endochondral 
ossification through a cartilage anlage, it has been demonstrated that intramembranous 
ossification plays a role in the fracture repair of long bones (Marsell and Einhorn, 2011). 
Evidence gathered in this series of work suggests that both processes may also take place 
in the repair of osteochondral defects, an observation previously made by Shapiro et al. 
in 1993 using a rabbit model. 
Here, it is observed that the top area of the defect, closer to the articular surface, shows 
hallmarks of endochondral ossification. Chondrocytes are present below the level of 
surrounding articular cartilage at 2 weeks and later are replaced with bone marrow and 
bone by 4 weeks, indicating a transition of the ECM as seen in the long bone development. 
These observations correlate with those reported in fracture repair where cartilage 
‘islands’ are observed within the fibrous tissue of the fracture callas and mark sites of 
endochondral ossification (Marsell and Einhorn, 2011). Chondrocytes would then 
transition to hypertrophic chondrocytes and begin to mineralise their surrounding 
microenvironment. Going forward, to confirm endochondral ossification is the process of 
bone repair in the model developed here, staining for markers of this transition could be 
performed such as type X collagen. Additional time points may also be required, between 
2 and 4 weeks, to capture the processes that transform a type II collagen rich ECM to that 
of bone and bone marrow.  
In contrast, observations in a sheep model of a 7 mm osteochondral defect by Lydon et 
al. (2017) reported a lack of chondrocyte islands within the centre of the defect. The 
evidence shown in this publication indicates that the formation of new cartilage begins at 
the upper margins of the defect site moving down along the damaged bone that lines the 
defect before endochondral ossification takes place. The authors suggest that the 
increased load at the interface with bone relative to elsewhere within the defect results in 
chondrogenesis of BMSCs at this location rather than in islands dispersed throughout the 
defect. This therefore perhaps highlights the difference in loading forces within the mouse 
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osteochondral defect generated here in the patella groove relative to the sheep femoral 
condyle.  
In addition to endochondral ossification, the results from the mouse osteochondral defect 
technique developed here also showed signs of intramembranous ossification occurring 
within the defect site. More specifically, within the lower region of the defect cuboidal 
osteoblasts that secrete bone matrix were identified. Additionally, by 2 weeks nuclei are 
observed within bone at the base of the defect whereas they are not present at 1 week. 
This indicates that osteoblasts have become embedded within the bone matrix they 
secrete and are now trapped becoming osteocytes. Further supporting the hypothesis that 
intramembranous ossification rather than endochondral ossification is the key process 
occurring within the lower portion of the defect is a lack of chondrocytes observed at this 
location unlike in the more superficial regions. Several differences may account for why 
intramembranous or endochondral ossification occurs within the different regions. For 
example, mechanical forces (Szarko and Xia, 2012) and oxygen levels (Zhou, Cui and 
Urban, 2004) will change with depth, and are known to alter repair processes. 
The observation of intramembranous ossification correlates with observations made by 
Shapiro and colleagues (1993) in a rabbit model. The sheep model by Lydon et al. (2017) 
on the other hand leads the authors to comment that no intramembranous ossification 
was seen in their model. One possible explanation for this is the variation in the depth of 
the defect. Whilst not comparable directly, as mice and sheep have different sized joints 
and articular cartilage thickness, the defect generated here was significantly deeper 
relative to the cartilage thickness. This might suggest that a deeper defect in sheep may 
induce intramembranous ossification in the repair of spongy bone located away from the 
articular surface of the distal femur.  
5.8.4. C57BL/6 mice can repair osteochondral defects 
The healing potential of mice is known to differ among strains with C57BL/6 mice being 
widely regarded as poor healers. Commonly the healing of ear notches have been used 
to assess the healing ability of different mouse strains but studies have observed that the 
poor capacity of C57BL/6 mice to heal is also present in the healing of osteochondral 
defects.  
Several studies have reported an inability of the articular cartilage of C57BL/6 mice to 
heal (Fitzgerald et al., 2008; Eltawil et al., 2009). However, in the results shown here we 
see the regeneration of matrix positive for proteoglycan and type II collagen, both key 
proteins of articular cartilage. Published studies have demonstrated a lack of these 
proteins in mice of a similar age and at similar time points after generation of an 
osteochondral defect similarly located in the patella groove.  
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One clear difference between the model described here and these other models is the 
depth of the defect (Eltawil et al., 2009; Fitzgerald et al., 2008). Whilst all studies classified 
their defects to be osteochondral, from the histology shown in these papers some only 
minimally enter the subchondral bone. Research has previously demonstrated that good 
quality bone is needed for good cartilage repair (Gomoll et al., 2010) and as described 
above deeper defects are hypothesised to repair bone by both endochondral and 
intramembranous ossification. The increased depth may be the key to improved repair in 
the C57BL/6 strain although a direct comparative study would be required to conclude 
this.  
At 4 and 8 weeks the animals with the best level of repair also showed over growth above 
the level of the neighbouring cartilage. The very superficial layer of this repair tissue 
stained more weakly for proteoglycan but had a high type VI collagen content than the 
cartilage below it, suggesting it is more fibrous. It would be interesting to use later time 
points to assess if this fibrous superficial layer is remodelled back to the joint surface over 
time. Further, whilst cartilage overgrowth is not reported in microfracture patients, there is 
evidence of subchondral bone overgrowth during the first 12 months post-surgery 
(Mithoefer, Venugopal and Manaqibwala, 2016). One might speculate that the time points 
used here are too early to show this, but that with continued endochondral ossficiation the 
subchondral bone may impede into the articular cartilage zone.   
5.8.5. Summary and future directions 
Here, a reproducible osteochondral model in C57BL/6 mice has been developed, refining 
previously published methods (see Table 5-1). This model shows the influx of different 
cell populations into the repair tissue in a temporal manner and the ability of this strain of 
mice to regenerate cartilage matrix at the articular surface as observed by restoration of 
tissue structure, an observation previously not demonstrated (Figure 5-18). Further, it may 
allude to the benefit of generating defects that penetrate further into the bone and bone 
marrow. 
Going forward this model provides an opportunity to study the mechanism and 
contribution of cells to osteochondral repair. To date the molecular mechanisms regulating 
osteochondral repair have been poorly understood due to an inability to identify key cell 
types in larger animal models. An understanding of how articular cartilage repairs after 
osteochondral damage is important in order to develop and improve the outcomes of 
treatments such as microfracture. Importantly the model developed here was generated 
using the C57BL/6 strain of mice, the background strain for many genetic mouse models. 
As well as inducible and conditional knock out strains, reporter strains will in the future 
allow for the role of specific proteins and different cell populations to be elucidated 
including BMSCs. 





Figure 5-18 – Temporal changes of cell populations and protein abundance in a 
mouse osteochondral defect 
Timeline of changes that occur in cell populations (CD68+ monocytes and NIMP+ 
neutrophils) and the protein abundance of a surgically induced osteochondral defect in 
the distal femur of mice. 
In the context of this thesis, the model also provides the opportunity to study the effect of 
G-CSF treatment on repair outcomes. Furthermore, cells that respond to G-CSF are now 
known to be present in the osteochondral repair tissues, including neutrophils and 
macrophages. This may in the future allow further insight into the mechanism by which 
G-CSF aids the repair of bone and cartilage.
   
125 
 
6. RESULTS: G-CSF TREATMENT POST SURGICAL TRAUMA 
INFLUENCES OSTEOCHONDRAL HEALING IN THE MOUSE 
6.1. Background and Rationale 
Bone marrow mesenchymal stem/stromal cells (BMSCs) are thought to be involved in the 
repair of surgically induced osteochondral defects. Their exact function, however, is yet 
to be fully elucidated. Possible roles involve both progenitor and/or a trophic function 
(Wang et al., 2014). The lack of an ability to identify these cells using a single marker has 
hindered the clear assessment of their location and function in vivo. As a result, few 
studies have looked at the fate of endogenous BMSCs in contrast to the numerous 
experiments that trace BMSCs after implantation. 
In recent years, the class VI intermediate filament protein nestin has become one of the 
more commonly used markers to identify BMSCs in vivo (Xie et al., 2015). A Nestin-GFP 
reporter mouse was developed by Migone and colleagues in 2004 allowing the 
identification of these cells in situ and their isolation ex vivo (Mignone et al., 2004). Nestin 
positive cells have been validated as a population of BMSCs in both mice and humans 
capable of both tri-lineage differentiation and the formation of a haematopoietic supportive 
environment in vivo (Isern et al., 2014; Méndez-Ferrer et al., 2010).  
Granulocyte colony stimulating factor (G-CSF) has been proposed as a therapeutic agent 
to aid bone and cartilage repair and has previously shown improved repair outcomes (see 
section 1.10). However, the mechanism through which this agent acts lack understanding. 
Currently it is known to influence haematopoietic lineage cells directly and there is 
evidence that it influences cells of the bone marrow microenvironment indirectly such as 
osteoblasts and BMSCs (Greenbaum and Link, 2011).  
6.2. Aim and objectives 
The aim of this chapter is to investigate the role Nestin-GFP labelled cells play during 
osteochondral repair in the defect model described in the previous chapter and to assess 
the influence of G-CSF on their response. The primary objective of this chapter was to 
identify BMSCs in situ utilising Nestin-GFP reporter mice. Secondly, the impact of G-CSF 
on these cells was investigated by analysis of peripheral blood and bone marrow of the 
spinal vertebrae. It was hypothesised that Nestin-GFP cells are involved in the repair of 
an osteochondral defect and also respond to systemically administered G-CSF. 
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6.3. Identification of Nestin-GFP reporter mice 
Nine Nestin-GFP reporter mice were genotyped to confirm their expression of GFP under 
the Nestin promoter. Figure 6-1 A depicts the design of the cassette developed by Migone 
et al. (2004). Using primer sequences from Migone et al. (2004), GFP expression was 
confirmed in all mice by using PCR analysis of ear biopsies (Figure 6-1 B). A single mouse 
had a significant lower abundance of PCR product possibly due to technical reason such 
as lack of starting material or possibly the animal was heterozygous rather than 
homozygous - it is not possible to delineate between the two. Further, confocal images of 
cryo-sectioned spinal cord and femoral bone marrow cavity of a Nestin-GFP mouse, 
Figure 6-1 C, demonstrated the presence of, and the ability to image, GFP positive cells 
within both tissues.  
 
Figure 6-1 – Genotyping and assessment of GFP expression in Nestin-GFP reporter 
mice.  
Mice were assessed for the confirmation of GFP construct insertion and the presence of 
detectable GFP cells within tissues. (A) Schematic of the Nestin-GFP construct where the 
enhanced version of GFP (eGFP) has been placed under control of the Nestin promoter 
and the second intron of the Nestin gene. (B) Image of agarose gel run with the genomic 
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DNA PCR product to confirm the presence of the GFP insertion, expected fragment of 
510 bp. (C) Confocal imaging of cryosections, DAPI nuclear staining (blue) and reporter 
GFP (green) merged. (i) Spinal cord (ii) femoral bone marrow cavity. Arrowhead highlights 
a bone marrow Nestin-GFP positive cell. Dashed line indicates bone contours. Scale bars 
indicate 100 µm. 
6.4. Experimental design 
The second objective of this chapter was to use the Nestin-GFP reporter mice to assess 
the effect of G-CSF on BMSCs. Figure 6-2 describes the experimental design used. The 
nine genotyped mice were divided into three groups of three. All mice underwent 
osteochondral defect surgery as in Chapter 5. Mice in Group 1 were sacrificed 24 hours 
after surgery with no G-CSF administration whilst mice in Group 2 and Group 3 were given 
G-CSF for three days. Group 2 mice were sacrificed 24 hours after the final dose whilst 
Group 3 mice were sacrificed at 7 days post-surgery.  
 
Figure 6-2 - Schematic of experimental approach 
Nine Nestin-GFP reporter mice underwent surgery to create a osteochondral defect in 
their distal femur under the patella groove. Three mice were sacrificed 24 hours (D1) after 
surgery, Group 1. The remaining six mice (Groups 2 and 3) were given administered 
G-CSF for three days. Three mice were sacrificed 24 hours after the final injection 
(Group 2) (D4) and the remaining three mice were sacrificed after a further 3 days, 7 days 
(D7) post-surgery (Group 3).  
6.5. GFP signal is present in the osteochondral defect  
Nestin-GFP mice that had undergone osteochondral surgery were sacrificed at 24 hours 
or 4 days after the procedure and their operated limb prepared for cyro-sectioning.  
In Figure 6-3 sagittal sections are shown for the defects are shown. At 24 hours (D1) 
(Figure 6-3 A) and 4 days ((Figure 6-3 B) after surgery GFP signal was detected within 
the defect. At both time points spindle-like nestin-GFP cells are observed in the bone 
marrow cavity (marked by *). However, the appearance of GFP fluorescence in the defect 
differed as it was more punctate (indicated by white arrowheads) and less associated with 
discrete cell structure. 




Figure 6-3 – Confocal imaging of an osteochondral defect in Nestin-GFP mice.  
Saggital cryo-sections of osteochondral defects at 24 hours (A) and 4 days (B) after 
surgery were imaged by confocal microscopy. DAPI nuclear staining (blue) and reporter 
GFP (green) merged. Arrowheads highlight punctate GFP fluorescence within the defect 
and * indicate spindle-like cells positive for GFP. Dashed line indicates bone and cartilage 
contours; AC, articular cartilage, B, bone; BM, bone marrow; D, defect. Scale bars indicate 
(A i and ii) 100 µm, (B i) 50 µm, (B ii and iii) 200 µm.  
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6.5.1. Change in peripheral blood cell populations following surgery and G-CSF 
treatment  
The most explored action of G-CSF is its ability to mobilise hematopoietic stem and 
progenitor cells (HSPCs) into the peripheral circulation. Blood samples from sacrificed 
mice were taken by cardiac puncture and analysed by flow cytometry for the presence of 
HSPCs using the lineage negative, Sca-1 positive and c-Kit marker panel as previously 
used in result chapter 1. The results are shown in Figure 6-4 show changes in the 
proportions of different haematopoietic cell fractions. Firstly, analysis of lineage markers 
(Figure 6-4 A i) demonstrate a change in the cellular composition of the peripheral blood. 
Interestingly the lineage positive cells are seen as a single cluster in group 1 and 2 
whereas group 3 show sub-populations, this was consistent across the three mice at each 
time point. Furthermore, the number of lineage negative cells changed but whilst the mean 
percentage of these cells relative to the total population reduced, there was large variation 
between the animals in groups 2 and 3, i.e. those post-surgery and G-CSF treatment.  
The lineage negative fraction of cells from blood were further assessed for the number of 
haematopoietic stem and progenitors marker by Sca-1+ and c-Kit+ (LSK+) staining and 
Sca-1- and c-Kit+ (L-S-K+) staining respectively. No significant changes were identified but 
the number of LSK+ cells was observed to decrease after treatment whilst L-S-K+ numbers 
remained at 8.5 to 11.8%.   
6.5.2. Bone marrow cells proliferate following surgery and G-CSF treatment 
Ki67 was used to identify cell proliferation in the bone marrow cavities of the distal femoral 
epiphysis of the right hind leg that had no surgical intervention (contralateral limb) (Figure 
6-5 A). A lack of staining was observed in the three animals in group 1 and group 2. 
However, in group 3 positively stained cells were observed indicative of proliferating cells. 
Ki67 staining was also performed on the contralateral limb of animals sacrificed at 24 
hours and 1 week in the previous chapter (chapter 5). Similarly, this animals show an 
increase in positively stained cells from 24 hours post-surgery to 1 week (Figure 6-5 B).   
 





Figure 6-4 – Analysis of peripheral blood cell populations after G-CSF 
administration 
Cardiac puncture peripheral blood samples were analysed by flow cytometry for the 
expression of mature haematopoietic lineage markers and Sca-1 and c-Kit expression. 
(A) Cells were identified based on forward versus side scatter area (not shown) and gated 
(i) on a logarithmic scatter plot for viable lineage positive or negative cells. (ii) Lineage 
negative cells were serially gated for Sca-1- and c-Kit+ expression. (B) Graph of the 
percentage of each population (i) Lineage positive cells as a percentage of total cells, (ii) 
lineage negative, Sca-1+ and c-Kit+ and (iii) lineage negative, Sca-1- and c-Kit+. Gates set 
against unstained controls.  




Figure 6-5 – Analysis of cell proliferation in the bone marrow cavity of the 
contralateral limb  
Sagittal sections of the contralateral limb (non-surgical) from each of the three treatment 
groups were stained by immunohistochemistry for Ki67 (A). This was repeated for the 
contralateral limbs of the mice sacrificed in chapter 5 at 24 hours and 1 week. Images 
were taken from the bone marrow cavities in the femoral epiphysis of three animals per 
group (i, ii and iii). Brown DAB staining identifies positively stained cells. Nuclei are 
counterstained with methyl green. Scale bars indicate 100 µm.  
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6.5.3. The number of peripheral blood and spleen GFP+ cells increases following 
surgery and G-CSF treatment 
Peripheral blood samples for all mice were collected by cardiac puncture and analysed 
by flow cytometry for the presence of GFP+ cells. As shown in Figure 6-1, the spinal cord 
contains a large number of GFP+ cells and therefore this tissue was used as a positive 
control showing 12% of cells were GFP+. A significant increase in the number of GFP+ 
cells was observed in the peripheral blood samples increasing by over 5-fold between 
groups 1 or 2 and group 3.  
GFP staining of spleens demonstrated the presence of GFP in the spleen of animals. 
Interesting GFP+ spindle-like cells increased in number in the spleen of group 3 animals, 
whilst only a minimal number of these cells were present in animals in groups 1 and 2 
(indicated by black arrowheads in Figure 6-7) 
 
Figure 6-6 – Analysis of Nestin-GFP positive cells in the peripheral blood.  
Cardiac puncture peripheral blood samples were analysed by flow cytometry for the 
expression of GFP. (A) Cells were identified based on forward versus side scatter area 
(not shown) and gated for the expression of GFP. Cells from the spinal cord were also 
analysed as a positive control. (B) Graph of the percentage GFP positive cells as a 
percentage of total cells. Statistical significance was calculated using a one-way ANOVA 
with Tukey’s test for multiple comparisons, with * indicating a p<0.1.  




Figure 6-7 – Analysis of Nestin-GFP positive cells in the spleen 
Spleens were harvested from all sacrificed mice, processed for paraffin sections and 
immunohistochemically stained for the GFP. Brown DAB staining identifies positively 
stained cells. Nuclei are counterstained with methyl green. Black arrowheads indicate 
positive staining of spindle-like cells. Scale bars indicate 200 µm. 
6.5.4. Gene expression changes in GFP+ cells  
Bone marrow was isolated from the spinal vertebrae of all mice after the removal of the 
spinal cord. CD45- cells were enriched by immunomagnetic depletion of CD45+ cells 
before FACS isolation of GFP+ cells (Figure 6-8 B). The number of GFP+ cells as a 
percentage of the total single cells ranged from 0.2 to 3% however, no difference was 
observed between the groups (Table 6-1). Interestingly, the animal with the ID BR ♀ that 
showed a weaker band for the presence of the nestin-GFP construct (Figure 6-1) also 
showed the lowest percentage of GFP+ cells.  
Table 6-1 – GFP cells isolated from spinal vertebrae bone marrow 
 Animal ID % of GFP+ singlets 
Number of CD45- 
GFP+ cells  isolated 
Group 1 
TR ♂ 1.00 13,000 
BL ♀ 1.40 33,851 
TLBL ♀ 1.70 33,464 
Group 2 
BR ♂ 3.40 19,068 
TR ♀ 1.00 92,000 
BR ♀ 0.20 31,000 
Group 3 
TL ♀ 0.60 34,000 
TL ♂ 3.00 46,000 
BL ♂ 1.30 38,000 
 
The CD45-GFP+ cells were analysed by qRT-PCR for the expression of Runx2, Bglap, 
Sp7, and AdipoQ (Figure 6-8 C). Large variation was observed between animals in each 
group and no significant difference in the expression was calculated for Bglap, Sp7, and 
AdipoQ transcripts. The expression of Runx2 however did show an increase in expression 
with time and a significant difference between groups 1 and 3.  




Figure 6-8 – Gene expression analysis of spine bone marrow Nestin-GFP cells. 
Bone marrow from spinal vertebrae was isolated and analysed by qRT-PCR. (A) 
Vertebrae were harvested, and the spinal cord removed. (i) vertebrae pieces, (ii) 
transverse histological section of a vertebrae stained (Safranin  O / Fast green). SC, spinal 
cord; BM, bone marrow. Scale bar indicates 200 µm (B) CD45- cells were enriched by 
immunomagnetic depletion and subsequently GFP+ cells isolated by FACS. (i) Cells were 
identified based on forward versus side scatter area and (ii) single cells by forward scatter 
area versus forward scatter width. (iii) Viable GFP+ cells were isolated. (C) Gene 
expression analysis for (i) Runx2, (ii) Bglap, (iii) Sp7, (iv) AdipoQ normalised to Hprt. Error 
bars indicate the standard deviation of the mean for three animals per group (N=3). 
Statistical significance was calculated using a one-way ANOVA with Tukey’s test for 
multiple comparisons, with * indicating a p<0.1.




The aim of experiments presented in this chapter was to produce preliminary data 
assessing the role of BMSCs and G-CSF in osteochondral repair. There are two main 
hypotheses that address the role of BMSCs in the repair of bone and cartilage tissue. 
Firstly their function as tissue progenitors, which has long been thought of as their primary 
role. Secondly, the more recently described role in the orchestration and immune-
modulation of repair processes through the secretion of trophic factors.  
Nestin is an intermediate filament protein that is known as a neural stem/progenitor cell 
marker and the nestin-GFP mouse model has become widely utilised as a method to 
identify BMSCs in vivo (Xie et al., 2015). In these preliminary studies, a nestin-reporter 
mouse line was used to elucidate the fate of BMSCs after trauma-induced osteochondral 
repair.  
6.6.1. Are nestin positive cells present in osteochondral repair tissue? 
The first question to be addressed was whether nestin positive cells were present in the 
defect site. Mice were sacrificed at 1 day and 4 days post-surgery and histological 
sections analysed to identify the presence of nestin positive BMSCs. However, whilst 
these cells were present in the bone marrow cavities of the distal femur, their identification 
within the osteochondral defect was inconclusive. The majority of GFP signal appeared 
very bright and punctate and not in clear cell-associated aggregations as seen in the bone 
marrow cavities. Importantly, this signal was deemed not to be the autofluorescence of 
red blood cells commonly seen in fluorescence imaging of vascular tissues, as the vessels 
within the bone marrow cavities themselves did not reproduce this bright staining. 
Furthermore, the advantage of using a reporter line removes the possibility of non-specific 
antibody staining. Therefore, it is concluded that the green fluorescence observed was 
derived from nestin positive cells but this raises the question of what this punctate 
fluorescence represents.  
6.6.1.1. Cell death 
In the early stages after trauma many cells die as a result of the injury, either by necrosis 
or apoptosis, and either of these processes could be responsible for the fluorescence 
observed in these experiments. Firstly, the induction of the necrotic pathway in BMSCs 
would result in the release of the cell’s contents into the local environment, including GFP. 
Secondly, controlled cell death by apoptosis would also likely show punctate green 
staining as the cell forms and releases apoptotic bodies. Importantly, necrosis might be 
viewed as detrimental to wound repair by increasing the inflammatory status of the area 
but is likely a key initial response that triggers the innate immune system to the site of 
tissue damage. Apoptosis is a regulated cell response and is an important part of the 
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spatial and temporal coordination of cell events that are responsible for effective wound 
repair. 
Apoptotic cells release membrane-bound extracellular vesicles termed, apoptotic bodies, 
in a highly regulated process that accompanies the disassembly of the cell cytoskeleton. 
In addition, apoptotic cells have been reported to release smaller extracellular vesicles 
that contain ‘find-me’ signals to attract phagocytes for the clearance of apoptotic cells 
(Caruso and Poon, 2018). Phagocytes are an important cell type in the early stages of 
wound repair and the recruitment of these cells is thought to be a key factor in preventing 
apoptotic cells from undergoing secondary necrosis where they can release potentially 
damaging pro-inflammatory contents. Investigation into the release of extracellular 
vesicles by BMSCs has become a key area of research in the understanding of the 
BMSCs trophic action in recent years (Vonk et al., 2018) but little research has been 
conducted into the effects of dying BMSCs on cell and tissue specific processes.  
As well as the release of ‘find-me’ signals, other downstream events could be induced by 
phagocytosis itself. As discussed in the previous chapter macrophages are important 
phagocytic cells in the osteochondral defect being a predominant cell type at 1 week after 
their migration into the defect. Phagocytic cells have the ability to make a critical decision 
as to whether or not initiate an immune response depending upon the molecules released 
by and/or exposed on the dying cells. Phagocytes can ultimately either actively suppress 
or elicite inflammation (Arandjelovic and Ravichandran, 2015). Macrophages are well 
accepted to have pro-inflammatory and anti-inflammatory phenotypes but whether this is 
a transient state, or distinct subtypes remains unclear. In vitro co-cultures have shown the 
ability of BMSCs to down-regulate pro-inflammatory responses in macrophages (Németh 
et al., 2009; Chiossone et al., 2016) and extracellular vesicles play a part in this 
(Hyvärinen et al., 2018). One can hypothesise that the phagocytosis of apoptotic BMSC 
fragments could induce a more immune-suppressive response thought to be of benefit to 
wound repair. For example, early apoptotic leukocytes have similarly been reported to 
deliver immunosuppressive signals to dendritic cells (Morelli, 2006). Moreover, in an 
animal model of graft-verus-host-disease, Galleu and colleagues (2017) demonstrated 
that the engulfment of apoptopic BMSCs by phagocytes led to the production of 
indoleamine 2,3-dioxygenase, a marker of immunosuppression (Galleu et al., 2017). 
Therefore, nestin BMSCs could modulate the early wound microenvironment by 
undergoing apoptosis. 
There is evidence in the published literature that exogenous BMSCs aid the repair of 
osteochondral defects however, they disappear over time from the wound site. The 
mechanism of this cell loss, whether through cell death or migration remains unknown. 
For example, de Windt and colleagues (2017) published a first in man trial where 
autologous chondrons (chondrocytes isolated with their pericellular matrix) were 
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transplanted with allogenic BMSCs. The clinical trial reported that, whilst 80 to 90% of the 
cell transplanted were allogenic BMSCs, they were not detectable in the repair tissue at 
1 year, as assessed by DNA analysis (de Windt et al., 2017). Similarly, in an 
osteochondral model by Mak and colleagues (2016), synovial mesenchymal stem cells 
(sMSCs) were transfected with GFP using lentivirus and injected intra-articularly. This 
study showed GFP+ cells were detectable in the defect at two weeks but not at four weeks. 
The authors suggest the “loss” of the sMSCs is suggestive that the cells may differentiate 
(silencing the GFP) but also that they migrate away from the defect area or die. Overall, 
both Mak and Windt with their respective colleagues’ present results that could be 
suggestive that implanted BMSCs die within the repair tissue and do not contribute directly 
to repair. The data presented in this chapter may represent this response in the 
endogenous BMSCs marked by nestin-GFP.  
6.6.2. Increase in BMSCs in the peripheral circulation 
One confounding factor about the design of this study is the delineation between effects 
of the surgical procedure and the exogenous administration of G-CSF. Data presented 
here demonstrates an increase in the number of GFP positive cells in the systemic 
circulation as assessed by flow cytometry analysis of peripheral blood. Nestin positive 
cells have previously been reported to increase in number systemically as a response to 
trauma (Yang et al., 2015) but BMSCs are also known to increase in the peripheral 
circulation in response to G-CSF (Lund, Baso and Orchard, 2006).   
6.6.2.1. Nestin-GFP cell response to trauma 
BMSCs marked by nestin positivity have been reported to respond to trauma by an 
increase in their number in the peripheral circulation and bone marrow (Yang et al., 2015), 
supporting the hypothesis that creation of an osteochondral defect leads to the increase 
seen here. Furthermore, BMSC are recruited to sites of injury (Rustad and Gurtner, 2012; 
Yang et al., 2015). Due to limited animal numbers, GFP signal was only analysed at 1 and 
4 days post-surgery and at these time points, only bright punctate staining was observed 
within the defect. Going forward, it would be of interest to use later time points to assess 
if GFP signal similar to that seen in the bone marrow, which is more cell associated, is 
observed within the defect site. If observed this would suggest that nestin-BMSCs can 
move through the extracellular matirx scaffold into the wound during the repair process 
as observed for other cell types e.g. monocytes, as described in the previous chapter and 
synovial MSCs in Mak and colleagues’ (2016) study.  
It is important to note that nestin positive cells are not confined to the bone marrow and 
have been located in many tissues including the central nervous system where nestin 
marks neural stem cells (Xie et al., 2015). It is not possible to say if the GFP positive cells 
identified in the peripheral blood in this study are derived solely from haematopoietic 
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tissues or the multiple tissues where these cells reside. For example, an increase in GFP 
positive cells was seen in the spleen in the present study. Results from Yang et al. (2015) 
indicate that nestin positive cells increase in the bone marrow after skin injury and using 
a chimeric mouse model they show that at least a proportion of these cells are derived 
from the bone marrow. This therefore supports a hypothesis that the increase in peripheral 
blood GFP signal here at least partly is derived from the mobilisation of bone marrow 
nestin positive cells.  
6.6.2.2. Nestin-GFP cell response to G-CSF 
The bone marrow microenvironment is known to respond to the systemic administration 
of G-CSF. It leads to both increased hematopoietic stem cells (HSCs) numbers and 
importantly their mobilisation from the bone marrow into the bloodstream. The mechanism 
of action of this cytokine is not well understood but it is known to disrupt the interactions 
between haematopoietic stem and progenitor cells (HSPCs) and cells of their bone 
marrow microenvironment. BMSCs are known to have a role within this microenvironment 
but the action of G-CSF on these cells has not been thoroughly explored except that it is 
known to cause an increase in their number in the peripheral circulation (Lund, Baso and 
Orchard, 2006).  
Nestin positive BMSCs specifically are components of HSC niches and G-CSF treatment 
selectively downregulates the HSCs maintenance gene CXCL12 in these cells (Mendez-
Ferrer et al., 2010). However, whilst this suggests that G-CSF affects nestin positive 
BMSCs, their mobilisation is not seen (Yang et al., 2015) unlike the global BMSC 
population (Lund, Baso and Orchard, 2006). This can be explained by the heterogeneity 
of the BMSCs as nestin positive cells only represent a fraction of the total BMSC 
population. Pdgfr and Sca-1 (Morikawa et al., 2009), and Leptin receptor (Zhou et al., 
2014), are other mouse in vivo markers associated with distinct subgroups of BMSCs. 
In summary, whilst both trauma and G-CSF treatment could be responsible for the 
increase in numbers of GFP+ cells in the peripheral blood, data from the literature suggest 
that the effect of systemic signals from the injured osteochondral environment may 
predominate. In the future, analysis of GFP+ cell numbers within the bone marrow in 
animals with only one of the variables, osteochondral defect surgery or G-CSF treatment, 
would allow a clearer understanding of nestin positive cell dynamics in this context. 
6.6.3. G-CSF and the expression of osteogenic differentiation genes in nestin 
positive cells 
Whilst the cause of an increase in GFP signal in the peripheral circulation requires further 
exploration, in 2010 Mendez-Ferrer and colleagues (in supplementary material), 
presented results which showed a change in the gene expression profile of bone marrow 
nestin positive cells after G-CSF treatment. The authors showed a significant decrease in 
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the expression of differentiation genes by these cells following G-CSF treatment (Méndez-
Ferrer et al., 2010). In data presented here, cells of the same phenotype were isolated 
from the bone marrow of the spinal vertebrae and expression of differentiation associated 
genes investigated. Assessment of AdipoQ expression was performed both here and in 
the aforementioned published work. Whilst Mendez-Ferrer and colleagues showed a 
decrease in expression of this gene, the expression changes showed large variation 
between animals in the data described here.  Increased transcripts of this gene are 
indicative of adipogenic differentiation.  
There is strong evidence of a relationship between bone and G-CSF treatment and 
therefore osteogenic genes were also investigated. In both mice and humans, sustained 
G-CSF administration is known to cause osteopenia – the loss of bone matrix (Sekhar et 
al., 2001; Kokai et al., 2002). A significant reduction in the number of bone lining 
osteoblasts in mice, caused by apoptosis, has been observed within 1 day of G-CSF 
administration (Christopher and Link, 2008; Winkler et al., 2010). Further, gene 
expression analysis of whole bone marrow by Christopher and Link (2008) showed a 
dramatic reduction in the expression of late osteogenic genes. Most interestingly, 
evidence from Winkler and colleagues (2010), shows that whilst bone lining osteoblasts 
are significantly reduced during G-CSF treatment, after treatment is complete there is a 
resurgence in these cells to 2-fold higher than before treatment began. This rebound has 
been associated with the recruitment of new osteoblasts rather than the recovery of 
quiescent osteoblasts (Christopher and Link, 2008). Consequently, a hypothesis can be 
put forward suggesting that G-CSF administration leads to an inhibition of progenitor 
maturation to fully differentiated osteoblasts, and when treatment ends progenitors held 
at this bottleneck are able to differentiate leading to a dramatic resurgence in osteoblast 
numbers.  
In this chapter, analysis of osteogenic genes from CD45 negative, nestin-GFP positive 
spinal vertebrae bone marrow cells did not follow this hypothesis. Only the transcription 
factor Runx2 showed a significant difference between untreated and G-CSF treated mice, 
with transcript levels increasing from day 0 to day 7 where animals had osteochondral 
surgery and 3 days G-CSF treatment followed by 3 days of no G-CSF treatment. Whilst 
not reaching statistical significance the transcription factor Sp7 did follow a trend in line 
with the hypothesis described. Here, after G-CSF treatment a small decrease in 
expression was seen which increased above baseline levels at 3 days after ending 
treatment. The data gathered in this study are not going to be conclusive due to the lack 
of animal numbers but this work does show the feasibility of this analysis strategy, 
however before moving forward to a larger study some of the limitations should be 
considered. 
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The CD45 negative, nestin-GFP cells analysed by Mendez-Ferrer et al. (2010) used a 
similar isolation strategy to that employed in the experiments presented here, although 
bone marrow from long bones was used in the original study in contrast to marrow from 
spinal vertebrae in this work. A factor that may contribute to a difference in the results 
between this published study and that reported in this chapter, is the possibility of spinal 
cord contamination. Neural stem cells within the central nervous system express nestin 
and whilst removal by careful dissection should have reduced their influence, some carry 
over is likely. Furthermore, a comparison between the effect of G-CSF on long bone and 
spinal vertebrae has not been conducted. Here, this tissue was used as a method to gain 
as much data as possible from the nine mice available.    
6.6.4. Future directions 
As discussed the main limitation of this chapter was the study design and the use of nine 
mice to try to gain insight into multiple hypotheses. The role of trauma and G-CSF were 
assessed in the same animals and therefore the independent effects of these two 
variables cannot be truly deconstructed. With hindsight, perhaps it would have been more 
effective to answer a single question. On the other hand, the preliminary data gathered 
does aid in the design of a more detailed study or studies on the role of G-CSF and nestin 
positive BMSCs in osteochondral repair. Some of the limitations of this work and how they 
can be addressed are discussed further:  
6.6.4.1. Confirmation of G-CSF functionality 
This piece of work was the first time G-CSF was studied within our research group in mice, 
and it was therefore thought important to confirm the bioactivity of the product and 
compare response to that reported in the literature. Firstly, analysis of haematopoietic 
populations in the peripheral circulation was assessed by flow cytometry analysis but 
whilst differences were observed between the three treatment groups, the quantification 
strategy was flawed. The relative number of HSCs by LSK+ staining and HSPCs by L-S-
K+ were expected to increase. However, the influence of G-CSF on mature populations 
within the haematopoietic system is likely to have obscured any increases in these cells. 
For this reason, in the future the number of LSK+ cells per mL of blood would be a more 
accurate way to assess this effect of G-CSF rather than quantification as percentage of 
total cells.  
Secondly, proliferation in the bone marrow compartment of the right hind distal femur (the 
contralateral limb to surgery) of mice was assessed. G-CSF’s principle role is to increase 
the number of myeloid cells by the activation of proliferative pathways through binding to 
the G-CSF receptor. As expected, an increase in proliferation marker Ki67 was seen after 
the administration of G-CSF. However, the analysis of the bone marrow from a similar 
location in mice described in the previous chapter also showed an increase in cell 
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proliferation. This suggests that creation of the osteochondral defect leads to a systemic 
bone marrow response and therefore this is not a usable method to determine the 
functionality of the G-CSF administered.  
Consequently, as the functionality of the G-CSF was not confirmed in this study (although 
this was demonstrated for the same batch in an in vivo sheep study (Lydon et al., 
unpublished) a second preliminary study is required before further work using this cytokine 
is conducted. This assessment does not require the use of reporter mice and could be 
performed in wild type animals. Importantly this should be done in a model where no 
surgical injury is performed unlike the study described here.  
6.6.4.2. G-CSF and osteochondral repair 
Investigation into the effect of G-CSF on osteochondral repair could also be carried out in 
wild type mice with output measures such as those developed and discussed in the 
previous chapter 5. In the introduction to this thesis studies that demonstrate an 
improvement in musculoskeletal repair with G-CSF are discussed (see section 1.10). It 
would be worthwhile to explore if these findings can be reproduced using the 
osteochondral defect model developed in this thesis. If the results demonstrate improved 
outcomes, investigations into the cell and molecular mechanisms could subsequently be 
carried out. For example, to assess the role of G-CSF on nestin positive BMSCs and the 
influence of this on osteochondral repair, larger group sizes would be required than those 
used here and vitally control animals where no G-CSF is administered at parallel time 
points would be required. 
6.6.4.3. Role of nestin positive BMSCs in osteochondral repair – tissue progenitor 
Whether nestin positive cells are able to contribute to osteochondral repair tissues as 
tissue progenitors will require the use of animals that have been allowed to heal over a 
longer period of time. 1 and 4 days after defect creation, as used here, only represent the 
very early stages of repair, as demonstrated in chapter 5. In addition to using just nestin-
GFP mice a ROSA26 mouse where tdtomato is expressed (a red fluorescent reporter) for 
the remaining lifespan of the cell, would be advantageous in identifying the cells even 
after the nestin promoter is switched off. In this way if the cells differentiate and remain in 
the repair tissue, they will be identifiable.  
6.6.4.4. Role of nestin positive BMSCs in osteochondral repair – tissue orchestrator 
In the early time points where nestin-GFP expression was assessed here, only punctate 
staining was observed. As discussed previously this may be suggestive of apoptosis and 
an immunomodulatory action or even the ability to promote survival or a tissue 
regenerative response of other cells as previously reported (Wu et al., 2011, 2012; Vonk 
et al., 2018; Bekkers et al., 2013).  
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The small numbers of animals used in these studies presented here meant that there was 
a low abundance of RNA isolated for each experimental group and therefore only a limited 
number of genes could be analysed. Based on the data of published work (Christopher 
and Link, 2008; Winkler et al., 2010; Méndez-Ferrer et al., 2010), it was decided to analyse 
the expression of genes that represented differentiation. In the future, analysis of genes 
related to the immunomodulatory properties of cells may elucidate if G-CSF exposure 
changes these properties of the cells, with and without surgery. In vitro work using nestin 
positive cells may be worthwhile starting points as immuno-regulatory properties of this 
population is yet to be explored in the literature. 
6.6.5. Summary 
In summary, the work described in this chapter has produced preliminary data analysing 
the role of nestin positive cells and G-CSF in osteochondral repair. Initial results suggest 
that in the early phases of osteochondral healing nestin positive cells die and evidence 
from the literature suggests that this might be part of the immunomodulatory function of 
BMSCs. Additionally data shows that nestin positive cells react to trauma and/or G-CSF 
treatment by increasing their numbers in the peripheral circulation. To determine whether 
G-CSF improves the outcomes of osteochondral repair through the response on nestin 
positive cells further work is required. 
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7. RESULTS: NON-HAEMATOPOIETIC CELLS ARE TARGETED BY 
G-CSF IN MUSCULOSKELETAL REPAIR 
7.1. Background and Rationale 
Granulocyte colony stimulating factor is well established to have a significant biological 
effect on cells of the haematopoietic system. It has an important role in the regulation of 
neutrophils under basal conditions but is also important in disease and injury, for example 
in response to infection (Cebon et al., 1994). It is able to increase the proliferation and 
survival of multiple haematopoietic cell lineages. In addition to its role in haematopoietic 
system, G-CSF is also thought to have actions upon non-haematopoietic cells that display 
its transmembrane receptor including cardiomyocytes, neuronal precursors, endothelial 
cells (Touw and van de Geijn, 2007). Additionally, there is some evidence that bone 
marrow stem/stromal cells (BMSCs) display the receptor.  
G-CSF treatment has been reported to lead to mobilisation of BMSCs into the peripheral 
circulation in response to G-CSF treatment (Lund, Baso and Orchard, 2006). However, it 
is unknown if this is a reaction to G-CSF binding directly to BMSCs or due to changes in 
the bone marrow microenvironment as a whole where interactions between 
haematopoietic stem and progenitor cells (HSPCs) and their niche are disrupted. 
Furthermore, little investigation into the downstream effects of potential ligand binding to 
the G-CSF receptor (G-CSF R) in BMSCs has been conducted. Importantly, if this binding 
does occur it may have consequences for BMSC fate. What’s more, this may have 
consequences for the response of BMSCs in bone and cartilage repair such as 
osteochondral repair.  
7.2. Aim and objectives 
The work in this chapter aims to elucidate this and the consequences of this binding for 
BMSC fate. Firstly, analysis of the G-CSF R expression in BMSCs was analysed and the 
downstream signalling pathways known to be induced in other cell lineages on G-CSF 
binding assessed. Secondly, the impact of G-CSF on the proliferation and differentiation 
of BMSCs was investigated using in vitro assays. It was hypothesised that the G-CSF R 
can be found on BMSCs and G-CSF binding activates downstream intracellular signals. 
7.3. Bone marrow MSCs express the G-CSF R  
BMSCs isolated at orthopaedic joint replacement surgery and BMSCs purchased from 
Lonza (UK) were analysed for the presence of the G-CSF R by Western blot analysis of 
cell lysates. In parallel, peripheral blood mononuclear cells (MNC) were used as a positive 
control for expression of the receptor as well as recombinant G-CSF R originally isolated 
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from a mouse myeloma cell line. G-CSF R has four isoforms with the predicted molecular 
weight varying between 85 kDa and 95 kDa (UniProt, 2018). The recombinant G-CSF R 
used in the work presented here has a strong band at this molecular weight range (Figure 
7-1). When quantified by densitometry the two Lonza purchased BMSC populations also 
have a quantifiable band at this molecular weight, whilst the patient derived BMSCs do 
not. The patient samples however do have a band at a molecular weight of 68 kDa. When 
normalised to β-actin the Lonza purchased BMSCs have a higher abundance of this 
protein.  
To investigate the presence of the receptor further Lonza BMSCs were examined by 
immunocytochemistry (Figure 7-2 and Figure 7-3). Confocal microscopy evaluation shows 
positive staining in cell populations from both Lonza patients. Immunocytochemistry 
evaluation indicates the presence of G-CSF R localised to the cell membrane as Alexa 
488 green fluorescence is seen across the cell surface. Additionally the G-CSF R is also 
localised in intracellular organelles 
 
Figure 7-1 – G-CSF R detection in BMSCs by Western blotting  
BMSCs derived from patients (Pt-) and purchased from Lonza (L-) were analysed for the 
presence of G-CSF R protein by Western blotting. (A) Cell lysates were run on a single 
gel. (i) The blot was probed for G-CSF R, then an 800nm secondary antibody, antibody 
predicted molecular weight 92 kDa. MNC protein lysate and recombinant G-CSF R is 
included for reference alongside the molecular weight marker. (ii) The blot was probed for 
β-Actin as a loading control, chemiluminescence detection. (B) Graphs of densitometry 
values normalised to β-actin. (i) 68kDa molecular weight bands, (ii) 92 kDa molecular 
weight bands. 




Figure 7-2 – G-CSF R detection in BMSCs by immunocytochemistry (L27766) 
L2777 BMSCs purchased from Lonza were analysed for the presence of G-CSF R protein. 
Cells were grown in 0.7 mm2 wells of glass slides and fixed before immunocytochemistry 
staining for G-CSF R (Alexa 488 secondary antibody) (A). Nuclei were counterstained 
with DAPI and the actin cytoskeleton with phalloidin (Alexa 555). (B) G-CSF R primary 
antibody negative control, (C) secondary antibody and phalloidin negative control. Imaged 
by confocal microscopy (63x objective), maximum projection shown. G-CSF R, green; 
actin filaments, red; nucleus, blue. Scale bar indicates 50 µm. 
 




Figure 7-3 – G-CSF R detection in BMSCs by immunocytochemistry (L30654) 
L2777 BMSCs purchased from Lonza were analysed for the presence of G-CSF R protein. 
Cells were grown in 0.7 mm2 wells of glass slides and fixed before immunocytochemistry 
staining for G-CSF R (Alexa 488 secondary antibody) (A). Nuclei were counterstained 
with DAPI and the actin cytoskeleton with phalloidin (Alexa 555). (B) G-CSF R primary 
antibody negative control, (C) secondary antibody and phalloidin negative control. Imaged 
by confocal microscopy (63x objective), maximum projection shown. G-CSF R, green; 
actin filaments, red; nucleus, blue. Scale bar indicates 50 µm. 
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7.4. Functional G-CSF R on BMSCs is activated through JAK2/STAT3 and 
MAPK/ERK pathways 
To determine whether the G-CSF R is functional in BMSCs, the phosphorylation kinetics 
of the JAK2/STAT3 and MAPK/ERK pathways were examined. Cells were serum starved 
and then exposed to G-CSF (100 ng/mL) for specific time periods and protein lysates 
were submitted to Western blotting. Quantification by densitometry shows an increase in 
the phosphorylation of the STAT3 transcription factor in both BMSC populations over time 
when normalised to total STAT3 (Figure 7-4). Interestingly, the cells derived from patient 
L30654 had apparent increased phosphorylation compared to patient L27766 cells. This 
difference was further highlighted for the phosphorylation of the MAPK/ERK signalling 
proteins p42 and p44 where only L30654 showed a marked increase in phosphorylation. 
For L30654 BMSCs phosphorylation was highest at 15 minutes after stimulation with G-
CSF and remained elevated at 30 minutes. In contrast, p42 and p44 phosphorylation was 
unchanged for L27766 cells whilst STAT3 phosphorylation peaked 30 minutes after 
stimulation.  
Whilst G-CSF R protein of 92 kDa was identified by Western blot analysis for three 
orthopaedic patient derived BMSCs, the cells were subjected to the same phosphorylation 
kinetics evaluation of the STAT3 pathway. Densitometry analysis revealed that the 
phosphorylation of STAT3 increased by over 1.5 times. Together these results identify the 
presence of functional G-CSF receptors on the cell surface of BMSCs.  




Figure 7-4 – Analysis of Lonza BMSC G-CSF R functionality 
BMSCs purchased from Lonza (L27766 an L30654) were analysed for the activation of 
the JAK2/STAT3 and MAPK/ERK pathways by the detection of STAT3 and p42/p44 
phosphorylation respectively. (A) A schematic describes the treatment of BMSCs prior to 
the exposure to G-CSF for the two patients. Cell lysates were analysed by Western 
blotting. (B) (i) The blot was probed for phosphorylated STAT3 (88 kDa) and total STAT3 
(86 kDa) on the same membrane using 800nm and 680nm secondary antibodies 
respectively. (ii) Graphs of densitometry values of phosphorylated STAT3 normalised to 
total STAT3. (C) (i) The blot was then probed for phosphorylated p42/p44 (42 and 44 kDa) 
and total p42/p44 (42 and 44 kDa) on the same membrane using 680nm and 800nm 
secondary antibodies respectively. Graphs of densitometry values of (ii) phosphorylated 
p42 normalised to total p42 and (iii) phosphorylated p44 normalised to total p44. 




Figure 7-5 – Analysis of orthopaedic patient BMSC G-CSF R functionality 
BMSCs derived from three patients (Pt-) were analysed for the activation of the 
JAK2/STAT3 pathway by the detection of STAT3 phosphorylation. (A) The blot was 
probed for phosphorylated STAT3 (88 kDa) and total STAT3 (86 kDa) on the same 
membrane using 800nm and 680nm secondary antibodies respectively. (B) Graphs of 
densitometry values of phosphorylated STAT3 normalised to total STAT3. One-way 
ANOVA, Tukey Test, * p<0.05, all others non-significant.  
7.5. Synovial derived MSCs have increased response to G-CSF 
compared to BMSCs 
As well as from bone marrow, mesenchymal stem/stromal cells have been isolated from 
other tissues of the knee joint including the synovium lining the fat pad. These cells have 
also been reported to be involved in the repair of articular cartilage defects. To evaluate 
whether these cell populations may also respond to G-CSF treatment, the presence of 
the receptor and its activation were assessed in BMSCs and synovial mesenchymal 
stem/stromal cells (sMSCs) from the same orthopaedic patient. As observed for other 
patient derived samples, no band was seen for the G-CSF R with molecular weight 
between 85 kDa to 95 kDa, whilst a band of 68 kDa was detected. When normalised to a 
loading control, β-actin, the sMSCs had a 36-fold increased abundance of this protein. 
Although it is likely that this molecular weight corresponds to intracellular located G-
-CSF R, increased levels of the 68 kDa protein does correlate with increased 
phosphorylation of the STAT3 pathway in the Lonza derived BMSCs. In terms of STAT3 
phosphorylation sMSCs showed a 2.7-fold increase compared to a 1.5-fold in the BMSCs 
from the same patient.  




Figure 7-6 – Comparison between BMSCs and synovial derived MSCs from the 
same patient for G-CSF R presence and functionality 
BMSCs and sMSCs derived from the same patient were analysed for the presence of 
G-CSF R protein by Western blotting. (A) (i) Cell lysates were run on a single gel alongside 
a molecular weight marker. The blot was probed for G-CSF R (predicted molecular weight 
92 kDa), then with an 800nm secondary antibody. (ii) The blot was probed for β-Actin as 
a loading control, chemiluminescence detection. (B) Graphs of densitometry values 
normalised to β-actin for 68 kDa protein. (C) BMSCs and sMSCs were exposed to G-CSF 
after 24 hours serum starvation for various lengths of time as indicated. Cell lysates were 
analysed by Western blot. Blots were probed for phosphorylated STAT3 (88 kDa) and 
total STAT3 (86 kDa) on the same membrane using 800nm and 680nm secondary 
antibodies respectively. (D) Graphs of densitometry values of phosphorylated STAT3 
normalised to total STAT3.  
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7.6. Further characterisation of STAT signalling in response to G-CSF 
using small molecular weight pathway inhibitors 
To verify the significance of the JAK2/STAT3 pathway in BMSCs the JAK inhibitor 
CP 690550 citrate (CP69) and the JAK2 specific inhibitor Cucurbitacin I (Cucu) were used. 
Protein lysates were prepared from cells exposed to one of the inhibitors for 1 hour before 
cytokine stimulation. CP69 is a potent JAK inhibitor and under control conditions reduced 
endogenous phosphorylation dramatically whilst Cucu caused a minimal decrease (Figure 
7-7). Peripheral blood mononuclear cells (PB MNCs) were used as a control alongside IL-
6 stimulation, a cytokine widely described to induce downstream signalling in both BMSCs 
and PB MNCs.   
Figure 7-7 C shows that both inhibitors effectively blocked STAT3 phosphorylation 
stimulated by IL-6 in BMSCs and MNCs at 15 and 30 minutes; CP69 reduced the 
response by 10 times, from a 22-fold increase to 2-fold and Cucu by over half to a 10-fold 
increase relative to baseline levels at 15 minutes. No clear stimulation of PB MNCs was 
seen by stimulation with G-CSF and therefore responses to G-CSF in the presence of 
inhibitors were equivalent to the phosphorylation without the addition of G-CSF. This was 
also seen for the response to G-CSF in BMSCs.  




Figure 7-7 – Assessment of the integrity of G-CSF induced JAK2/STAT3 signalling 
using small molecular weight pathway inhibitors 
BMSCs purchased from Lonza (L27766) were analysed for the inhibition of the 
JAK2/STAT3 pathway by two JAK inhibitors after its induction by G-CSF exposure. 
BMSCs were grown to 70% confluency and then serum starved for 24 hours. Peripheral 
blood (PB) MNCs were isolated and cultured in serum starvation media for 24 hours. 
Selected cells were then exposed to either CP 690550 citrate (CP69) or Cucurbitacin I 
(Cucu) (prepared in DMSO) for 1 hour. Controls were either left in starvation media or the 
equivalent amount of DMSO added. G-CSF at 100 ng/mL or IL-6 at 20 ng/mL was then 
added for 15 or 30 minutes. (A) (i) Cell lysates were run across four gels alongside a 
molecular weight marker. Blots were probed for phosphorylated STAT3 (88 kDa) and total 
STAT3 (86 kDa) on the same membrane using 800nm and 680nm secondary antibodies 
respectively. (B and C) Graphs of densitometry values of phosphorylated STAT3 
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normalised to total STAT3. (B) BMSCs, (i) 15 minutes or (ii) 30 minutes exposure to 
cytokines (C) PB MNCs, (i) 15 minutes or (ii) 30 minutes exposure to cytokines.  
7.7. Activation of the G-CSF R does not increase human BMSC 
proliferation 
G-CSF is known to be a mitogen for cells expressing its receptor such as neutrophils. To 
investigate whether G-CSF is able to induce proliferation in BMSCs, cells were cultured 
in xCELLigence E-plates under reduced serum conditions (1% v/v FCS) for 24 hours 
before stimulation with 10 ng/mL G-CSF or 10% (v/v) FCS. The addition of FCS to BMSCs 
induced proliferation as seen in Figure 7-8 A, whilst the addition of G-CSF resulted in no 
increase in impedance values, rather a small decrease over 4 days. Cells were run in 
parallel in 96-well plates and after 4 days the amount of DNA quantified. This study 
supported the xCELLigence data showing a significant DNA increase in wells treated with 
10% FCS whilst no difference was seen in G-CSF treated wells.  
 
Figure 7-8 – Analysis of BMSC proliferation induction by G-CSF 
BMSCs purchased from Lonza were analysed for proliferation by (A) real time analysis 
using xCELLigence E-plates and (B) assessment of DNA quantity. Cells were grown in 
either 1% FCS, 10% FCS or 1% FCS supplemented with 100 ng/mL G-CSF. xCELLigence 
cell index values were normalised to the time at which the cytokines were added. Data 
shown for values at every 6 hours. DNA quantity at 4 days was determined using the 
CyQuant assay. One-way ANOVA, Dunnett’s Test, * p<0.0001.  
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7.8. No significant change in expression of STAT-3 responsive genes in 
response to G-CSF in human MSCs 
The expression of STAT3-responsive genes were then examined by qRT–PCR, alongside 
genes associated with immunomodulatory properties, in G-CSF treated BMSCs. Figure 
7-9 shows that no significant difference was detected for any of the transcripts studied 
between wells where G-CSF was added relative to wells where it was not.  
 
Figure 7-9 – Gene expression analysis of BMSCs after G-CSF exposure 
BMSCs purchased from Lonza (L27766) were analysed for gene expression. Cells were 
grown to 70% confluency and then serum starved overnight before the addition of 100 
ng/mL G-CSF. After 24 hours cells were lysed and analysed by qRT-PCR. Gene are 
shown subdivided into four categories (A) genes downstream of STAT3, (B) early markers 
of osteogenesis, (C) genes indicative of angiogenesis and (D) genes related to 
immunomodulatory properties. Bars indicate the expression of mRNA for each gene 
normalised to HPRT. Error bars indicate the standard deviation of the mean for biological 
replicates of a single experiment (N=3).  
7.9. G-CSF and BMSC differentiation  
Next, the effect of G-CSF on the differentiation of BMSCs towards osteogenic, 
chondrogenic and adipogenic lineages was assessed. BMSCs purchased from Lonza 
(UK) were grown in 12-well plates and osteogenic or adipogenic inductive medium added. 
For the assessment of chondrogenic differentiation cells were cultured in high-density 
pellets with chondro-inductive medium. In treated wells 100 ng/mL G-CSF was added to 
the differentiation media. Each differentiation pathway was assessed in BMSCs isolated 
from two patients.  
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Figure 7-10 shows representative images of Alizarin red staining for calcium in osteogenic 
differentiated wells. Calcium deposition, representative of osteogenic differentiation, was 
unaffected by the addition of G-CSF within the culture medium. Likewise, representative 
images of Oil Red O staining in Figure 7-11 demonstrate the ability of BMSCs to 
accumulate lipid-filled vesicles in response to adipogenic inductive medium. Further the 
level of adipogenic differentiation was unaffected by the presence of G-CSF.  
Chondrogenic differentiation of BMSCs was determined by histological thionin staining of 
cell pellets after 21 days of differentiation. Whilst osteogenic and chondrogenic 
differentiation of BMSCs was unaffected by the presence of G-CSF in the culture medium, 
the production of proteoglycan was seen to be lower in cell pellets of both patients 
exposed to G-CSF. This was illustrated by weaker purple thionin staining (Fig 1-12). 
Additionally, variation in response was observed between control samples of the two 
patients. Interestingly, BMSCs from patient L30654 deposited more calcium than L27766 
during osteogenesis but cells from this second patient showed a better chondrogenic 
potential with stronger proteoglycan staining.  
 
Figure 7-10 – Analysis of the influence of G-CSF on the osteogenesis of BMSCs 
BMSCs purchased from Lonza (L27766 and L30654) were exposed to osteo-inductive 
media with and without the addition of 100 ng/mL G-CSF. After 21 days cells were stained 
with Alizarin red and imaged microscopically. Respresentative images shown. Scale bar 
200 µm. 




Figure 7-11 – Analysis of the influence of G-CSF on the adipogenesis of BMSCs 
BMSCs purchased from Lonza (L27766 and L30654) were exposed to adipogenesis 
inductive media with and without the addition of 100 ng/mL G-CSF. After 21 days cells 
were stained with Oil Red O and imaged microscopically. Respresentative images shown. 
Scale bar 200 µm. 
 
Figure 7-12 – Analysis of the influence of G-CSF on the chondrogenesis of BMSCs 
(L27766 and L30654) by histological evaluation 
BMSCs purchased from Lonza (L27766 and L30654) were cultured in high-density cell 
pellets and exposed to chondrogenic inductive media with and without the addition of 100 
ng/mL G-CSF. After 21 days cells were processed for paraffin sectioning and 5µm 
sections cut prior to staining with thionin. All sections were stained at the same time. Scale 
bar 100  µm. 




Figure 7-13 – Analysis of the influence of G-CSF on the chondrogenesis of BMSCs 
by gene expression over time 
BMSCs purchased from Lonza (L27766 and L29518) were cultured in high-density cell 
pellets and exposed to chondrogenic inductive media with and without the addition of 
100 ng/mL G-CSF. At the time points indicated cells were lysed for RNA isolation and 
qRT-PCR conducted for chondrogenic genes; (A) SOX9, (B) COL2A, (C) ACAN and (D) 
COMP. Bars indicate the expression of mRNA for each gene normalised to HPRT. Error 
bars indicate the standard deviation of the mean for technical replicates for qRT-PCR run 
in triplicate. A minimum of three pellets were combined for each condition (N=>3). 
 




To investigate further the reduction in chondrogenesis by BMSCs caused by the presence 
of G-CSF, gene expression analysis was conducted at different time points. BMSCs 
(Lonza, UK) were used from two different patients, one of which was used for the 
assessment in Figure 7-12 (L27766) and a second patient (L29518). The cells were grown 
in high-density pellets with and without the addition of 100 ng/mL G-CSF to chondrogenic 
inductive medium. Figure 7-13 demonstrates that for both patients there was no significant 
difference in the number of transcripts for the transcription factor SOX9 or the 
chondrogenic specific proteins type II collagen (COL2A), aggrecan (ACAN) and cartilage 
oligomeric matrix protein (COMP).  The lack of difference in these two culture conditions 
was also seen by proteoglycan staining for L27766 using thionin, Figure 7-14, where 
pellets for histological assessment were produced alongside the gene expression 
samples. These results differ from those shown in Figure 7-12 for the same patient.   
 
Figure 7-14 – Analysis of the influence of G-CSF on the chondrogenesis of BMSCs 
(L27766 repeat) by histological evaluation 
BMSCs purchased from Lonza (L27766) were cultured in high-density cell pellets and 
exposed to chondrogenic inductive media with and without the addition of 100 ng/mL G-
CSF. After 21 days cells were processed for paraffin sectioning and 5µm sections cut prior 
to staining with thionin. All sections were stained at the same time. Scale bar 100  µm.




The G-CSF receptor is well documented to be expressed by a range of haematopoietic 
cells including myeloid progenitors, neutrophils, monocytes and lymphocytes (Singh et 
al., 2012). Additionally, the expression of the receptor has been reported in cells of non-
haematopoietic tissues such as cardiomyocytes, neuronal precursors, endothelial cells 
and placental tissue (Touw and van de Geijn, 2007). As discussed previously, G-CSF 
administration to patients and experimental animal models causes the mobilisation of 
haematopoietic stem and progenitor cells as well as the proliferation of cells from the 
haematopoietic myeloid lineage in the bone marrow.  
The mechanism by which G-CSF leads to the mobilisation of HSPCs from the bone 
marrow is not well established. However, the interruption of interactions between the cells 
and their microenvironment is known to be part of the response. BMSCs are one 
component of the haematopoietic stem cell niche and have been reported in some studies 
to respond to G-CSF. To understand how G-CSF influences osteochondral repair it is 
important to investigate the action of this cytokine on BMSCs as they are thought to be a 
key cell type in the regeneration of bone and cartilage.  
7.10.1. G-CSF receptor 
Firstly, to confirm the potential of BMSCs to respond to this cytokine, analysis was 
conducted to confirm the presence of the G-CSF receptor in these cells. Previously other 
authors have reported the presence of the receptor in both human and mouse BMSCs 
(Ponte et al., 2012; Hokari et al., 2009) and here Western blot and immunocytochemistry 
analysis confirmed the presence of the receptor in human BMSCs.  
The G-CSF R is a transmembrane protein consisting of 813 amino acids to which G-CSF 
binds on the cell surface. However, the localisation of the receptor here was not solely 
associated with the membrane. Firstly, Western blot analysis identified the G-CSF R to 
be of a lower molecular weight (68 kDa) than the predicted molecular weight (92 kDa) for 
this protein. Secondly, immunocytochemistry imaging showed the receptor to be located 
within an intracellular organelle.  
Previous studies (Ponte et al., 2012) investigated the G-CSF R by Western blot using 
membrane fractions from BMSCs as the authors found G-CSF R protein levels too low for 
detection in total cell extracts. Consequently, no comment was made on intracellular 
localised G-CSF R. In the data presented here, studying orthopaedic patient isolated 
BMSCs, detection of the higher molecular weight (92 kDa) G-CSF R was unsuccessful. It 
may therefore be worthwhile in the future to isolate enriched fractions of membrane 
proteins to confirm the presence of the full length receptor at the cell surface.  
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Several hypotheses can be made to account for the presence of the 68 kDa form of G-
CSF R in BMSCs. One suggestion is that a significant proportion of the G-CSF R within 
BMSCs is accumulated in an un-glycosylated form within the endoplasmic reticulum 
awaiting post-translational modification. The G-CSF R has multiple N-glycosylation sites 
and glycosylation of the receptor has been shown necessary for the transport of the 
receptor to the cell surface (Li and Sartorelli, 1994). A second hypothesis is that there 
may be a soluble form of the receptor contained within the cells. Fukunaga et al. (1990) 
demonstrated the presence of a human G-CSF R mRNA transcript encoding a receptor 
with an 88 base pair deletion corresponding to the transmembrane domain, and so a lower 
molecular weight protein than the membrane receptor (Fukunaga et al., 1990). Either way, 
these results raised the question of whether BMSCs are able to respond to extracellular 
G-CSF.  
7.10.2. Intracellular signalling pathways activated by G-CSF 
The binding of G-CSF to its receptor is known to induce a conformational change and 
subsequently the transduction of several intracellular signalling cascades including the 
JAK2/STAT3 and PI3K/AKT, and MAPK/ERK pathways (Dwivedi and Greis, 2017). To 
study if the G-CSF receptor found in BMSCs is functional, the activation of these pathways 
following G-CSF treatment was assessed using phospho-specific antibodies. Results 
demonstrated the induction of both JAK2/STAT3 and MAPK/ERK pathways in BMSCs 
but showed patient variability. Additionally, the JAK2/STAT3 pathway was activated in 
BMSCs from older orthopaedic patients to a similar level even though the presence of the 
higher molecular weight receptor species, predicted to be glycosylated, G-CSF receptor 
was undetected by Western blot analysis in these patients.  
Following the observation that L27766 and L30654 showed activation of the JAK2/STAT3 
pathway after G-CSF exposure, the significance of the pathway was assessed using 
inhibitors of Janus kinase (JAK). JAKs are enzymes which associate with the cytosolic 
domain of cytokine receptors and on binding of a cytokine to its receptor JAKs are brought 
into apposition resulting in trans-phosphorylation and the initiation of downstream 
signalling events through the recruitment and phosphorylation of signal transducers and 
activators of transcription (STATs). By inhibition of the JAK enzymatic function STAT 
protein phosphorylation is prevented.  
Unfortunately, whilst positive controls using IL-6 confirmed the suitability and functionality 
of the assay and inhibitors used here, the activation of the JAK2/STAT3 pathway by 
G-CSF was not successful both in BMSCs and in peripheral blood mononuclear cells 
(PB MNCs) on the single occasion this assay was conducted. L27766 was used due to 
availability of low passage cells whilst use of L30654, which showed a stronger response 
to G-CSF, may have been more appropriate for this analysis. However, the failure to 
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activate the signalling pathway in PB MNCs suggests the G-CSF used for this assay was 
non-functional. For this reason, the ability of the inhibitors to decrease the G-CSF induced 
phosphorylation of STAT3 was not observed and these studies need to be repeated to 
confirm the activation of the JAK2/STAT3 pathway by G-CSF in BMSCs. Of note, one way 
to confirm the functionality of G-CSF in the future could be the use of the cell line NFS-60 
which is dependent on G-CSF for survival (Weinstein et al., 1986).  
7.10.3. Downstream effects of G-CSF treatment of BMSCs 
The observation of increased phosphorylation of STAT3 in BMSCs following treatment 
with G-CSF led to experimentation into the downstream consequences of this interaction. 
Activation of the JAK2/STAT3 signalling pathway is known to lead to transcriptional 
changes in cells, which can ultimately influence cell survival, proliferation and 
differentiation each of which is relevant to the potential of BMSCs to aid osteochondral 
repair.  
7.10.3.1. Proliferation 
G-CSF is well established to increase the proliferation of myeloid lineage cells (Touw and 
van de Geijn, 2007). In 2017, Sasaki and colleagues reported that G-CSF increases the 
proliferation of rabbit BMSCs, as assessed by cell counting. In the current work, both DNA 
assessment and real time analysis of the cell surface coverage of human BMSCs 
contradicted the findings of Sasaki and colleagues. This could potentially be due to a 
species difference. Rabbits are known to have stronger spontaneous healing capabilities 
than humans although whether this correlates to the ability of BMSCs to response to G-
CSF is unexplored. Furthermore, Sasaki et al. used BMSCs isolated from juvenile rabbits 
at 12 weeks of age which are likely more responsive to proliferation induction signals that 
could be induced by G-CSF exposure than cells isolated from adult humans.    
There is evidence from in vivo studies that G-CSF administration in humans leads to an 
increase in the number of BMSCs present in the peripheral circulation (Lund, Baso and 
Orchard, 2006). However, whether this is the result of movement of BMSCs from the bone 
marrow or an increase in the number of BMSCs is unknown. The results acquired from 
this in vitro study suggest that BMSC proliferation does not occur through the direct action 
of G-CSF on these cells although this does not rule out the possibility that BMSCs 
proliferate through changes within the overall bone marrow microenvironment.  
7.10.3.2. Differentiation  
G-CSF is known to drive haematopoietic progenitors to differentiate towards the 
granulocytic lineage and therefore the ability of G-CSF to influence the differentiation of 
BMSCs was assessed. Foremost, these experiments demonstrated that the exposure of 
BMSCs to G-CSF during differentiation does not prevent their differentiation down 
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osteogenic, chondrogenic and adipogenic lineages. Evaluation of matrix production after 
osteogenic and adipogenic differentiation showed the production of calcium enriched 
matrix and lipid vacuoles for each lineage respectively with no observed differences 
between the untreated and G-CSF treated cells. Chondrogenic differentiation on the other 
hand did demonstrate a difference in the ECM content when G-CSF was added to the 
culture media and was therefore this observation was investigated further. The expression 
of chondrogenic genes in BMSC pellets was assessed over the first 14 days of 
differentiation but this showed no change when G-CSF was included in the media.  The 
histology of chondrogenic pellets from this individual experiment prepared at the same 
time as the expression analysis did not show such pronounced differences in matrix 
staining, in contrast to the earlier data.  
On both occasions when chondrogenic differentiation was assessed, BMSCs from more 
than a single patient were assessed in parallel and importantly altered matrix staining 
observed in chondrogenic cultures across patients. Furthermore, the cells from a single 
patient (L27766) were used both for the initial assessment and the second experiment 
where gene expression was determined. Interestingly, BMSCs from this patient showed 
a difference in the matrix composition when cultured with G-CSF on the first occasion but 
not the second. One likely reason for this difference ties with the previously mentioned 
non-functionality of G-CSF suggested in experiments studying STAT3 phosphorylation 
and its inhibition by JAK inhibitors. For this reason, more studies are required to better 
understand how G-CSF treatment alters the ECM of chondrogenic pellets, by reducing 
proteoglycan content.  
This finding is perhaps somewhat unexpected given that G-CSF has been shown to 
improve cartilage repair in some animal models (Okano et al., 2014; Sasaki et al., 2017). 
However, there are important key differences. Firstly, G-CSF acts on a multitude of cells 
and therefore the signals received by BMSCs and other progenitors undergoing 
chondrogenesis is considerably more complex than the direct effect of G-CSF modelled 
in the in vitro studies presented here. Secondly, the G-CSF administered in these studies 
was used for a short period of time only. From studies investigating G-CSF and bone that 
this is known to be an important factor (Christopher and Link, 2008; Winkler et al., 2012, 
2010). Whilst here G-CSF had no significant influence on the ability of BMSCs to 
differentiate into cells that deposit a calcium rich matrix, possibly due to the simplicity of 
the assay, in vivo long-term G-CSF administration causes osteopenia through osteoblast 
apoptosis. On the other hand, short term G-CSF is seen to increase the number of 
osteoblasts (Winkler et al., 2012, 2010). It is therefore important going forward to analyse 
the difference between the transient exposure to G-CSF and its presence in culture 
medium throughout chondrogenic differentiation.  
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An important point of note here is also that it cannot be said if chondrogenesis is impeded 
or whether the matrix produced by differentiating BMSCs is degraded by another molecule 
produced by these cells, for example matrix metalloproteinases (MMPs). These enzymes 
are vital during developmental processes and in wound repair allowing the turnover of 
tissue and the migration of cells through the wound matrix (Caley, Martins and O’Toole, 
2015). Lopez Ponte and colleagues’ (2012) showed that G-CSF treatment causing an 
increase in the expression of the inactive pro-MMP2. This might suggest an increase in 
the MMP2 activity in a microenvironment where BMSCs are exposed to G-CSF. This may 
be of relevance as MMP2 knock out mice have delayed fracture repair and bone 
remodelling (Lieu et al., 2011) and therefore by increasing MMP2 levels G-CSF may 
improve bone and cartilage repair outcomes after long bone fracture and in osteochondral 
defects.  
7.10.3.3. Immunomodulation 
The immunomodulatory function of BMSCs after G-CSF exposure was not evaluated 
here. However, there is evidence in the literature to suggest this might be worth 
investigation. This cytokine has anti-inflammatory actions on monocytes (Boneberg and 
Hartung, 2002), suppresses the proliferation of T cells after mitogen-stimulation (Reyes 
et al., 1999), and systemic administration of G-CSF reduces prostaglandin E2 production 
by ex vivo BMSCs (Ok Bozkaya et al., 2015). With the knowledge that G-CSF can act 
directly on BMSCs as presented here, one can hypothesis that G-CSF might induce an 
immunomodulatory trophic phenotype in these cells.  
7.10.4. Summary  
In summary, this chapter has shown that the G-CSF receptor is present in BMSC and that 
these cells are able to respond directly to G-CSF through the JAK2/STAT3 signalling 
pathway. Data present here suggest that one of the biological effects of this could be an 
altered extracellular matrix when cells are differentiated under chondrogenic condition 
whilst adipogenic and osteogenic lineages were unaffected. Additionally, whilst G-CSF 
induces the proliferation of myeloid lineage cells, this was not observed in BMSCs.
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8. OVERALL DISCUSSION 
The aim of this thesis was to extend the understanding of haematopoietic and bone 
marrow stem/stromal cells in osteochondral repair as well as the impact of G-CSF on the 
response of these cells to the surgical injury. Bone marrow stimulation techniques have 
been used for many years to treat focal articular cartilage defects however the outcomes 
are often suboptimal (Fellows et al., 2016). The ability to repair articular cartilage, and 
also bone in osteochondral repair, have focused on the differentiation of bone marrow 
stem/stromal cell (BMSC) although their trophic role is becoming better understood. The 
use of G-CSF as an adjuvant to bone and cartilage healing strategies has demonstrated 
positive outcomes in previously published work (Table 1-1) (Marmotti et al., 2013b; Sasaki 
et al., 2008; Okano et al., 2014). However, the mechanism by which G-CSF is able to 
bring about an improved response still lacks understanding but it could be through altering 
the differentiation and trophic properties of BMSCs. 
8.1. Generation of a mouse osteochondral repair model 
One of the key objectives of this thesis was to develop a model in which the mechanisms 
and key therapeutic targets of osteochondral repair could be established. This was 
successfully achieved and the establishment of this consistent and reliable model is 
described in the second results chapter of this thesis (chapter 5). One surprising outcome 
of this work was the ability of the poor healing C57BL/6 strain to heal osteochondral 
surgical defects, as this contradicts previously published work (Fitzgerald et al., 2008; 
Eltawil et al., 2009). It is hypothesised that this is due to the increased depth of the defect 
made in this study, which allows for greater access to the underlying bone marrow and 
results in both intramembranous and endochondral ossification zones within the defect. 
The time points analysed in the data presented here were similar to those previously 
conducted, but it is possible that the integrity and quality of repair could deteriorate 
overtime and therefore longer time points will be required. 
8.2. BMSCs as tissue progenitors  
Whilst the trophic potential of BMSCs has been shown to be a significant part of the in 
vivo function of these cells, their contribution as tissue progenitors is an essential 
component of BMSCs as cell therapy for some diseases (Huang et al., 2015; Thompson 
et al., 2002; da Silva Meirelles, Caplan and Nardi, 2008). Recent studies however have 
questioned whether these cells are able to act in this way in the context of cartilage repair 
(Mak et al., 2015; de Windt et al., 2017). Histological analysis of the osteochondral model 
developed in the work presented here, identified isolated chondrocyte clusters deep within 




and supports a conclusion that chondrocyte precursors such as BMSCs, independently 
differentiate at spatially distinct sites away from the surrounding cartilage and bone that 
neighbours the defect. It is therefore argued that further investigation into factors that drive 
the temporal and regional differentiation of endogenous BMSCs in the context of surgically 
induced osteochondral trauma is warranted.  
8.2.1. Haematopoietic stem and progenitor cells influence the differentiation of 
BMSCs 
G-CSF is known to increase the number of haematopoietic stem and progenitor cells 
(HSPCs) within the bone marrow. HSPCs and BMSCs interact directly with each other in 
vivo in the bone marrow niche, a microenvironment specialised to maintain the survival 
and quiescence of haematopoietic stem cells (HSCs). Therefore, chapter 4 investigated 
the influence of this interaction on the differentiation and cell fate of BMSCs as this could 
be of relevance to the understanding of G-CSF’s role in the repair of bone and cartilage 
tissues. The study conducted here describes the ability of HSPCs to reduce the matrix 
deposition of calcium and thus inhibit the osteogenic differentiation of the BMSC cell line 
D1 ORL UVA. This demonstrates that HSPCs can influence the make-up of their 
surrounding microenvironment that in vivo consists of both BMSCs and osteoblasts 
(Durand, Charbord and Jaffredo, 2018). Additionally, this series of work adds to 
mechanistic insight into the use of G-CSF by illustrating how one of its target cell types, 
HSPCs directly influence osteogenesis. 
8.2.2. BMSCs can respond directly to G-CSF altering their differentiation 
progression 
The bone marrow is a complex microenvironment and the most dramatic and well 
characterised effect of G-CSF is on the components of the haematopoietic system. 
However, there is also evidence that G-CSF acts directly on BMSCs. Results presented 
in chapter 7 of this thesis support this with demonstration that human BMSCs express the 
receptor for this cytokine and intracellular signalling pathways can be activated upon 
G-CSF treatment of these cells. Whilst one paper indicates that G-CSF is able to induce 
rabbit BMSC proliferation in vitro (Sasaki et al., 2017), data presented here does not 
support this for human BMSCs. However, experiments in chapter 6 perhaps suggest that 
these cells do increase their number when G-CSF is administered in vivo as the number 
of nestin positive cells do increase in both the spleen and the systemic circulation, 
although it cannot be ruled out that the trauma induced in these mice may have 
contributed to this observation.  
The effect of G-CSF on BMSC differentiation status was assessed in the nestin-GFP 
reporter mice by assessing GFP positive cells in the spinal vertebrae. Unfortunately, the 




being drawn from this study. However, earlier data from Mendez-Ferrer et al. (2010) has 
shown a decrease in differentiation genes in these mice. In light of this, the influence of 
G-CSF on the in vitro differentiation of human BMSCs was evaluated (chapter 7). Whilst 
adipogenesis and osteogenesis were unaffected, the production of proteoglycan by 
BMSCs was reduced under chondrogenesis inductive culture. This is perhaps contrary to 
what one might expect as G-CSF has been shown to improve articular cartilage repair in 
animal models (Sasaki et al., 2008; Okano et al., 2014).  
Although osteogenesis was unaffected by G-CSF in the in vitro assay performed here 
(chapter 7), it is well accepted that in vivo administration of G-CSF leads to the apoptosis 
of osteoblasts (Christopher and Link, 2008) and osteopenia in both mice and human 
patients (Kokai et al., 2002; Sekhar et al., 2001). However, short-term administration has 
been shown in mice to lead to a resurgence in the number of osteoblasts once treatment 
has ended (Winkler et al., 2012, 2010). This short-term exposure might be the key and 
therefore it would be worthwhile to repeat the in vitro experiments with G-CSF included in 
the media for only a proportion of the differentiation assay. One might hypothesise that 
the reduction in proteoglycan production by chondro-induced BMSCs is a result of 
continued exposure throughout the culture period and results might be altered if G-CSF 
were only present for the initial period of the assay.  
8.3. BMSCs and their trophic/immunomodulatory response 
Within the repair tissue of the surgically induced osteochondral defect in mice in chapter 
5, both neutrophils and monocytes were identified. These cell types have a major role in 
wound healing as part of the granulation tissue, clearing potential pathogens and wound 
debris. Additionally, they are thought to help regulate inflammation and produce mediators 
that activate other cells involved in the repair process (Wilgus, Roy and McDaniel, 2013). 
Interestingly, both G-CSF (Martins, Han and Kim, 2010; Boneberg and Hartung, 2002) 
and BMSCs (Chiossone et al., 2016; Németh et al., 2009) are thought to enhance this 
ability of monocyte lineage cells, whilst G-CSF also increases the number of neutrophils 
and monocytes within the circulation.  
8.3.1. Cell death is an immunomodulatory function of BMSCs 
The trophic and immunomodulatory role of BMSCs is reflected in their ability to respond 
and migrate to injury sites where they secrete reparative factors such as paracrine growth 
factors, cytokines and extracellular vesicles. Through this action they influence the 
viability and proliferation of neighbouring cells, induce angiogenesis, reduce inflammation 
and alter immune cell responses (Wang et al., 2014). Here it is proposed that another 
potential mechanism through which BMSCs carry out this action that is cell death. 




nestin positive BMSCs die within the first few days of repair. The death of these cells may 
be a mechanism through which these cells release signals to the surrounding 
microenvironment, such as through the release of apoptotic bodies and other extracellular 
vesicles or the phagocytosis of cell debris by cells such as neutrophils and monocytes. 
Importantly macrophages are progeny for the monocytic-lineage and are able to influence 
repair by either exhibiting a pro-inflammatory or a reparative phenotype. The mechanisms 
by which BMSCs drive the more reparative macrophage phenotype through their death is 
worthy of future investigation.   
8.3.2. G-CSF and trophic/immunomodulatory properties 
G-CSF is known to both increase the proliferation and prevent the apoptosis of neutrophils 
as well increase the number of monocytes in the circulation. For this reason, in addition 
to G-CSF’s clinical use as a method to increase and mobilise HSCs into the periphery, it 
is also used to treat neutropenia where white blood cell counts are reduced. In this way, 
G-CSF treatment may influence the haematopoietic composition of the initial haematoma 
and the granulation tissue. Moreover, rather than just increasing the numbers of 
haematopoietic cells, G-CSF has also been shown to alter the phenotype and milieu 
secreted by haematopoietic cells.  For example, it induces monocytes to produce anti-
inflammatory mediators and attenuates their capacity to release pro-inflammatory 
cytokines (Boneberg and Hartung, 2002).  
The ability of G-CSF to alter the trophic and immunomodulatory properties of BMSCs has 
not directly been investigated in this thesis. However, preliminary gene expression data 
from human BMSCs cultured in vitro with G-CSF does show changes, although not 
statistically significant, in genes associated with these properties. Furthermore, as 
previously mentioned, G-CSF is shown to reduce the expression of differentiation genes 
in nestin positive BMSCs (Mendez-Ferrer et al., 2010) and therefore a different 
phenotype, such as an immunomodulatory phenotype, may be driven by G-CSF 
exposure. Finally, in chapter 4, the co-culture of HSPCs, known to increase with G-CSF 
administration, with a BMSC cell line demonstrates the reduction of an osteoblastic 
phenotype of these stromal cells and therefore this could suggest a shift to either the 
maintenance of the original phenotype, a more niche supportive phenotype and/or a more 
trophic phenotype.  
8.4. Overall conclusions 
Overall, this thesis has added to understanding of the role of BMSCs and haematopoietic 
cells in the repair of bone and cartilage in the context of osteochondral repair. Evidence 
presented here further supports a role for BMSCs as both tissue progenitors and 




environment is complex with cross talk of multiple bone marrow cells influencing the cell 
fate of BMSC and immune cells. Moreover, this is additionally influenced by the 
exogenous administration of G-CSF, a cytokine that can exert direct effects on a diverse 
range of cell types involved in the repair process including BMSCs. Finally, this thesis 
reports the development of a refined osteochondral model in mice. This model will be 
used in the future to elucidate the role of many of the cell types involved in osteochondral 
wound repair, with feasibility demonstrated here with the BMSC Nestin-GFP reporter 
mouse line. Going forward, this will aid a better understanding of BMSC as a cellular 
therapy and G-CSFs mechanism of action, allowing greater precision, translation and 
clinical utility. 
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10.1. Patient Details 
Patient ID Source Age  Sex 
Pt 329 Addenbrooke’s Hospital Patient 89 years Female 
Pt 398 Addenbrooke’s Hospital Patient 55 years Female 
Pt 399 Addenbrooke’s Hospital Patient 72 years Female 
L27766 Lonza 23 years Female 
L30654 Lonza 22 years  Male 
L29518 Lonza 31 years Male 
 
10.2. Human qRT-PCR Housekeeping Gene Stability Data 
Raw qRT-PCR data (average CT values shown for three technical replicates) of BMSCs 
cultured to 70% confluency and then serum starved overnight before the addition of 10% 
FCS, 100 ng/mL G-CSF or 50 ng/mL G-CSF.   
Gene name No serum 10% FCS 100 ng/mL G-CSF 50 ng/mL G-CSF 
HPRT 23.65 24.27 24.10 23.96 
GAPDH 17.59 18.37 17.55 17.44 
B2M 17.38 18.50 17.96 17.79 
 
NormFinder results using the data above.  
Gene name Stability value Standard error 
HPRT 0.013 0.007 
GAPDH 0.014 0.007 
B2M 0.008 0.009 
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10.3. qRT-PCR Primers 
Target Gene Sequence Validation 




D10 osteo D1ORLUVA -3.366 0.99 98.181 
Runx2 Fw:CGGCCCTCCCTGAACTCT 
Rv:TGCCTGCCTGGGATCTGTA 
D7 osteo D1ORLUVA -3.301 0.997 100.864 
Sp7 Fw:ATGGCGTCCTCTCTGCTTGA 
Rv:GAAGGGTGGGTAGTCATTTG 
D10 osteo D1ORLUVA -3.244 0.997 103.363 
Col1a2 Fw:GTAACTTCGTGCCTAGCAACA 
Rv:CCTTTGTCAGAATACTGAGCAGC 
D10 osteo D1ORLUVA -3.157 0.997 107.361 
Col2a1 Fw:CGAGTGGAAGAGCGGAGACT 
Rv:AACTTTCATGGCGTCCAAGGT 
Mouse costal chondrocytes -3.247 0.998 103.229 
Sox9 Fw:AGTACCCGCATCTGCACAAC 
Rv:ACGAAGGGTCTCTTCTCGCT 
Mouse costal chondrocytes -3.311 0.998 100.454 
Tgfβ Fw:GAGCCCGAAGCGGACTACTA 
Rv:TGGTTTTCTCATAGATGGCGTTG 
D7 chondro D1ORLUVA -3.004 0.984 115.196 
Lpl Fw:GGGAGTTTGGCTCCAGAGTTT 
Rv:TGTGTCTTCAGGGGTCCTTAG 
D7 adipo D1ORLUVA -3.192 0.988 105.719 
Fabp4 Fw:AAAGAAGTGGGAGTGGGCTT 
Rv:CTCTTGTGGAAGTCACGCCT 
D7 adipo D1ORLUVA -3.154 0.953 107.543 
Pparγ Fw:GGTGAGGAGAGCTCTGGAAG 
Rv:GACTGAGGAAGGGCTGGAAG 
D7 adipo D1ORLUVA -3.312 0.972 100.395 
Flt3 Fw:GAGCGACTCCAGCTACGTC 
Rv:ACCCAGTGAAAATATCTCCCAGA 
Primary lineage negative BM -3.533 0.952 91.876 
Hck Fw:TCCTCCGAGATGGAAGCAAG 
Rv:ACAGTGCGACCACAATGGTAT 
Primary lineage positive BM -3.307 0.925 100.631 








Primary lineage positive BM -3.053 0.984 112.602 
Hprt Predesigned QuantiTect Qiagen primers 
 





































Predesigned QuantiTect Qiagen primers  
STAT3 
 
Predesigned SYBR green primers from Sigma 
EFNB2 
 
Predesigned SYBR green primers from Sigma 
FGG 
 
Predesigned SYBR green primers from Sigma 
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